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General introduction and outline of this thesis
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General Introduction
Our body is involved in a daily battle with many intrudingmicroorganisms, such as bacteria, fungi and viruses. Fortunately, we are
equiped with a defense mechanism against these foreign intrudors, i.e. our immune
system is trained to recognize all kind of structures, but only from invaders, not
structures from the body itself. However, sometimes the immune system fails.
Systemic lupus erythematosus (SLE) is the consequence of such a failure in our
immune mechanism. SLE is an autoimmune disease, which means that the immune
system produces antibodies against self structures, which include many different
autoantigens in SLE. Since autoantibodies circulate in the blood stream, they can
lead to inflammation throughout the body, such as in the skin and joints, but also in
organs like the kidneys, the central nervous system, heart, lungs and blood vessels.
These inflamation reactions cause the disease manifestations of SLE, which are very
different between patients. Characteristic for SLE is the facial skin erythema in the
form of a butterfly. The term lupus (Latin for wolf) is attributed to the thirteenth
century physician Rogerius who used it to describe erosive facial lesions that were
reminiscent of a wolf’s bite. In the United States 1.4 million people suffer from SLE,
but the prevalence of SLE in the world is not exactly known, however the number
of SLE patients seemed to be increased during the last decades. Most likely several
factors play a role in the development of the disease, such as environmental (sun
light), hormonal, genetic factors and infections. SLE is more commonly found in
woman (90%) and can develop at each age, but most frequently between 20-40
years. Since the cause is not known yet, the disease itself cannot be cured. Presently,
corticosteroids are the primary therapy for the majority of patients with SLE.
Antimalarials are used principally for patients with skin and joint involvement and
cytotoxic immunosuppressive drugs are used for patients with glomerulonephritis,
systemic vasculitis, and other severe life-threatening manifestations.
History of SLE research
Despite decades of research, the cause(s) of SLE still remain a jig-saw
puzzle. The history of modern research on SLE began with the discovery of the LE
cell by Hargraves and colleagues in 1948 (3). They postulated that: “this cell is the
result of phagocytosis of free nuclear material with a resulting round vacuole
containing this partially digested and lysed nuclear material”. In the 1950s, Friou
applied the technique of indirect immunofluorescence to demonstrate the presence
of antinuclear antibodies in the blood of patients with SLE (4). Subsequently,
autoantibodies against deoxyribonucleic acid (DNA), extractable nuclear antigens
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(ENA), i.e. nuclear ribonucleoprotein (nRNP), Sm, Ro, La, and anticardiolipin were
described. A major advance in SLE research was the development of animal models
for SLE. The first animal model for SLE was the F1 hybrid of New Zealand Black
and New Zealand White mouse (NZWBF1) (5). These mice developed symptoms
similar to SLE patients, including the formation of anti-nuclear autoantibodies and
the development of lupus nephritis. Later SLE disease was also found in certain
strains containing a gld or lpr mutation (6), which results in a deficiency for the Fas
ligand (FasL) or the Fas protein, respectively. An abnormal Fas-FasL pathway,
which is involved in the apoptosis and removal of certain cells of the immune
system, leads to the persistence of both autoreactive T- and B-cells. Importantly,
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Figure 1. The role of nucleosomes in the development of the anti-chromatin response and
glomerulonephritis in lupus: A disturbed apoptosis or removal of apoptotic cells leads to the release
of modified apoptotic material, including nucleosomes. Modifications on the nucleosome associated
with apoptosis are depicted in the inset. Dendritic cells digest the nucleosomes and present
(modified) histone peptides to histone-specific T cells. Activated histone-specific T cells, in
cooporation with activated DNA- and nucleosome-specific T cells, stimulate B-cells to produce anti-
histone, nucleosome-specific and anti-DNA autoantibodies. Finally, anti-nucleosome/nucleosome
complexes are formed, which bind to negatively charged residues in heparan sulfate, present in
basement membranes, such as the glomerular basement membrane in the kidney.
PS: phosphatidyl serine, Ph: phosphorylation, Ac: acetylation, Me: methylation, Ox: oxidation
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onset and severity of symptoms in mice bearing the lpr or gld mutation is dependent
on the genetic background (7). These and other SLE mice models have led to a much
better understanding of the processes that lead to the development of the disease.
SLE was found to be driven by autoantigens and was dependent on T and B cells.
Until now, more than 100 autoantigens have been identified that are targeted by SLE
autoantibodies (8). The autoantigens that are targeted by autoantibodies are different
between patients. Since anti-DNA autoantibodies were found in nearly all patients,
these autoantibodies were considered as the serological marker for SLE. However,
DNA is not immunogenic by itself, only when bound to proteins (i.e. histones or
viral proteins) it can induce an anti-nucleosome and anti-DNA response (9, 10).
Therefore, the DNA/histone complex, the nucleosome, was proposed as the major
autoantigen (11). Indeed, the last decade cumulating evidence points to the
nucleosome as the major autoantigen that drives the autoimmune response in SLE
(12, 13), as depicted in Figure 1. 
The nucleosome
The nucleosome is the basic unit of chromatin, the nuclear structure in which
2 meters of DNA is densily packed (Figure 2a). Each nucleosome is made up of 146
base pairs (bp) of double stranded (ds)DNA wrapped twice around a histone octamer
formed by pairs of the histones H2A, H2B, H3 and H4 (Figure 2b). In chromatin,
nucleosomes are connected by 15-80 base pairs of linker DNA, to which histone H1
is attached. The nucleosome contains domains that are positively charged due to
basic amino acids especially in the N-terminal tails of the core histones, and
domains that are negatively charged due to the negative charge of DNA. These
charges enable nucleosomes to bind easily to other positively or negatively charged
molecules. Especially, the histone tails protruding from the nucleosome core particle
may act as ‘sticky fingers’ for negatively charged molecules, such as heparan
sulfate. 
Normally, i.e. in their physiological context, histones can be heavily
modified especially at the N-terminal tails. These histone modifications include
phosphorylation of serine or threonine, acetylation of lysine or arginine, (mono-, di-
or tri-) methylation of lysine or arginine, citrullination of arginine, ubiquitination of
lysine, transglutamination of glutamine or lysine and sumoylation of sofar
unidentified residues (Figure 2c). It has now become clear that a histone
modification or a combination of histone modifications in a certain chromatin region
greatly determines the activity of that domain, i.e. recruitment of other proteins,
involved in transcriptional silencing, activation, DNA repair, mitosis or meiosis.
Furthermore, one histone modification may effect the presence or absence of other
13
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Figure 2. Chromatin structure and
histone modifications. A. From the
the 'double helix' to the
chromosome structure, reproduced
from Richmond et al. in Nature
(2003) (1). B. 3D model of the
nucleosome (PDB: 3AOI) (1).
Protruding tails of the histones are
mostly not present in this model.
However, a part of one tail of
histone H3 is present, where the
SAPAT epitope (Chapter 7) is
located (marked by an arterisk). C.
Modifications on the core histones
as described in the literature.
Specific modifications linked to
apoptosis are underlined. 
Abreviations used are: 
Ac (acetylation) 
P (phosphorylation)
Me (methylation) 
Ub (ubiquitination)
Tg (transglutamination)
A
B
C
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histone modifications. These observations led to the proposal of a histone code (14),
which links specific histone marks to distinct (cell) biological processes.
Apoptosis-induced autoantigen modifications
Apoptosis is a mechanism of programmed cell death that leads to the
removal of cells from our body without exposing their dying contents to the our
system, including the immune system. During apoptosis, many proteins are cleaved
by proteases, in addition DNA and RNA are cleaved by endonucleases. These
proteases involve a large family of so called caspases that are able to cleave a still
increasing list of about 300 proteins with various functions (15). The caspase
substrates include caspase family members that become activated upon proteolytic
cleavage thereby activating the downstream caspase cascade pathway of cell death.
Inactive caspase activated DNase (ICAD) also becomes activated to caspase
activated DNase (CAD) by proteolytic cleavage by caspases. This leads to the
cleavage of chromatin into individual nucleosomes. Cytotoxic T cells or natural
killer cells can induce apoptosis via another pathway by the release of protease
granzyme B, cleaving a number of proteins that are essential for cells to survive. In
fact susceptibility for cleavage by granzyme B greatly determines whether a non-
histone protein can become an autoantigen (16, 17). Although it has been
demonstrated that chromatin-associated SLE autoantigens are substrates for
caspases and/or granzyme B, not much is known about proteolytic processing of the
nucleosome and/or the separate core histone proteins by caspases and/or granzyme
B.
As already mentioned, histones can be heavily modified, which also includes
modifications induced during apoptosis. Recently, a caspase-actived kinase (twenty
kinase) has been shown to phosphorylate histone H2B at serine 14 (S14) during
apoptosis using several inducers for apoptosis in various cell lines(18). In addition,
apoptosis-induced phosphorylation has been shown for histone H2B at other serine
residues (S32 and S35), for histone H2A at unknown residues, for the minor histone
H2A variant, H2A.X, at S139, and for histone H3 at S10 or S28 (18-24). Both
apoptosis-induced histone deacetylation and acetylation have been described (25-
28). For instance, cis-platin induced apoptosis resulted in global hyperacetylation of
histones. Moreover, treatment by several histone deacetylase (HDAC) inhibitors,
which also results in hyperacetylation of histones, induced apoptosis, while HDAC
inhibitors and apoptosis inducers can act synergistically. Other specific apoptosis-
induced modifications that have been described include poly(ADP-)ribosylation and
dephosphorylation of histone H1, de-ubiquitination of histone H2A and
transglutamination of H2B (29-32). Recently, the involvement of histone H1 variant
15
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H1.2 in the induction of apoptosis has also been reported (33). Until now, a clear
histone code linked to the process of apoptosis has not been identified. Besides
histones, DNA can be modified by cleavage, methylation or oxidation by radicals
(34, 35). Despite the identification of apoptosis-induced histone/DNA
modifications, there is little knowledge about the relevance of these modifications
for the recognition by SLE autoantibodies. 
Removal of apoptotic cells
A paramount report by Cascialo-Rosen and co-workers showed that
autoantigens become clustered in apoptotic blebs after exposure of keratinocytes to
UV light (36). The larger blebs contained DNA, SS-A (Ro), SS-B (La) and the small
nuclear ribonucleoproteins, while the smaller blebs contained fragmented
endoplasmatic reticulum (ER), ribosomes and SS-A (Ro). This observation provided
for the first time a mechanism how seemingly unrelated and deeply hidden nuclear
and cytoplasmatic antigens can serve as autoantigens that challenge the immune
system. In addition, a recent report shows that anti-nucleosome autoantibodies can
bind to nucleosomes exposed at the surface of apoptotic blebs (37). The expression
of SLE-targeted autoantigens at the surface of apoptotic cells may be an important
intitial event in the induction of autoimmunity. Normally, apoptotic cells are swiftly
removed by either professional (i.e. macrophages) or non-professional phagocytes
(i.e. neighbouring cells) before the formation of apoptotic blebs. However, apoptosis
at the wrong environment and/or at the wrong time-point can lead to an overload of
apoptotic cells for the local cleaning machinery, resulting in the release of histones
and nucleosomes with apoptosis-induced modifications (11, 13, 38, 39). 
Presentation of phosphatidyl serine on the cell surface, is the first ‘eat me’
signal for apoptotic cells. However, recognition of apoptotic cells is a complex
process, involving many phagocytic receptors, bridging molecules and markers on
the apoptotic cell (40).  Studies involving these molecules have shown that a
disturbed removal of apoptotic cells results in the development of SLE (39, 41).
Mice deficient for molecules involved in apoptotic cell removal, developed anti-
nuclear autoantibodies, glomerular deposits containing immunoglobulins and
complement factors, and in some cases glomerulonephritis. In addition to the direct
removal of apoptotic cells, a ‘back-up’ system seems to exist in case this removal is
impaired. Here, apoptotic material and potential autoantigens such as nucleosomes
are either masked and tethered for removal by C1q, serum amyloid P (SAP) or
pentraxin 3 (PTX3), or directly broken down by DNaseI. Mice deficient for these
molecules also developed a SLE-like syndrome. In SLE mouse models, like the
16
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MRL/lpr and (NZBxNZW)F1, there is evidence for an impaired removal of
apoptotic cells (42, 43). In SLE patients it has been demonstrated that the
phagocytosis of apoptotic cells is disturbed (44-46). In addition, increased levels of
apoptotic cells have been found in plasmas from SLE patients, however this was not
correlated to disease activity and was also found in non-SLE patients (45, 47, 48).
Nucleosomal material (i.e. DNA and histones) has also been detected in plasmas of
SLE patients (49, 50) and SLE mice (51). 
Immunogenicity of apoptotic cells and nucleosomes
Nucleosomes, present due to an impaired removal of apoptotic cells, are able
to inhibit the uptake of apoptotic cells (52), which could lead to an perpetuing circle.
Moreover, the release of apoptotic and thus modified nucleosomes may lead to the
activation of the immune system. Macrophages act as the professional garbish men,
without inciting an inflammatory response. The uptake of apoptotic cells by
macrophages suppresses the release of pro-inflammatory cytokines and stimulates
the production of anti-inflammatory cytokines (40). Ineffective removal of apoptotic
cells leads to the persistence of apoptotic material in the circulation, which can be
encountered by dentritic cells (DCs), thus promoting a pro-inflammatory response.
DCs are the professional antigen presenting cells and mature in response to ‘danger
signals’. Immature DCs are capable of ingesting large amounts of material from
apoptotic cells, subsequently, upon maturation DCs will present the processed
apoptotic material to T cells. Apoptosis-induced modifications could enhance the
immunogenicity of nucleosomes. Indeed, DCs have been shown to present apoptotic
material to T cells (53). In case of nucleosomes, DNA is only immunogenic when it
is attached to proteins, like histones or viral proteins, leading to the uptake and
presentation of peptides from these proteins. Indeed, histone-specific and
nucleosome-specific T helper cells have been identified (54), which also resulted in
the identification of several T cell epitopes on the core histones (55-58). In contrast
to the normal immune response, T cell and B cell epitopes frequently overlap in SLE
(59, 60). The nucleosomal and/or histone T cell epitopes that have been identified in
humans and mice are located in histone H2A (amino acids (aa) 34-48), H2B (aa 10-
33), H3 (aa 85-114) and H4 (aa 14-39, aa 49-63 and aa 71-99). Another T cell
epitope has been found in H3 (aa 53-85) for mice that were immunized with
apoptotic cells. Some established histone modifications are located in the identified
T cell epitopes, i.e. acetylation of K12, K15 and K20 and phosphorylation of S14 in
H2B, methylation of K79 in H3, and acetylation of K16 and methylation of K20 in
H4. However, only the phosphorylation of S14 in H2B has been related to apoptosis
so far (18). The lack of modifications on the histone peptides that have been used
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for the identification procedure of T cell epitopes may have hampered the
identification of modified T cell epitopes in these potentially heavily modified
regions. Histone-specific T cells are able to provide help for the production of
nucleosome-specific and anti-DNA autoantibodies by stimulating T cells specific for
nucleosomes and DNA (54, 60), a process known as ‘antigen spreading’. The
majority (50%) of these T cells have been identified as nucleosome-specific, again
underlining the importancy of the nucleosome as autoantigen (60). Antigen
spreading can also explain why activation by apoptosis-modified chromatin may
result in the development of autoantibodies specific for ‘normal’ chromatin.
Histone-, DNA-, and nucleosome-specific T cells augment the production of anti-
DNA, anti-histone and nucleosome-specific autoantibodies by B cells. A defective
apoptosis can also play a role in the survival of autoreactive T and B cells (39), as
has been shown in mice with mutations in genes encoding molecules involved in the
regulation of T and B cell apoptosis. Mice deficient for Fas, Fas ligand, Bim or
TACI, or mice overexpressing Bcl-2 or Blys developed a SLE-like disease.
Seemingly contradictive to the earlier suggested increased rate of apoptosis leading
to the release of apoptotic material, these mice do not sufficiently remove their
autoreactive T and B cells. Importanly, both mutations in genes encoding proteins
involved in the removal of apoptotic cells and genes encoding proteins involved in
the apoptosis of (autoreactive) cells leads only to the development of autoimmune
disease in certain genetic backgrounds. This latter fact underlines the importance
that SLE is a multifactorial disease.
Nucleosomes and anti-nucleosome autoantibodies as complex
troublemakers in the development of SLE
As mentioned, the release of modified nucleosomes leads eventually to the
production of anti-nucleosome autoantibodies. These autoantibodies can be divided
into three categories: i) antibodies which recognize DNA (anti-DNA); ii) antibodies
which recognize histones (anti-histone); and iii) antibodies which exclusively or
predominantly recognize nucleosomes or subnucleosomal structures (nucleosome-
specific). Several studies regarding anti-nucleosome autoantibodies have been
performed in both SLE mice and patients. In total 1356 SLE patients and 1807
patients with other rheumatic diseases have been tested (summarized in Table I).
Anti-nucleosome autoantibodies are found in the majority of SLE patients, with an
average prevalence of 63%. Levels of anti-nucleosome (and anti-DNA)
autoantibodies correlate with disease activity and the presence of lupus nephritis
(72, 79). Especially, anti-nucleosome autoantibodies have been demonstrated to be
specific for SLE (68, 70), although ome reports described that these autoantibodies
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were also present in patients with scleroderma or mixed connective tissue disease
(68). However, this latter observation may be related to the contamination of for
instance topoisomerase I in the applied nucleosome preparations (67). Anti-histone
autoantibodies are more commonly found in drug-induced lupus (DIL), but they are
neither as sensitive nor specific for SLE and DIL as anti-nucleosome autoantibodies
(80). The methods commonly applied to detect anti-DNA autoantibodies are an
immunoprecipitation assay of radioactive-labelled DNA, called the Farr assay, or on
immunofluorescence staining test using Crithidia lucilae, which has no histones, as
substrate. Recently, anti-DNA and especially anti-nucleosome, ELISAs have
become commonly available and accepted for diagnostic testing, but it should be
mentioned that these tests also measure low avidity antibodies (81). Although
considerable progress has been made in recent years, the anti-nucleosome response
has been poorly characterized for several reasons. Studies show that a number of the
patients posess anti-nucleosome reactivity, without anti-DNA or anti-histone
19
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reactivity (65). Indeed, after absorption of sera by collumns with covently coupled
DNA and histones, 25-60% of the anti-nucleosome reactivity was due to anti-DNA
reactivity and 10-20% to anti-histone reactivity. In this case, 20-60% of the anti-
nucleosome reactivity was due to really nucleosome-specific autoantibodies. These
nucleosome-specific autoantibodies have been implicated in the development of
lupus nephritis (82) and seem to appear early in disease before anti-DNA
autoantibodies arise (83, 84). However, anti-DNA and anti-histone autoantibodies
will also bind when nucleosomes are used as antigen for the analysis of patients sera.
Moreover, anti-nucleosome/nucleosome complexes can bind to DNA (via histones)
and histones (via DNA), so aborption by DNA and histone columns could also lead
to the removal of nucleosome-specific autoantibodies. Because of these limitations,
a method bypassing the absorption would be of great importance. The use of
synthetic overlapping peptides has revealed epitopes for anti-histone and anti-
spliceosome autoantibodies. For obvious reasons, this method cannot be used for
nucleosome-specific autoantibodies, since these antibodies recognize
conformational epitopes partially consisting of DNA and of histone proteins. For
such epitopes, mimotopes should be identified. Mimotopes are peptides that mimick
partially or completely non-protein structures, such as carbohydrates or DNA. The
selection of mimotopes for nucleosome-specific autoantibodies can be performed by
screening random peptide phage display libraries with these autoantibodies (Fig 3a).
These libraries contain a random peptide fused to one of the phage coat proteins,
with a complexity of about 108-1012 random sequences (Figure 3b). Random peptide
phage display has been succesfully applied to identify mimotopes for antibodies
against carbohydrate epitopes, which have a great potential for the development of
vaccins (85, 86). Recently, this technique has also been aplied in several studies to
identify mimotopes for SLE-derived anti-DNA topes, containing negatively
charged, positively charged and/or aromatic residues. Further autoantibodies (87-89)
(Table II). This led to the identification of completely different mimostudies with the
D/E-W-D/E-Y-S/G mimotope has revealed the finding that a peptide comprising this
mimotope sequence could prevent the binding of anti-DNA autoantibodies to the
GBM (87). This peptide could also induce SLE in BALB/c and (NZBxNZW)F1
mice (90, 91). In addition, cross-reactivity of anti-DNA autoantibodies with an D/E-
W-D/E-Y-S/G epitope in the NR2 glutamate receptor in the brain was reported (92).
Mimotope peptides for nucleosome-specific autoantibodies may be used for
diagnostic applications to monitor nucleosome-specific autoantibodies, or to
evaluate their biological effect in normal and SLE mice. For instance, these
mimotopes could be used to induce tolerance or to prevent the formation of anti-
nucleosome/nucleosome complexes by competing with the nucleosome for the
binding to the nucleosome-specific antibody.
The formation of anti-nucleosome/nucleosome immune complexes forms
20
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Figure 3. Random peptide phage display. A. Screening of random peptide libraries. In the first
round, a portion of the phage library is added to a monoclonal antibody (mAb) coupled to magnetic
beads. After washing, bound phages are eluted and amplified.  In the next rounds, phages are first
incubated with a decreasing concentration of uncoupled mAb and phage/mAb complexes are
captured by Ig-coated mangetic beads, to remove phages selected for the Ig-coupled beads.
Individual phage clones are picked and sequenced, and one or more motifs are deduced from these
sequences. B. Phage containing a DNA insert (green) encoding a random protein sequence fused to
the pIII coat protein of the phage (green triangles) (2).
A
B
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the final phase for the role of nucleosomes in the development of SLE. As
mentioned already, nucleosomes contain both negatively (i.e. DNA) and positively
(i.e. histones) charged  regions. Binding of anti-DNA or nucleosome-specific
antibodies to the negatively charged regions in the nucleosome, could lead to
masking of the negative charge and an enhanced binding of the formed complexes
to negatively charged molecules. Previous research has shown that anti-
nucleosome/nucleosome complexes can bind via the positive charges in the histones
to heparan sulfate, which is present in the glomerular basement membrane (GBM)
and contains many negative charged residues (93-95). The binding of complexes to
the GBM initiates the development of local inflamation in the glomerulus, resulting
in lupus nephritis, the most serious manifestation of SLE. 
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Outline of this thesis
The major aim of this thesis was to identify and characterize the epitopes fornucleosome and histone-specific autoantibodies and to evaluate their role in the
lupus autoimmune response. Recent studies mainly from our laboratory, assessing
the role of the nucleosome in the development of lupus were summarized and put
into perspective in chapter 2 (13).
As outlined above, nucleosomes are probably not immunogenic by themselves.
However, apoptosis-induced histone modifications could initiate the anti-
nucleosome autoimmune response. In chapter 3, we assessed whether apoptosis-
induced histone modifications are targets for SLE autoantibodies. In addition, the
effect of administering peptides containing apoptosis-induced histone modifications
on the development of SLE was evaluated.
Normally, apoptotic cells are directly removed. However, a disturbed apoptosis
could lead to the release of apoptotic material into the circulation, including
modified histones and nucleosomes. Using an in vitro phagocytosis assay, we
analysed the phagocytic efficacy of resident peritoneal macrophages for apoptotic
cells from pre-diseased and diseased SLE mice (chapter 4) (96) . 
The release of apoptotic nucleosomes leads eventually to the activation of the
immune system and the production of anti-nucleosome autoantibodies (i.e. anti-
DNA, anti-histone and nucleosome-specific antibodies). In chapter 5, we
performed an analysis of the reactivity of anti-nucleosome, anti-DNA, anti-histone
and anti-C1q autoantibodies in plasmas of patients from a prospective study on the
treatment of proliferative lupus nephritis. 
Since specific detection of nucleosome-specific autoantibodies is very difficult
sofar, identification of mimotopes for nucleosome-specific autoantibodies could
lead to more insight into the significance of this class of autoantibodies. For this
purpose we screened random peptide phage display libraries to identify mimotopes
for monoclonal nucleosome-specific autoantibodies derived from SLE mice
(chapter 6) (97). In this study we also evaluated previously identified mimotopes
for anti-DNA autoantibodies. In chapter 7, the same phage display technique was
used to identify the epitope of a SLE-derived anti-histone autoantibody (98).
Moreover, the influence of modified residues and amino acid variations between
histone variants, residing in the identified epitope, on the binding of this antibody to
histone peptides was assessed.
23
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Complexes of anti-nucleosome autoantibody and nucleosomal material (i.e. histones
and DNA) can bind to (charged) proteins and peptides which plays a decisive role
in the initiation of lupus nephritis. This ‘cross-reactivity’ may not only lead to false
positive reactivity in diagnostic assays, but may also play a role in the development
of antigen-spreading in SLE. Therefore, we evaluated the binding of DNA or
nucleosomes to the cationic major autoepitope of the SmD1 antigen, i.e. SmD1(83-
119) (chapter 8).
The research of our group in previous years on the binding of anti-
nucleosome/nucleosome complexes to heparan sulfate in the glomerular basement
membrane is summarized in chapter 9.
Finally, in chapters 10 and 11 all findings are summarized and put into perspective.
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Chapter 2.
Triggers for anti-chromatin autoantibody
production in SLE
Jürgen W. Dieker, Johan van der Vlag & Jo H. Berden
Published in Lupus 2002; 11:856-64
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Abstract
The formation of autoantibodies against chromatin is the main feature of
systemic lupus erythematosis (SLE), an autoimmune disease, which is T-cell dependent
and autoantigen-driven. Historically, antibodies against dsDNA, one of the
components of chromatin, are considered as a hallmark of SLE. However, dsDNA is
poorly immunogenic. Nucleosome-specific T helper cells have been identified. These T
cells propagate not only nucleosome-specific antibodies, but also anti-DNA antibodies.
Nucleosomes are formed during apoptosis by cleavage of chromatin, and evidence of
disturbed apoptosis has been found especially in certain murine models of lupus. In
addition to an increased rate of apoptosis, autoimmunity against chromatin might also
result from an impaired phagocytosis of apoptotic material, for which strong evidence
has been provided by studies in certain knock-out mice (C1q, SAP, DNaseI). The
induction of an immune response to nucleosomes could be enhanced by modifications
of histones or DNA during apoptosis, altered presentation by antigen presenting cells
or a viral infection. The release of nucleosomes and the formation of anti-chromatin
autoantibodies result in formation of complexes, which bind to the glomerular
basement membrane via heparan sulfate. This deposition incites glomerulonephritis,
the most serious manifestation of SLE.
The human cell nucleus contains our genetic information encoded in 2mof double-stranded DNA(dsDNA). These very long strands of dsDNA
are packed in the tiny nucleus by a complex folding of higher order chromatin
structures, that consist of DNA and numerous proteins. The basic structure of
chromatin is the so-called ‘beads on a string’ fibre. An individual ‘bead’, a
nucleosome, consists of 146 base pairs of dsDNA wrapped around pairs of four
different core histones. The core histones are histone H2A, H2B, H3 and H4, while
another histone (H1) is bound outside the nucleosome. The string between the beads
is formed by linker DNA connecting the individual nucleosomes. 
The formation of autoantibodies against chromatin is the main feature of
systemic lupus erythematosus (SLE), an autoimmune disease which is T cell
dependent and autoantigen-driven.(99) Chromatin autoantibodies have been
detected in 88% of SLE patients (64) and have also been found with high incidence
in lupus mouse models. Moreover, 50% of the pathogenic T helper cells are
nucleosome-specific.(60) It has been reported that in other autoimmune diseases,
such as scleroderma and mixed connective tissue disease, anti-chromatin antibodies
are also formed (68), but this was not confirmed in another study (70).
Autoantibodies against the basic structure of chromatin can be divided in three
groups: antibodies reacting with either DNA or histones, and antibodies that have a
much higher affinity for the intact nucleosome than the individual components,
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DNA and histones. Historically, antibodies against dsDNA are considered as a
hallmark of SLE. These antibodies can be detected in 70% of SLE patients, correlate
with disease activity, and an increasing titre of anti-DNA precedes exarcerbations
(100). Later, it appeared that nucleosome-specific antibodies have an even higher
prevalence in SLE and a better correlation with lupus nephritis (70, 101). Since
naked DNA is a poor immunogen, it is believed that the nucleosome is the primary
antigen, also resulting in the induction of anti-DNA and anti-histone responses via
antigen spreading (64).
Nucleosomes are formed during apoptosis by cleavage of the
internucleosomal linker DNA. These nucleosomes, probably altered during the
apoptotic process, appear with other autoantigens in apoptotic blebs at the surface of
apoptotic cells (36). Normally, these apoptotic cells are removed swiftly by
phagocytic cells, before apoptotic blebs can be released. Increased presentation of
(modified) apoptotic debris and/or impaired removal of apoptotic cells may lead to
an immune response against the contents of these blebs (Figure 1). 
Furthermore, anti-nucleosome/nucleosome complexes can mediate tissue
lesions, since these complexes can bind to negatively charged components in
basement membranes (94), such as heparan sulfate. This binding is due to the
interaction of positively charged residues in the N-terminal tails of the core histones
(102). In particular, anti-DNA and nucleosome specific antibodies are
nephritogenic, since they neutralize the negative charges in dsDNA within the
nucleosome (82). Deposition of these complexes in the glomerular basement
membrane (GBM) incites glomerulonephritis, the most serious manifestation of
SLE (Figure 1). The discussion of the characteristics of this nucleosome mediated
autoantibody binding to the GBM is beyond the scope of this review. In this article
we will focus on the mechanisms that are thought to be involved in the formation of
autoantibodies against chromatin/nucleosomes.
Dysregulated apoptosis
Apoptosis is the process of programmed cell death. During apoptosis
intracellular structures, including the nucleus, are broken down via certain pathways
by specific enzymes. It is specific for apoptosis that chromatin is cleaved into
nucleosomes by specific Dnases. This pleads for a possible connection between
apoptosis and SLE. Indeed, it now seems clear that a disturbance in the apoptotic
process is important in the induction of an anti-chromatin immune response (103). 
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One of the pathways which leads to apoptosis involves Fas (CD95) and Fas
ligand (FasL). Fas and its specific ligand are cell-surface proteins and their
interaction triggers a cascade of intracellular events that results in apoptosis of the
Fas-expressing targets. In contrast to FasL, which is only expressed on immune
cells, expression of Fas is more widespread. Mouse models with abnormalities in the
Fas/Fas ligand system initially showed the relation between disturbed apoptosis and
SLE. Mutations in the genes encoding Fas or FasL, termed lpr and gld, respectively,
give rise to both lymphoproliferation and autoimmune disorders (104-106), which
could be prevented by transgenic correction of the respective deficiencies (107).
Inhibition of Fas-mediated apoptosis by the injection of soluble Fas into CD1 female
mice also resulted in autoimmunity (108). Fas-FasL interactions are involved in the
elimination of peripheral anergic or self-reactive B cells. An insufficient elimination
could lead to the survival of autoreactive lymphocytes and consequently cause
autoimmune phenomena. It is important to note that lpr or gld mutations alone do
not cause, but accelerate, lupus-like syndromes, while this depends on the
background in which the mutation is generated. Overexpression of Bcl-2, an
inhibitor of apoptosis, is another example of disturbed apoptosis leading to
autoimmunity. Here, the overexpression leads to an increased number of
autoreactive B cells and autoimmunity (109). Altogether, these mouse models
indicate that a disturbed apoptosis can lead to SLE. 
In humans, however, the evidence for a disturbed apoptosis is not so clear.
Patients with a defect in the Fas molecule or Fas-ligand develop a non-malignant
lymphoproliferation accompanied by haemolytic anaemia, the so called
autoimmune lymphoproliferation syndrome (ALPS) (110). Only a quarter of the
patients develop anti-nuclear autoantibodies. In humans with SLE, the Fas-
dependent pathway appears to be unaffected (110). However, some evidence points
to a dysregulation of apoptosis at another level. In SLE patients, the soluble form of
Fas appeared to be upregulated (111, 112), although others report no or little
evidence of any elevation in serum levels of soluble Fas (113-115). In addition, Bcl-
2 expression was increased (116) and the fraction of peripheral blood lymphocytes
expressing Fas was increased (117). Moreover, elevated levels of apoptotic cells (47,
48) and an increased rate of in vitro apoptosis of mononuclear blood cells (118, 119)
were found. However, these results did not always correlate with disease activity
and similar data have been obtained in non-SLE patients. If the rate of apoptosis
really is increased in patients with lupus this phenomenon may be explained by an
elevated number of circulating lymphocytes prone to apoptosis. In conclusion,
unlike murine models of lupus, evidence of disturbed apoptosis in patients with SLE
is somewhat conflicting and thus its contribution to the pathogenesis of the disease
has to be clarified.
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Disposal of apoptotic material
In addition to an increased rate of apoptosis, as described above, elevated
levels of nucleosomes might result from an impaired phagocytosis of apoptotic
material. The linkage between the source of autoantigens and apoptosis made us (11)
and others (120) believe that a defective or impaired phagocytosis of apoptotic cells
underlies the generation of autoantibodies in SLE. Rosen et al. described
autoantigens, such as nucleosomes, becoming clustered in blebs on the surface of
apoptotic keratinocytes after exposure to UV light (36). These autoantigens may
become extra immunogenic, since they can be modified by several processes
operative during apoptosis (detailed below), so it is important that clearance is fast
and efficient. Normally, apoptotic cells are recognized by phagocytic cells at an
early stage of apoptosis. Surface changes on the apoptotic cell, such as flipping of
phosphadityl serine (PS) from the inside to the outside of the cell membrane, mark
the cell for clearance. Several receptors on the phagocyte are involved in the
recognition of apoptotic cells, but the whole process is far from clear at this moment
(121).
In addition to a direct contact of receptor and ligand, a role for mediators has
been described. These are molecules like C1q, b2- glycoprotein I, thrombospondin,
C-reactive protein (CRP) and serum amyloid P (SAP). Their relevance for an
adequate removal of apoptotic cells is underlined by several high-impact studies
using knock-out mice. These studies are summarized in Table I. C1q can bind
directly and specifically to surface blebs of apoptotic human keratinocytes in vitro
and in vivo (122, 123), thereby facilitating clearance of apoptotic material.
Homozygous deficiency of C1q in mice (129.C57Bl/6) resulted in the development
of antinuclear antibodies and glomerulonephritis in 25% of the mice at 8 months of
age (124). These mice also showed an increase in apoptotic bodies in the
glomerulus. Indeed, clearance of apoptotic cells after i.p. inoculation was less
efficient in these C1q-deficient mice (125). However, no difference in the rate of
clearance of apoptotic keratinocytes could be observed between C1q knock-out and
wild-type mice (126). Thus, this suggests that C1q is not required for the clearance
of apoptotic keratinocytes. Deficiency of C1q alone is not sufficient for
development of autoimmunity, since other genetic factors are also needed. In these
C1q deficient mice the background is of great importance. Mice with the disrupted
C1q gene were backcrossed for seven generations into C57Bl/6 and MRL/+ strains.
This MRL/+ strain is the background of the earlier mentioned lpr (Fas) mutation,
which develops autoimmunity at a later age than MRL/lpr mice. Fas and/or C1q-
deficient C57Bl/6 mice showed absolutely no autoimmunity, but in C1q-deficient
MRL/+ mice an acceleration of autoimmunity was observed (126). Disease was
particularly pronounced in female mice, as in human SLE patients. Only a minor
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decrease of in vivo clearance of apoptotic cells by activated macrophages was found.
In humans a C1q-deficiency is strongly associated with SLE. Monocyte-derived
macrophages of a C1q-deficient patient displayed a defective clearance of apoptotic
Jurkat T cells in vitro . Purified C1q could correct this in a dose-dependent manner.
Antibodies to C1q have been detected in lupus mice (127) and SLE patients, which
correlated with disease activity and nephritis (128). These antibodies could block the
protective function of C1q, by preventing binding of C1q to apoptotic cells.
Beside C1q, priming of apoptotic cells for phagocytosis is also mediated by
serum IgM. Mice deficient for serum IgM developed an autoimmune response and
glomerular deposits after 12-18 months, but no glomerulonephritis was observed
(134). When secretion of IgM was blocked in MRL/lpr mice an enhanced
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production of IgG antibodies to dsDNA occurred, with more abundant deposits of
immune complexes in the glomeruli leading to a more severe form of
glomerulonephritis (132). However, selective IgM deficiency in humans has been
described only rarely and is not associated with systemic autoimmunity. Serum
amyloid P (SAP) is another mediator related to the removal of apoptotic cells. SAP
binds in vivo to apoptotic cells, apoptotic blebs and chromatin, thereby preventing
recognition by the immune system of these autoantigens. SAP also provides a
clearance mechanism through opsonization by polymorphonuclear leukocytes
(PMN), since it also binds to Fcγ-receptors (135). SAP-deficient mice develop an
anti-chromatin response, severe glomerulo-nephritis at 8 months in 4% of the male
and 42% of the female mice (129). However, another study showed that SAP-
deficient mice had high anti-chromatin antibody titres, but no severe
glomerulonephritis (130). This latter study suggested an important role for SAP in
preventing LPS toxicity rather than autoimmunity. SAP-deficient mice also showed
an enhanced anti-chromatin response upon immunization with chromatin from
chicken erythrocytes. These findings indicate that SAP plays an important role in the
regulation of chromatin disposal. Indeed, the presence of SAP/DNA complexes is
lower in SLE patients compared with healthy controls, especially in patients with
high anti-DNA antibody titres (136). SLE patients have a normal level of circulating
SAP, but CRP, functionally related to SAP, is decreased during flares in SLE (137). 
In addition to processes that protect or prime chromatin for disposal,
impaired degradation of chromatin is another process that may be involved in the
developmentof SLE. DNaseI is an important enzyme involved in the degradation of
chromatin by cleavage of dsDNA. It is also the major nuclease in serum and is
present at sites of high cell turnover. Mice deficient for DNaseI showed an anti-
chromatin antibody response and glomerulonephritis at 8 months (131). This was
more evident in female (31%) than in male (19%) mice. Recently, a mutation in
exon 2 of the DNaseI gene was found in 2 SLE patients (138). These patients
showed an extremely high titre of IgG antibodies against nucleosomal antigens. It is
known that DNaseI activity is decreased in murine and human lupus (139), but
treatment with recombinant DNaseI failed to attenuate glomerulonephritis (140).
These findings suggest an important role for DNaseI in the development of anti-
chromatin responses in SLE. Moreover, DNaseI is involved in the induction of
apoptosis by cleavage of chromatin into nucleosomes, as was described above. 
Very recently, the involvement of a new receptor for the clearance of
apoptotic cells has been described. Macrophages of knock-out mice with a truncated
cytoplasmic tail of the Mer receptor tyrosine kinase (merkd) showed a defect in the
clearance of apoptotic cells (133). Earlier it has been shown that the protein encoded
by growth arrest-specific gene 6 (GAS6), a ligand for the Mer receptor, mediated the
binding of phosphatidyl serine to macrophages (141). Mice with a defective Mer
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receptor, which were injected with dexamethasone to induce apoptosis of cortical
thymocytes, showed a seven-fold increase in the number of apoptotic cells
compared with wild-type mice. A difference in the rate of apoptosis was eliminated
as an explanation. Moreover, injection of fluorescent-labeled apoptotic thymocytes
intraperitoneally or intravenously confirmed that mice with the abnormal Mer
receptor could not adequately phagocytose these cells. The impairment of
phagocytosis was not due to an inability to bind apoptotic cells, because binding did
not differ between wild-type and Mer-deficient macrophages, but only macrophages
from wild-type mice were able to ingest apoptotic thymocytes. Interestingly, more
than 50% of the merkd mice showed autoimmunity against DNA at 4-5 months of age
(similar to MRL/lpr mice) (133). Macrophages of SLE patients have been shown to
have a decreased ability to phagocytose apoptotic cells (44). Instead of being a
cause, this can also be a secondary effect of the disease, because nucleosomes (52)
and autoantibodies can inhibit the binding of apoptotic cells to phagocytes. We
analysed the phagocytosis in premorbid SLE mice with an newly developed assay
(142). No constitutive defect could be found in these mice (42), however in lupus
mice phagocytosis was impaired (96). 
In conclusion, these studies in knock-out mice provide strong evidence for
the contribution of a disturbed disposal of apoptotic cells in the triggering of an anti-
chromatin response, and the subsequent development of glomerulonephritis.
Modification of autoantigens
Disturbances in apoptosis or phagocytosis of apoptotic cells are a plausible
cause for an increased release of apoptotic material. Still, self-antigens are released,
which should not be recognized by the immune system. An explanation for the
development of autoantibodies could be modifications on these autoantigens during
apoptosis. Although tolerance may be intact for the unmodified autoantigen, the
modified antigens may fail to tolerize T cells.
Various modifications on known autoantigens have been described to occur
specifically during apoptosis (16, 143). Importantly, chromatin is also susceptible to
modifying enzymes. Most of these modifications are related to the functions of
chromatin in the regulation of transcription, but several have also been shown to
occur during apoptosis. Constituents of chromatin, proteins and dsDNA can be
modified. Histone acetylation has an important role in maintaining chromatin
transcriptional activity, but also in DNA replication and DNA repair. Deacetylation
is linked to transcriptionally inactive chromatin parts. The core histones are
reversibly acetylated at specific lysine residues located in the N-terminal tail
domains, and specific acetylation patterns may have a specific function.
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Involvement of histone hyperacetylation in the triggering of apoptosis has been
described (23), in contrast to deacetylation of chromatin, which occurs during
inactivation of transcription. Phosphorylation of histones plays an important role in
regulation of transcription and has also been linked to apoptosis (144). The core
histones and H1 undergo phosphorylation at specific serine and threonine residues.
In particular, histone H3 is known to contain several sites which can be
phosphorylated. Phosphorylation of serines 10 and 28 on histone H3 has been
coupled to mitotic chromatin condensation (145). Histone H2B (22) and H1 (30,
144) have been shown to be (de)phosphorylated during apoptosis. Interestingly,
other phosphorylated or dephosphorylated intracellular proteins have been shown to
be specifically recognized by sera from SLE patients (143, 146). Indeed,
immunoprecipitation of 32P-labeled apoptotic Jurkat cells using sera derived from
SLE patients revealed different proteins, depending on the patient. In some patients
proteins between 12 and 17 kD were also found, which could point to the presence
of phosphorylated histones. Histone methylation has different functions that range
from transcriptional regulation to the higher-order packaging of chromatin. Histone
methylation can occur on arginine or lysine residues, at specific positions in the N-
termini of histones H3 and H4. Thus, methylation joins acetylation and
phosphorylation as a third component of a ‘histone code’ that modifies the
chromatin structure. Methylation of histones has not yet been reported during
apoptosis.
In addition to these three described modifications, other protein
modifications such as citrullination, transglutaminase cross-linking and poly(ADP-
ribosyl)ation may be important. Differences in the state of poly(ADP-ribosyl)ation
have been described in relation to apoptosis (29). Autoimmunity to ubiquitin or
ubiquitinated proteins has been reported in SLE (147, 148). A ubiquitin molecule is
attached to the C-termini of histone H2A and H2B (148). Another described
modification related to autoimmunity is citrullination, a posttranslationally
modified arginine. Citrullin is specifically recognized by autoantibodies from
rheumatoid arthritis patients (149). The expression of transglutaminase, which
crosslinks proteins, has been observed during apoptosis. The role of crosslinking
here may be the stabilization of apoptotic bodies, thus preventing the leakage of
their content. Substrates of transglutaminase targeted in autoimmune disorders
include histone H2B (150). Besides histones, DNA is also modified during
apoptosis, including abnormal DNA methylation and CG contents which make DNA
more immunogenic (34). Exposure to reactive oxygen species (ROS) or UV-light
may also induce immunogenic DNA modifications (151). 
Caspases cleave several proteins that are necessary for the execution of
apoptosis. The cleavage products are often targets for lupus autoantibodies and are
in most cases better recognized than the original protein (152). Recently, granzyme
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B, one of the proteases involved in apoptosis induced by cytotoxic T cells, was
found to be involved. The susceptibility of autoantigens to cleavage in unique
fragments by granzyme B may be predictive for a protein to become an autoantigen
(16). The precise role of chromatin modifications in the induction of an anti-
chromatin autoimmune response remains to be investigated further, as has been
found for non-nucleosomal chromatin-proteins (153). 
Immunogenicity of chromatin
Although dsDNA often is regarded as the major autoantigen in SLE, in vivo
DNA has only been found complexed to histones in human and murine lupus (49).
T helper cells specific for chromatin, especially histones, have been detected in
human and murine lupus (55, 56), which also indicates that nucleosomes rather than
dsDNA were driving the autoimmune response in SLE. Indeed, these nucleosome-
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Figure 1. Hypothesis for the development of anti-chromatin responses in systemic lupus
erythematosus. (1) Disturbed apoptosis either at the wrong timepoint and/or at the wrong micro-
environment; (2) defective removal of apoptotic cells leading to the release of apoptotic blebs
containing chromatin; (3) stimulation of immune response by chromatin; (4) formation of anti-
chromatin/chromatin complexes; (5) binding of these complexes to heparan sulfate in basal
membranes due to interaction between the cationic N-termini of the core histones and the anionic
heparan sulfate.
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specific T cells can also induce autoantibodies to dsDNA and chromatin by epitope
spreading (54). Antibodies which react specifically with nucleosomes, not with
DNA or histones alone, have been detected in lupus mice(84, 154) and patients (64,
65). Formation of nucleosome-specific antibodies appeared to precede the anti-DNA
and anti-histone response (84, 154). Most SLE patients that have nucleosome-
specific antibodies also have anti-DNA and anti-histone antibodies. Nucleosome-
specific antibodies without other anti-chromatin antibodies have been found in 16-
30% of the patients. Although there are at present no large prospective analyses
available on the diagnostic accuracy of anti-nucleosome antibodies, in two recent
retrospective studies a good correlation was found with disease activity and the
occurrence of lupus nephritis (12, 70). There was even a claim that anti-nucleosome
reactivity was a better marker than anti-DNA (70). Normally, uptake of apoptotic
cells induces an anti-inflammatory response of macrophages (155). Efficient
engulfment of apoptotic cells, prior to their lysis, is critical for the suppression of
inflammation. When apoptotic cells are recognized by macrophages, production of
proinflamatory mediators is downregulated. Such anti-inflammatory mediators
profoundly influence whether an immune response will be activated. 
Dentritic cells (DCs) are also able to phagocytose apoptotic cells, although
less efficiently than macrophages. The DCs can probably mature and present the
autoantigens derived from apoptotic cells. So, delayed clearance of apoptotic cells
may result in uptake by DCs and presentation to T cells. Modified forms of
autoantigen might enhance the response of the immune system after presentation on
DCs. Beside presentation of modified forms of nucleosomal peptides, a defective
function of antigen-presenting cells could be involved. Abnormalities in APC
surface membrane molecules, such as B7 and IgG Fc-receptors, were found in SLE
(156, 157). Breakdown of selftolerance may be enhanced by viral infections. The
relation between SLE and viral infection has been shown in various studies (158,
159). In addition, the viral T antigen of polyomavirus BK could bind to mammalian
DNA and enhanced immunogenicity (160). Viral antigens also become clustered in
apoptotic blebs together with chromatin and other autoantigens (161). In conclusion,
chromatin is the major autoantigen in SLE, and its immunogenicity might be
enhanced by chromatin modifications, defective presentation by antigen-presenting
cells or viral infections.
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Conclusion
The importance of chromatin and anti-chromatin autoantibodies for SLE has
been proven by the detection of nucleosome-specific T helper cells and nucleosome-
specific autoantibodies. Importantly, nucleosome/anti-nucleosome complexes can
bind to the glomerular basement membrane, which induces lupus nephritis, the most
serious disease manifestation in SLE (102).The trigger for the production of anti-
chromatin autoantibodies remains to be discovered and is most likely multi-
factorial, including genetic susceptibility. The genetic basis of SLE has been
investigated by several studies. In mice several genes have been linked to the
susceptibility to develop SLE. In the NZW/NZB-related NZM2410 lupus-prone
strain three recessive loci (Sle1, Sle2 and Sle3) have been strongly associated with
SLE-susceptibility (162). Characterization of strains containing one of these
susceptibility loci resulted in the linking of Sle1 with the loss of tolerance to nuclear
antigens, especially for the H2A-H2B/DNA subnucleosome particle. Sle2 lowers the
threshold of B cells and Sle3 mediates T cell dysregulation. Studies of combinations
of these loci have shown that loss of tolerance to chromatin mediated by Sle1 is
essential for development of disease. The co-expression of Sle1, Sle2 and Sle3
resulted in systemic autoimmunity and fatal glomerulonephritis (163). 
The exclusive formation of nucleosomes in apoptosis has put the focus on
the relation between apoptosis and SLE. Mouse models with an abnormal apoptotic
process (MRL/lpr, gld) develop lupus-like disease features. Recently, several studies
with mouse models deficient for molecules involved in the removal of apoptotic
cells have proven the importance of this process for the induction of autoimmunity.
Most of these mice developed an anti-chromatin response and sometimes
glomerulonephritis. In addition to a defect in the removal of chromatin,
modifications of histones or DNA induced during apoptosis, altered presentation by
APCs or a viral infection might increase the chance that the immune system
develops a response to chromatin. Since SLE is a multi-factorial disease, even more
factors may be involved and most likely a cascade of functions needs to be altered.
More research has to be performed to identify the finger that pulls the trigger.
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Abstract
Systemic lupus erythematosus (SLE) is an autoantigen driven and T cell-
dependent autoimmune disease, in which the nucleosome has been identified as a
major autoantigen. In lupus an inadequate removal of apoptotic cells may lead to the
challenge of the immune system with immunogenic self-antigens that have been
modified during apoptosis. Using different approaches, we demonstrated that a lupus-
derived monoclonal antibody specifically recognizes apoptosis-induced acetylation of
histones H4 and H2A. In addition, plasmas from both lupus patients and mice showed
a higher reactivity with hyperacetylated histones extracted from cells treated with a
histone deacetylase inhibitor or an apoptosis inducer. Importantly, administration of a
histone H4 peptide containing the identified apoptosis-induced acetylation motif to
pre-diseased lupus-prone mice accelerated the disease, and aggravated mortality,
proteinuria, skin lesions and glomerular IgG depositions. Administration of the
corresponding non-acetylated histone H4 peptide had no pathogenic effect.
Furthermore, the delayed type hypersensitivity response in lupus mice against the tri-
acetylated histone H4 peptide was higher than against the non-acetylated histone H4
peptide, while BALB/c mice did not show a response. Therefore, we conclude that
apoptosis-induced histone acetylation represents an important driving force in the
autoimmune response in lupus.
The formation of autoantibodies against chromatin components (i.e.DNA, histones, and nucleosomes) is a major feature of systemic lupus
erythematosus (SLE), an autoantigen driven, T cell-dependent autoimmune disease
that affects millions of people world-wide. In SLE, the nucleosome is a major
autoantigen, and nucleosome and histone-specific autoreactive T and B cells have
been identified (64). Years before clinical manifestation of the disease anti-nuclear
antibodies can be detected in the circulation of future SLE patients (164). Anti-
chromatin autoantibodies in complex with chromatin are targeted to basement
membranes, including the dermal and the glomerular basement membrane. The
deposition of chromatin-containing immune complexes incites glomerular
inflammation, which is one of the most serious clinical manifestations of SLE (82,
94, 99, 165).
Nucleosomes can be detected in the circulation during disease in lupus
patients and mice (49-51). There is evidence that in lupus either an aberrant
apoptosis or a reduced clearance of apoptotic cells, or a combination of both, leads
to an overflow of the cleaning machinery and the presence of apoptotic chromatin
in the circulation (39, 40). The contribution of an aberrant apoptosis for the
development of SLE is supported by mouse models with an abnormal function of
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factors involved in apoptosis. Deficiency of Fas (lpr), FasL (gld), Bcl2/Bim,
PDCD1, PTEN, BLyS, and TACI leads to the formation of anti-nuclear antibodies
and glomerulonephritis (105, 106, 109, 166-170). In addition, an impaired removal
of apoptotic cells also predisposes to the development of SLE. Mice deficient in
factors required for a proper clearance of apoptotic cells such as DNaseI, SAP/CRP,
C1q, IgM and Mer develop anti-nucleosome autoantibodies and glomerulonephritis
(40, 124, 129, 131, 133, 134). Most importantly, it has been demonstrated that the
clearance of apoptotic material by phagocytes is impaired in both lupus patients and
mice (44, 96). 
Autoantigens targeted in SLE are clustered in blebs at the surface of late
apoptotic cells (36, 37). Autoantigens may contain apoptosis-induced modifications
that constitute epitopes that normally are not encountered by the immune system
when clearance of apoptotic cells is adequate. Apoptosis-induced autoantigen
modifications include cleavage by caspases, endonucleases or granzyme B (16, 17).
Furthermore, autoantigens may be modified by the addition or removal of covalently
linked moieties through acetylation, methylation, phosphorylation, ubiquitination,
citrullination, ADP-ribosylation or transglutamination (17, 290). These covalently
linked modifications have also been reported for nucleosomes/histones, but not
exclusively and uniformly in the context of apoptosis, and primarily in the context
of regulation of transcription (291). Although it has been demonstrated that
apoptotic cells may induce a lupus-like immune response, nothing is known about
apoptosis-induced chromatin modifications as targets for autoantibodies in SLE (58,
171-173). 
We show here that a monoclonal lupus-derived autoantibody specifically
recognizes histone H4 peptides acetylated at lysine residues 8 and/or 12 and/or 16.
Furthermore, plasmas from lupus mice and patients showed a higher reactivity with
acetylated H4 peptides and hyperacetylated histones extracted from cells that were
treated with either a histone deacetylase inhibitor or an apoptosis inducer. Most
importantly, administration of a H4 peptide tri-acetylated at lysine residues 8, 12 and
16 accelerated disease development in MRL/lpr mice, while administration of a non-
acetylated H4 peptide had no effect. Finally, in lupus mice the delayed type
hypersensitivity response against the tri-acetylated H4 peptide was higher than
against the non-acetylated H4 peptide.
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Materials & Methods
Cell culture, inhibition of histone deacetylases and induction of apoptosis.
Jurkat or U937 cells were routinely cultured. To inhibit histone deacetylase
activity, cells, at a concentration of 4*105 cells/ml, were treated with 100 ng/ml TSA
(Biomol) for 16 hours. To induce apoptosis, cells, at a concentration of 2*105/ml
were treated with 2 µg/ml camptothecin (CPT) (Sigma) or anti-Fas antibody diluted
1:1000 (Sigma) for the indicated periods of time. The progress of apoptosis was
determined by analyzing AnnexinV-FITC binding and Propidium Iodide staining
with flow cytometry.
Antibodies and random peptide phage display epitope mapping. 
KM-2 is a monoclonal anti-histone autoantibody derived from the MRL/lpr
lupus mouse, which recognizes the N-terminal tails of histone H2A and histone H4
(95). The exact epitope of KM-2 was determined by screening a 15-mer random
peptide phage display library (New England Biolabs) according to the
manufacturer's instructions. Other antibodies used in this study were #34, which
solely recognizes unmodified histone H3.1/H3.2 (98), and antibodies specific for
histone H4 acetylated at lysine residues 5, 8, 12 and/or 16, histone H2A acetylated
at lysine residues 5 or 9, histone H2B phosphorylated at serine residue 14, and CBP
(Upstate), actin, caspase-3, PCAF, HDAC1 and p300 (Santa Cruz).
Peptide, dsDNA and nucleosome ELISA. 
Peptides used in this study were either synthesized by the peptide synthesis
facility of the CNRS in Strasbourg or commercially obtained (Eurosequence B.V.)
and in all cases analyzed for integrity and purity by HPLC and mass spectrometry.
The reactivity of KM-2 (starting at a concentration of 5 µg/ml) and plasmas from
both MRL/lpr lupus mice and SLE patients (diluted 1:100) with coated peptides in
ELISA was tested as described previously (97). The use of plasma from SLE
patients was approved by the local ethical committee of the Radboud University
Nijmegen Medical Centre. For detection, the appropriate horseradish peroxidase-
conjugated antibody (Southern Biotechnology Associates) was used. For the peptide
inhibition ELISA, KM-2 was incubated in a 96-wells plate with different
concentrations of inhibiting peptides for 1 hour and then transferred to Maxisorb®
96-well plates (NUNC) coated with 2 µM non-acetylated histone H4 peptide and
incubated for 1 hour and an appropriate horseradish peroxidase-conjugated antibody
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was used. Histone, dsDNA and nucleosome ELISA were performed as described
previously (97).
Preparation of cell extracts, extraction of histones, and protein determination. 
For analysis of histones, total cell extracts were prepared directly from PBS-
washed and pelleted cells (2*105) in 250 µl Laemmli buffer followed by boiling for
5 min. Alternatively, total cell extracts were prepared by lysing PBS-washed and
pelleted cells (2*105) in 250µl lysis buffer (250 mM NaCl, 0.1% NP-40, 0.5 mM
dithiothreitol (DTT), 50 mM HEPES pH 7.0, 5 mM EDTA) containing a cocktail of
protease inhibitors (Roche) and sonicated on ice two times with bursts of 15 s.
Subsequently, histones were extracted with 0.2 M H2SO4, precipitated with 20%
TCA and washed with ice-cold, acidified (0.1% HCl) acetone and the pellet was
dissolved in 100 µl of 100 mM Tris.HCl pH 8.0. For histone acetyltransferase (HAT)
and histone deacetylase (HDAC) activity assays, total cell extracts were prepared in
ELB lysis buffer (without DTT), sonicated on ice two times with burst of 15 s, and
cellular debris was removed by centrifugation at 14,000 x g at 4°C for 10 min.
Protein concentration was determined by the Bicinchoninic acid assay (Sigma) with
BSA as a standard.
SDS-PAGE, Western blotting and immunofluorescence staining of cells. 
Proteins resolved by SDS-PAGE were transferred to nitrocellulose blots and
were probed with the indicated primary antibody. Blots were incubated with an
appropriate horseradish peroxidase-conjugated antibody (Southern Biotechnology
Associates). Finally, blots were developed using ECL (Amersham) and exposed to
Hyperfilm ECL X-ray films (Amersham). Cytospinned cells were fixed with 2%
paraformaldehyde, and permeabilized with 0.5% Triton X-100. Cells were incubated
with the indicated primary antibodies and an appropriate Alexa-488 conjugated
antibody (Molecular Probes) was used. DAPI and TUNEL (Roche) staining were
performed according to the manufacturer's instructions.
Histone acetyltransferase (HAT) and histone deacetylase (HDAC) activity
assays.
HAT activity was measured using the HAT activity Assay Kit (Biovision)
and HDAC activity was measured using the HDAC Fluorescent Activity Assay Kit
(Biomol) according to the manufacturer's protocols. 
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Mice and evaluation of albuminuria, DTH and IgG deposition. 
Eight-weeks-old MRL/lpr or BALB/c mice (Jackson Laboratory) were
injected subcutaneously with non-acetylated histone H4 peptide (residues 1-22), the
same histone H4 peptide tri-acetylated at lysine residues 8, 12 and 16, or PBS. Mice
received 100 µg peptide or PBS emulsified in CFA once and three booster injections
with 100 µg in IFA at 2 week intervals. Plasmas and urine were collected weekly.
Albuminuria was tested using Albustix (Bayer). Delayed type hypersensitivity
(DTH) was performed as described (174). Glomerular IgG depositions were
visualized in 2 µm frozen section of diseased mice by immunofluorescent staining
with Alexa-488 conjugated anti-mouse IgG antibody. For each group 50 glomeruli
were blindly scored on a scale from 0 to 3 by three independent observers.
Experimental handling of the animals was approved by the local animal ethical
committee of the Radboud University Nijmegen Medical Centre.
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Results
Identification of the epitope for the lupus-derived monoclonal
autoantibody KM-2
According to our hypothesis apoptosis-induced post-translational
modifications of histones may play an important role in the initial immune response
against chromatin in lupus. Therefore, we started to map the epitope of the lupus-
derived mouse monoclonal autoantibody KM-2. Previously, we showed that KM-2
reacts in ELISA with both a histone H4 peptide (residues 1-29) and a histone H2A
peptide (residues 1-20), which are very similar in amino acid sequence (95). KM-2
also reacts with whole histone H4 and histone H2A. Here, we applied the random
peptide phage display method to map precisely the epitope of KM-2, which yielded
the amino acid sequence RGGLGLVNGRSLRH. Amino acid sequence analysis
revealed 71.4% similarity with histone H4 (i.e. residues 5-KGGKGLGKGGAKRH-
18) and a much lower similarity of 42.8% with histone H2A (i.e. residues 6-
QGGKARAKAKSRSS-19). However, the positively charged lysine residues at
positions 8, 12 and 16 (K8, K12 and K16), which are normally present in histone
H4, could not be found in the identified motif. This result suggested that in the
epitope for KM-2 these lysine residues could be modified, i.e. acetylated, and
therefore were not identified by the random peptide phage display technique, which
makes use of a bacterial host not capable of histone acetylation by definition.
Therefore, the reactivity of KM-2 was determined with synthetic histone H4
peptides (residues 1-22), either non-acetylated or acetylated at K5, K8, K12 and/or
K16, directly coated in ELISA (Fig. 1A). Compared to the non-acetylated histone
H4 peptide, KM-2 showed an enhanced reactivity with histone H4 peptides
acetylated at K8, K12 and/or K16, while the acetylation of K5 did prevent the
binding of KM-2. In addition, an inhibition ELISA with competitor peptides in
solution was performed to rule out possible differences in coating efficiency. This
revealed that the reactivity of KM-2 with the non-acetylated histone H4 peptide was
strongly inhibited by histone H4 peptides acetylated at K8, K12 and/or K16, while
histone H4 peptides that were acetylated at K5 did not inhibit KM-2 binding (Fig.
1B).
To test whether KM-2 could also react with acetylated histone H4 in situ we
stained Jurkat cells that were either untreated or treated with Trichostatin A (TSA),
which is a specific histone deacetylase (HDAC) inhibitor that results in
hyperacetylation of histones. Staining of untreated cells with KM-2 revealed a weak,
fine granular nuclear staining that clearly increased after TSA treatment. A similar
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result was obtained by staining with commercially available antibodies that are
specific for histone H4 acetylated at K8 and K12, i.e. anti-H4-AcK8 and anti-H4-
AcK12 (Fig. 1C). In addition, acid-extracted histones derived from TSA-treated
Jurkat cells were resolved and blots were probed with KM-2, anti-H4-AcK8 and
anti-H4-AcK12 antibodies. TSA treatment strongly enhanced the reactivity of all
these antibodies with histone H4. As expected, using anti-H4-AcK5 and anti-H4-
AcK16 gave similar results (unpublished data). In addition to histone H4, the
reactivity of KM-2 with histone H2A was increased upon TSA treatment.
Apparently, the region within H2A that is homologous to the identified epitope motif
and the N-terminal region of histone H4 includes one or more residues that can be
acetylated (Fig. 1D). 
Taken these data together, the primary epitope for the monoclonal lupus-
derived autoantibody KM-2 is located within the N-terminal tail of histone H4 and
includes acetylated lysine residues at position 8 and/or 12 and/or 16.
Lupus-derived autoantibodies recognize apoptosis-induced histone
modifications
Since apoptosis-induced histone modifications may be the targets for lupus
autoantibodies, the reactivity of KM-2 was tested with equally loaded histones
extracted from both normal and apoptotic Jurkat cells. Apoptosis was induced by 4
hours incubation with camptothecin (CPT), a DNA topoisomerase I inhibitor. Cells
were either directly dissolved in Laemmli sample buffer or extracted by sulphuric
acid to ensure that all histones were efficiently extracted and recovered for analysis.
Induction of apoptosis clearly enhanced the reactivity of KM-2 with both histone H4
and histone H2A (Fig. 2A). Commercially available antibodies that are specific for
different acetylated forms of histone H4 or histone H2A also showed an enhanced
reactivity with histone H4 or histone H2A derived from apoptotic cells. As a control
we included an antibody specific for histone H2B phosphorylated at serine residue
14, which is a well-established apoptosis-induced histone modification that is also
associated with double stranded DNA breaks  (18, 292). Indeed, this latter antibody
also showed an enhanced reactivity with apoptotic histone H2B. On the other hand,
the reactivity of another monoclonal lupus-derived autoantibody, which is specific
for unmodified histone H3.1/3.2 variants (98), was not different for normal and
apoptotic cells (Fig. 2A). Immunofluorescent double staining of both normal and
apoptotic Jurkat cells by KM-2 and TUNEL, which stains for apoptotic DNA
fragmentation, clearly revealed co-staining, especially of apoptotic blebs (Fig. 2B).
The reactivity of KM-2 was also analyzed with histone H4 and histone H2A
extracted from normal and Jurkat cells that were apoptotic for different time periods.
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Figure 1. The lupus-derived autoantibody KM-2 recognizes acetylated histone H4. A. Reactivity of
KM-2 with acetylated H4 peptides (residues 1-22). B. Inhibition of binding of KM-2 to non-
acetylated H4 peptide by acetylated H4 peptides. C. Enhanced staining of TSA-treated Jurkat cells
by KM-2, anti-H4K8Ac and anti-H4K12Ac, respectively. D. Enhanced reactivity of KM-2, anti-H4-
AcK8 and anti-H4-AcK12 with acid extracted and equally loaded histones from TSA-treated Jurkat
cells. An antibody specific for actin was used as an internal loading control. 
A
B
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Figure 2. The lupus-derived autoantibody KM2 recognizes apoptosis-induced hyperacetylation of
histones H4 and H2A. A. Enhanced reactivity of KM-2, anti-H4-AcK5, anti-H4-AcK8, anti-H4-
AcK12, anti-H4-AcK16, anti-H2A-AcK5, anti-H2A-AcK9 and anti-H2B-PhS14 with histones
isolated from CPT-induced (for 4h) apoptotic Jurkat cells. An antibody specific for actin was used as 
an internal loading control. (continues next page)
Also anti-FAS-induced apoptotic cells were analyzed to exclude a solely CPT-
specific effect. Already 1 hour after CPT or 4 hours after anti-FAS treatment, the
reactivity of KM-2 with histone H4 and histone H2A increased with a concomitant
cleavage of caspase-3 (Fig. 2, C and D). Notably, one hour after induction of
apoptosis with CPT the percentage of apoptotic cells was still extremely low as
measured by AnnexinV-FITC staining, which indicates that apoptosis-induced
acetylation of histone H4 and histone H2A is a very early event that precedes the
flip-flop of phosphatidyl serine in the lipid bi-layer (Fig. 2, C and D). The enhanced
reactivity of KM-2 with apoptotic histone H4 and histone H2A was not Jurkat-
specific, since similar results were obtained with the monocytic cell line U937
(unpublished data).
We then tested whether apoptosis-induced changes in expression and/or
activity of histone acetyltransferases (HATs) or histone deacetylases (HDACs) could
serve as a mechanistic explanation for the observed hyperacetylation of apoptotic
histones. Indeed, in Jurkat cells an increased expression of the HAT protein p300
could be demonstrated already 1 hour after induction of apoptosis with CPT, while
the expression of the two HAT proteins CBP and pCAF, and the HDAC enzyme
HDAC1 did not change upon induction of apoptosis (Fig. 3A). In addition to protein
expression we also determined total HAT and HDAC activity in both normal and
apoptotic Jurkat cells. It appeared that total HDAC activity was significantly lower
4 hours after induction of apoptosis in either CPT- or anti-FAS induced apoptotic
Jurkat cells, while total HAT activity was significantly increased in the CPT-treated
cells, but not in the anti-FAS-treated apoptotic Jurkat cells (Fig. 3B). Taken together,
the apoptosis-induced hyperacetylation of histone H4 and histone H2A, which is
recognized by the lupus-derived autoantibody KM-2, is most likely mediated by an
increased HAT activity and/or a decreased HDAC activity. 
To extend the findings obtained with the lupus-derived monoclonal
autoantibody KM-2, the reactivity of plasmas derived from 6-9-weeks-old (pre-
diseased) and 20-weeks-old (diseased) MRL/lpr lupus mice with non-acetylated and
acetylated histone H4 peptides (residues 1-22) was tested in ELISA and expressed
as a ratio (acetylated/non-acetylated). Plasmas from both pre-diseased and diseased
lupus mice showed a significantly higher reactivity with histone H4 peptides
acetylated at K8, K12 or K16 compared to the non-acetylated histone H4 peptide,
i.e. the ratio acetylated/non-acetylated was significantly higher than 1, while the
reactivity with histone H4 peptide tetra-acetylated at K5, K8, K12 and K16 did not
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B. KM-2 recognizes apoptotic blebs of campthothecin-induced apoptotic Jurkat cells that positively
stain by TUNEL (see arrows). DAPI staining reveals defragmentation of the nucleus. C. and D.
Enhanced reactivity of KM-2 with histones H4 and H2A, extracted from CPT- and anti-Fas-induced
apoptotic Jurkat cells coincides with cleavage of caspase-3. The progress of apoptosis was analyzed
by AnnexinV and Propidium Iodide (PI) staining.  
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Figure 3. Expression and activity of histone acetyltransferases and histone deacetylases in non-
apoptotic and early apoptotic cells. A. Protein expression analysis of histone acetyltransferases CBP,
p300 and P/CAF, and histone deacetylase 1 (HDAC1) in non-apoptotic and campthothecin or anti-
Fas-induced early apoptotic Jurkat cells. An antibody specific for actin was used as an internal
loading control. B. HAT and HDAC activity in non-apoptotic and campthothecin or anti-Fas-induced
early apoptotic Jurkat cells. Significant differences are indicated. 
52
Apoptosis-induced acetylation is pathogenic in lupus
Figure 4. Lupus-derived plasmas recognize acetylated and apoptotic histones. A. Reactivity of
plasmas from pre-diseased (left panel) and diseased (right panel) MRL/lpr lupus mice with
(acetylated) histone H4 peptides (residues 1-22) [p<0.01, p<0.05 compared to non-acetylated]. B.
Reactivity of plasmas from SLE patients with (acetylated) H4 peptides (residues 1-22). C. Enhanced
reactivity of lupus-derived plasmas with histones extracted from both CPT- and TSA-treated Jurkat
cells
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Figure 5. Tri-acetylated histone H4 peptide accelerates disease in MRL/lpr lupus mice. Treatment
of 8-weeks-old MRL/lpr lupus mice with either non-acetylated H4 peptide (residues 1-22; n=7), H4
peptide tri-acetylated at lysine residues 8, 12 and 16 (n=11) or PBS as a control (n=6). A. Tri-
acetylated H4 peptide results in enhanced mortality (p<0.01). B. Tri-acetylated H4 peptide aggravates
proteinuria (p<0.05). C. and D. Tri-acetylated H4 peptide induces early and severe skin lesions
(p<0.05). E. Tri-acetylated H4 peptide enhances glomerular IgG depositions (score 2.1±0.2)
compared to non-acetylated H4 peptide (score 1.3±0.1) and PBS (score 0.8±0.2) treatment (p<0.01).
F. DTH response of 16-18-weeks-old MRL/lpr mice against tri-acetylated H4 peptide is higher than
against non-acetylated H4 peptide in all groups (p<0.05 in all groups). BALB/c mice did not show a
significant DTH response against the H4 peptides. PBS injections gave an average ear swelling of
0.2 mm. 
significantly differ (Fig. 4A, left and right panel). Plasmas from diseased lupus mice
showed reactivity with histone H4 peptide acetylated at K5 similar to the non-
acetylated histone H4 peptide (Fig. 4A, right panel). Therefore, acetylation of
histone H4 at lysine residues 8, 12 and 16 seems to be important. We also tested
plasmas from 6-9-weeks-old (pre-diseased) and 30-weeks-old (diseased)
(NZWxNZB)F1 lupus mice, that have a different MHC haplotype compared to
MRL/lpr lupus mice, but which yielded comparable results (unpublished data). The
reactivity of plasmas from several SLE patients with (acetylated) H4 peptides
revealed on average a 1.5-2-fold enhanced reactivity for all acetylated peptides, but
due to a large variance the observed differences were not statistically significant
(Fig. 4B). Notably, plasmas from MRL/+ control mice and healthy individuals did
not show any reactivity in ELISA with the histone H4 peptides, either acetylated or
non-acetylated (unpublished data). When acid-extracted histones from normal and
apoptotic Jurkat cells were used as a coating in ELISA, a 2-fold higher reactivity of
plasmas from both lupus patients and mice with apoptotic histones compared to non-
apoptotic histones could be demonstrated (unpublished data). Most likely, this
higher reactivity of lupus-derived plasmas with apoptotic histones compared to
normal histones may not only be explained by apoptosis-induced hyperacetylation
of histones but also by other apoptosis-induced histone modifications. Nevertheless,
probing of blots with plasmas from SLE patients revealed an enhanced reactivity of
the vast majority of plasmas with equally loaded and resolved histones H4, H2A,
H2B, H3 (and most likely H1) extracted from both TSA- and CPT-treated Jurkat
cells (Fig. 4C). The superior reactivity with histones derived from CPT-treated cells
compared to histones derived from TSA-treated cells may be explained by other
apoptosis-induced histone modifications. Taken together, lupus-derived plasmas do
recognize apoptosis-induced histone modifications that include histone acetylation.
Tri-acetylated H4 peptide accelerates disease development in lupus
mice
To evaluate whether apoptosis-induced histone acetylation is important for
the pathogenesis of SLE, non-acetylated histone H4 peptide (residues 1-22) and tri-
acetylated (at K8, K12 and K16) histone H4 peptide were subcutaneously
administered to BALB/c and pre-diseased MRL/lpr lupus-prone mice, while PBS-
injected mice were included as a control. Administration of histone H4 peptide,
either acetylated or non-acetylated, to BALB/c mice did not result in autoimmunity
and proteinuria (unpublished data). However, administration of the tri-acetylated
histone H4 peptide to pre-diseased MRL/lpr lupus-prone mice resulted in an
enhanced mortality compared to treatment with the non-acetylated histone H4
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peptide or saline (Fig. 5A). Furthermore, the development of proteinuria and
progression of skin lesions was significantly accelerated and affected more mice in
the group treated with the tri-acetylated histone H4 peptide compared to the saline-
treated or non-acetylated histone H4 peptide-treated groups (Fig. 5, B and C). In
addition, the severity of skin lesions was more pronounced in the group that received
tri-acetylated histone H4 peptide (Fig. 5D). The titers of the anti-dsDNA, anti-
histone and anti-nucleosome antibodies were not significantly different between the
different groups of mice as determined in ELISA (unpublished data). In lupus
glomerular IgG deposition is associated with the development and the severity of
proteinuria. Therefore, we analyzed frozen kidney sections from diseased mice for
the presence of IgG, and scoring on a scale of 0-3 revealed a glomerular IgG-
deposition index of 2.1 (± 0.2) for the group treated with the tri-acetylated histone
H4 peptide, which was significantly (p< 0.01) higher compared to 1.3 (± 0.1) and
0.8 (± 0.2) for the groups treated with the non-acetylated histone H4 peptide or PBS,
respectively (Fig. 5E). Next, we wanted to test whether the acceleration of disease
development by the tri-acetylated histone H4 peptide was associated with specific T
cell activity. Unfortunately, a mixed lymphocyte reaction (MLR) that included
syngeneic antigen presenting cells loaded with (acetylated) histone H4 peptides and
responder cells isolated from spleen and lymph nodes did not yield reliable data
(unpublished data). Therefore, we applied the delayed type hypersensitivity reaction
(DTH). Mice (16-18-weeks-old) pre-treated with the non-acetylated histone H4
peptide, the tri-acetylated histone H4 peptide or PBS, received either non-acetylated
histone H4 peptide or tri-acetylated histone H4 peptide in the left or right ear,
respectively, and subsequently ear swelling was measured after 24 and 48 hours. In
all groups ear swelling induced by the tri-acetylated histone H4 peptide was
significantly greater than the ear swelling induced by the non-acetylated histone H4
peptide (Fig. 5F). Apparently, mice that were pre-treated with only PBS showed
already a higher DTH response against the tri-acetylated histone H4 peptide than
against the non-acetylated histone H4 peptide. Thus, pre-treatment with tri-
acetylated histone H4 peptide did not further increase the DTH response against tri-
acetylated histone H4 peptide. As a control we determined the DTH against the tri-
acetylated and non-acetylated histone H4 peptide in BALB/c mice, which did not
reveal a significant different response against either peptide (Fig. 5F). Taken these
data together, administration of tri-acetylated histone H4 peptide, which corresponds
to the apoptosis-induced epitope for the lupus-derived autoantibody KM-2,
significantly accelerates disease development in MRL/lpr lupus-prone mice.
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Discussion
We show for the first time that a SLE-derived monoclonal autoantibody
(KM-2) shows an enhanced reactivity with hyperacetylated histone H4 and histone
H2A derived from either apoptotic cells or cells treated with a histone deacetylase
inhibitor. Most importantly, the primary epitope for KM-2 seems to be generated by
apoptosis. These observations were not limited to this specific autoantibody but
were also found with plasmas from both lupus patients and mice. Other groups also
have reported that lupus-derived sera show (enhanced) reactivity with apoptotic
histones, however, the nature of these histones was not evaluated (175).
We demonstrate that apoptosis-induced acetylation of histones was mediated by
changes in HDAC and/or HAT expression and/or activity. Both apoptosis-induced
histone deacetylation and acetylation have been described, which in some cases was
associated with changes in the HDAC or HAT activity and/or expression (25-28,
176, 177). These apparently contradictory results may be explained by differences
in applied experimental approaches, i.e. differences in cell types, methods of
apoptosis induction and extraction of histones, and subsequent analysis of histone
acetylation. In this study we have characterized and applied a sensitive tool that was
provided by nature itself, i.e. a lupus-derived monoclonal autoantibody, to analyze
apoptosis-induced histone acetylation. In agreement with our results, cis-platin
induced apoptosis results in global hyperacetylation of histones (25). In addition,
treatment by HDAC inhibitors like TSA, which results in global hyperacetylation of
histones, also leads to apoptosis, while HDAC inhibitors and other inducers of
apoptosis seem to act synergistically in apoptosis induction (177, 293). However, the
apoptosis-inducing capacity of HDAC inhibitors may be explained by the effect of
the induced histone hyperacetylation on the expression of genes operative in
apoptotic pathways or the cell cycle (294, 295), since in general hyperacetylation of
histones leads to a transcriptionally active and open chromatin structure (296). Other
apoptosis-induced histone modifications that have been described include de-
ubiquitination of H2A, transglutamination of H2B, and phosphorylation of H2A,
H2A.X, H2B and H3 at different residues (24). Apoptosis-induced phosphorylated
proteins have been demonstrated to be targets for SLE-derived sera, however
phosphorylated histones were not evaluated (143). As far as we know apoptosis-
induced methylation (or demethylation) or citrullination of histones has not been
assessed yet. This latter modification is of particular importance, since antibodies
specific for citrullinated autoantigens are predictive for the development of
rheumatoid arthritis (149). Nevertheless, until now none of the mentioned apoptosis-
induced histone modifications have been identified as targets of autoantibodies in
SLE.
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Several nucleosomal and/or histone T cell epitopes have been identified for
both lupus mice and patients in H2A, H2B, H3 and H4 (55-58, 178, 227). However,
in all these studies the T cell response was measured by presenting a panel of
unmodified histone peptides, which could have prevented the identification of T cell
epitopes containing modifications. Apoptosis-associated histone modifications that
may be located within the identified lupus T cell epitopes include de-ubiquitinaton
of histone H2A at position 119, phosphorylation of histone H2B at S14, and
acetylation of histone H4 at K16 (this work;18;179). It has been shown that
administration of apoptotic cells or apoptotic cells in combination with either
dendritic cells or incomplete Freund's adjuvant, results in the development of anti-
nucleosome antibodies and proteinuria in both normal and lupus mice (28, 171,
173). Here, we show that administration of a histone H4 peptide tri-acetylated at K8,
K12 and K16 accelerates disease development in pre-diseased lupus-prone mice, as
measured by the survival rate, the presence of glomerular IgG depositions, and the
development of proteinuria and skin lesions. In contrast to lupus-prone mice,
BALB/c mice treated with the tri-acetylated histone H4 peptide failed to develop
autoimmunity, which may be explained by the lack of genetic predisposition.
Importantly, the DTH response in MRL/lpr mice against the tri-acetylated histone
H4 peptide was higher than against the non-acetylated histone H4 peptide and was
independent from the pre-treatment, i.e. saline, non-acetylated histone H4 or tri-
acetylated histone H4 peptide. Moreover, BALB/c mice did not show a DTH
response against either the tri-acetylated or non-acetylated histone H4 peptide.
These findings strongly suggest that the tri-acetylated histone H4 peptide that caries
the apoptosis-associated acetylation motif incites a more vigorous immune response
than the corresponding non-acetylated histone H4 peptide, which depends on the
genetic lupus background. It remains to be established whether in addition to
apoptosis-induced histone acetylation other apoptosis-induced histone
modifications (or combinations of histone modifications) exist, i.e. a "histone code"
for apoptosis, which are targets of lupus-derived autoantibodies and pathogenic (14,
291). In this context it would be of considerable interest to determine in patients
whether antibodies specific for apoptosis-induced histone or nucleosome
modifications are predictive for the development of SLE and/or exacerbations of the
disease. Furthermore, the apoptosis-induced histone motifs that are targets for
autoantibodies in lupus could be applied in tolerizing strategies (297).
In conclusion, we have shown that lupus-derived autoantibodies recognize
apoptosis-induced histone modifications, in particular histone acetylation, and that a
histone H4 peptide carrying an apoptosis-induced acetylation motif accelerated
disease development and severity in pre-diseased lupus-prone mice. Therefore, the
challenge of the immune system by apoptosis-induced chromatin modifications may
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be an important initial event that leads to the disruption of the balance between
tolerance and autoimmunity and the formation of pathogenic chromatin
autoantibodies in SLE.
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Abstract
Antibodies against nucleosomes are a serological hallmark of systemic lupus
erythematosus (SLE). Apoptotic cells are the unique source of nucleosomes, which are
formed through cleavage of chromatin by nucleases. These nucleosomes and other
autoantigens targeted in SLE are expressed in apoptotic blebs or at the surface of
apoptotic cells. Therefore, it is conceivable that circulating antibodies can influence
apoptotic cell clearance. Using an in vitro phagocytosis assay, we analysed the
phagocytic efficacy for apoptotic cells of resident peritoneal macrophages from pre-
morbid and diseased lupus mice. The assay was carried out in the presence of
autologous serum, using autologous apoptotic thymocytes as targets. Under these
conditions macrophages from diseased MRL/lpr and NZBxNZW(F1) lupus mice, and
from age-matched NZB mice showed a decreased phagocytic efficacy (decrease 47%,
48% and 37%, respectively compared to measurements in pre-morbid mice). The
cause of this decrease resides in the serum, and is not due to an acquired defect of
macrophages. In conclusion, during disease progression in murine SLE, apoptotic cell
clearance becomes impaired, which might amplify further disease progression.
Normally, apoptotic cells are swiftly removed by phagocytosis due tosurface changes induced by the apoptotic process (40, 121). This
prevents the release of phlogistic intracellular constituents, including nucleosomes,
which are uniquely formed during apoptosis through cleavage of chromatin by
nucleases. However, antibodies against nucleosomes are a hallmark of systemic
lupus erythematosus (SLE) (13). Therefore, disturbances in either apoptosis or the
phagocytosis of apoptotic cells have been proposed to play a role in the development
of autoimmunity, especially in SLE (11, 13, 102, 121, 173, 180, 181). Several
reports using mice deficient for molecules (such as C1q, SAP and IgM) or receptors
involved in the phagocytosis of apoptotic cells (truncated Mer receptor) have shown
that a disturbed removal of apoptotic cells leads to autoimmunity against
nucleosomes and glomerulonephritis (40). Furthermore, defects in the clearance of
apoptotic cells have been described in lupus mice and patients (43, 44, 46, 118).
Nucleosomes are not only important for disease induction, they can also influence
the clearance of apoptotic cells (182). Furthermore, autoantibodies formed in SLE
can also modulate this process (183, 184). Therefore, during disease progression,
when nucleosomes and autoantibodies start to circulate, they might amplify disease
by inhibiting clearance of apoptotic cells. 
To test whether phagocytic efficacy is disturbed in murine lupus, we
developed an in vitro phagocytosis assay of apoptotic thymocytes to determine the
efficacy of resident peritoneal macrophages. During development of the assay we
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found that the uptake of apoptotic cells by mouse resident peritoneal macrophages
was fully dependent on serum (142). This allowed the evaluation of the impact of
autologous serum of pre-morbid and diseased SLE-mice on the phagocytic efficacy.
To mimic the in vivo situation measurements were performed in an autologous
system, using autologous apoptotic thymocytes as target cells and autologous
resident peritoneal macrophages as effector cells.
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Materials & Methods
Animals
For all experiments, female mice were used. Young, pre-morbid mice were
6–12 weeks of age. Diseased MRL/lpr mice were 20–24 weeks old. Age-matched
MRL/+ mice were also included in the study. Diseased NZBxNZW(F1) mice were
either 15 weeks or 30–34 weeks old (full blown disease), NZW and NZB mice of
30–34 weeks were also tested. Lupus disease was defined by the presence of
albuminuria of >0.3 g/l as determined by Albustix (Roche, Mannheim, Germany)
and an anti-DNA titer >5000 U/ml in ELISA determined as described previously
(51, 94). The animals were housed under specific pathogen-free conditions and were
fed standard food (Hope Farms, Woerden, The Netherlands) and acidified tap water
ad libitum. NZ mice were purchased from Harlan/Olac (Bicester, UK), MRL mice
from Bomholdgård (Ry, Denmark) and BALB/c, Swiss and CBA mice were
purchased from Harlan (Horst, The Netherlands).
Medium
RPMI Dutch modification (Gibco, Paisley, Scotland) was used as medium,
supplemented with 1 mM sodium pyruvate (ICN, Aurora, Ohio), 0.3 mg/ml L-
glutamine (Flow Laboratories, Zwanenburg, The Netherlands), 100 IU penicillin
(Gibco, Paisley, Scotland, UK), 100 µg/ml streptomycin. This solution is further
referred to as serum-free medium. Further supplements to serum-free medium were
either fetal calf serum (FCS) (Gibco, Paisley, Scotland, UK), heat inactivated for 30
min at 56°C, mouse serum (MS), not heat inactivated, or human serum albumin
(HSA) (CLB, Amsterdam, The Netherlands). These solutions are further referred to
as x% FCS, x% MS and x% HSA, respectively. Mouse serum was obtained by
bleeding from the retro-orbital plexus after ether anaesthesia. Serum was collected
in glass tubes, allowed to clot for 30 min at room temperature and 30 min at 4°C,
and centrifuged at 2300 x g, after which the supernatant was harvested. This
supernatant was again centrifuged at 2300 x g and its respective supernatant
harvested. The twice-spun serum was used immediately.
Isolation of thymocytes and induction of apoptosis
Thymocyte isolation and apoptosis induction was performed as described
(142). In short, from the thymus a single-cell suspension of thymocytes was
prepared, which was seeded at 5x106 cells/ml in 10% FCS and exposed to 1 µM
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dexamethasone (Genfarma, Maarssen, The Netherlands) at 37°C, 5% CO2. After 3
h, the cells were washed three times in serum-free medium and brought to a
concentration of 2.5x106/ml in either an autologous serum solution or in a FCS
solution. Dexamethasone induced apoptosis was analysed by annexin V-
FITC/propidium iodide double staining in a Coulter Epics XL flowcytometer
(Coulter Corporation, Hialeah, FL, USA).
Isolation of resident peritoneal macrophages
This isolation was performed as described (142). In short, non-anaesthetised
mice were injected with 10 ml ice-cold 10% FCS, followed by gravity drainage
through a 1.1 mm Ø needle. A sample was taken for forward scatter/sideward scatter
(FS/SS) analysis on a Coulter Epics XL flowcytometer (Coulter Corporation,
Hialeah, FL, USA) to determine the percentage of macrophages in the lavage.
Peritoneal macrophages were seeded on plastic coverslips at 7.5x104 cells/ml in 10%
FCS and allowed to adhere for 1.5 h at 37°C, 5% CO2, after which non-adherent
cells were removed by washing with 10% FCS. The coverslips were transferred to
new wells containing 1 ml of 10% FCS and the macrophages were kept at 37°C, 5%
CO2 for an additional 1.5 h, during which time the apoptic thymocytes were
prepared.
Macrophage and apoptotic cell interaction
Plastic coverslips with adherent macrophages were washed with serum-free
medium after which 1 ml of dexamethasone treated thymocytes (2.5x106/ml) in
medium containing the appropriate serum (either FCS or MS) was gently added to
each well. The cells were allowed to interact for 1 h at 37°C, 5% CO2, after which
the coverslips were washed with 0.4% HSA to remove non-phagocytosed cells. For
all autologous experiments, macrophages, serum and thymocytes were obtained
from the same mouse.
Scoring procedure
Scoring was performed as described (142). In short, resident peritoneal
macrophages were flattened and dried by centrifugation of the coverslips at 25 x g
for 10 min in a Hettich Universal 30F table centrifuge (Depex, De Bilt, The
Netherlands). Cells were fixed with methanol 99.9% (LabScan, Dublin, Ireland),
and stained with May–Grünwald/Giemsa (Merck, Darmstadt, Germany).
Preparations were scored at 400x magnification by regular light microscopy and the
number of apoptotic thymocytes per individual macrophage was determined for 100
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Mφs for each coverslip. Only thymocytes clearly within the perimeter of the
macrophage were counted. 
Statistical analysis
All tests were performed in duplicate or triplicate, and for each experiment
the counts of 200 or 300 Mφs, respectively, were used. The resulting mean is
expressed as “number of thymocytes per macrophage”. The results from two or
more experiments are given as mean±SD. Student’s t-test and one-way ANOVA in
combination with Bonferroni’s post-test correction for multiple comparisons were
applied when appropriate.
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Results
Titration of autologous serum concentration
The initial assay was developed with fetal calf serum (FCS) (142). In order
to determine the optimal concentration for mouse serum (MS), we compared the
phagocytic efficacy in FCS and MS. Fig. 1 shows the uptake of apoptotic BALB/c
thymocytes by BALB/c resident peritoneal macrophages in the presence of different
concentrations of BALB/c serum, compared to the uptake in the presence of FCS.
Autologous BALB/c serum is less efficient compared to fetal calf serum at
concentrations of 2.5% or lower. Therefore, a MS concentration of 5% was chosen
for further experiments. A higher concentration was not feasible from a practical
point of view.
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Figure 1. Effect of the concentration of autologous mouse serum or fetal calf serum on the efficacy
of phagocytosis of apoptotic cells. BALB/c resident peritoneal macrophages were allowed to
phagocytose apoptotic BALB/c thymocytes in autologous BALB/c serum or heterologous fetal calf
serum. Results are expressed as the number of thymocytes per macrophage and are the mean±SD of
at least two measurements per concentration (*P<0.05, **P<0.001).
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Apoptosis induction in autologous thymocytes
To test if apoptosis induction was comparable in thymocytes from mice of
6–12 weeks and from mice >20 weeks, thymocytes were treated for 3 h with
dexamethasone. Apoptosis induction was measured by annexin V binding. There
were no differences in the percentage of annexin V positive cells from the two
groups within a given strain, although there were marked differences between the
strains with respect to the sensitivity for dexamethasone induced apoptosis. This
sensitivity was highest in BALB/c thymocytes, and lowest in thymocytes from
NZW mice (Fig. 2). 
Phagocytic efficacy under autologous conditions 
The phagocytic efficacy of resident peritoneal macrophages from mice of
6–12 weeks and >20 weeks of lupus-prone strains and control strains under fully
autologous conditions is shown in Fig. 3. When disease becomes apparent, the
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Figure 2. Percentage of dexamethasone induced annexin V positive thymocytes in the different
mouse strains. Results are expressed as the percentage of annexin V positive thymocytes and are the
mean±SD of at least four measurements per strain. Although there were strain differences in the
magnitude of apoptosis induction, there were no differences within a given strain for mice of 6–12
weeks and mice of 20–24 weeks (MRL) or 30–34 weeks (NZ, BALB/c) (*P<0.001).
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efficacy of apoptotic cell phagocytosis becomes compromised in the SLE strains
NZBxNZW(F1) and MRL/lpr. In mice aged 30–34 weeks of the SLE-parental strain
NZB, phagocytic efficacy is also reduced in comparison to results obtained in NZB
mice of 6–12 weeks. When comparing different strains at 6–12 weeks, efficacy in
BALB/c is higher compared to efficacies from all other strains (P<0.05).
Phagocytosis efficacy in MRL/lpr of 6–12 weeks was not statistically different from
that in MRL/+ mice of the same age. To determine at which age the reduced efficacy
of phagocytosis would become apparent, the efficacy of albuminuria negative, but
anti-DNA positive, NZBxNZW(F1) mice of 25 weeks of age were tested. At 25
weeks of age, the efficacy was slightly reduced, but this difference was not
significant compared to NZWxNZBF1 mice of 6–12 weeks (Fig. 3).
Phagocytic efficacy under heterologous conditions
To determine which component in the autologous system causes the
reduction in phagocytic capacity, resident peritoneal macrophages from 30–34
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Figure 3. Phagocytic efficacy of resident peritoneal macrophages from mice under autologous
conditions. Mice were 6–12 weeks (pre-morbid), 25 weeks (early disease; NZ(F1)), 20–24 weeks
(diseased; MRLlpr and MRL/+) or 30–34 weeks (diseased; NZ(F1), or control NZB, NZW and
BALB/c). Resident peritoneal macrophages were allowed to take up apoptotic autologous
thymocytes in 5% autologous serum for 1 h. Results are expressed as the number of thymocytes per
macrophage and are the mean±SD of at least four measurements per strain (*P<0.05).
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weeks old, diseased NZBxNZW(F1) mice were exposed to their autologous
apoptotic thymocytes in the presence of 5% FCS (Fig. 4, bar 3). The differences
measured under fully autologous conditions now were no longer apparent.
Moreover, serum from 30–34 weeks old, diseased NZBxNZW(F1) mice caused a
decrease in the phagocytic capacity of macrophages from premorbid (6–12 weeks)
NZBxNZW(F1) mice (Fig. 4, bar 4). Furthermore, in both the MRL/lpr and the
NZBxNZW(F1) model there was no difference in phagocytosis by macrophages
from pre-morbid or diseased mice when the assay was performed with apoptotic
thymocytes from BALB/c as target cells and 10% FCS as source of serum (data not
shown). These findings suggest that there is no age-related or disease-related
decrease of macrophage function, and that the cause of the decrease in efficacy
resides in the serum.
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Figure 4. Phagocytic efficacy under autologous versus heterologous conditions of resident
peritoneal macrophages (NZWxNZB)F1 mice using autologous apoptotic thymocytes as targets.
Results are expressed as the number of thymocytes per macrophage and are the mean±SD of four
measurements per condition (*P<0.05). Bar 1: efficacy of macrophages of 6–12 weeks old premorbid
mice in the presence of serum of the same mice (premorbid serum). Bar 2: efficacy of macrophages
of 30–34 weeks old diseased mice in the presence of serum of the same mice (diseased serum). Bar
3: efficacy of macrophages of 30–34 weeks old diseased mice in the presence of fetal calf serum. Bar
4: efficacy of macrophages of 6–12 weeks old premorbid mice in the presence of serum of 30–34
weeks old mice (diseased serum).
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Discussion
This study shows that with disease progression the efficacy of peritoneal
macrophages to ingest apoptotic cells decreases in lupus mice. This finding is in line
with recent evidence that in lupus patients the phagocytosis of apoptotic cells is
impaired (43, 44, 46, 118). The described effect is likely to promote the release of
nucleosomes in the circulation, which in turn might enhance disease progression. 
When the autologous serum from premorbid SLE mice was replaced by
serum from diseased SLE mice, the phagocytosis of apoptotic cells decreased. In
addition, when the autologous serum from diseased SLE mice was replaced by FCS,
the decrease in phagocytic capacity was no longer observed. Furthermore, peritoneal
macrophages from diseased mice showed a normal phagocytic capacity when
apoptotic thymocytes from BALB/c mice were used as targets in the presence of
normal FCS. The decrease in phagocytic capacity was not seen in control mice,
except for the lupus-parental strain NZB. Therefore, the decreased phagocytosis of
apoptotic cells can not only be ascribed to an inherent defect of macrophages from
older lupus mice. This has been suggested in reports in SLE on decreased
complement-receptor (185) and Fc-receptor (186) mediated phagocytosis and the
Mer receptor deficient mouse (133), which suggested that SLE related phagocytic
defects are present at the macrophage level. At first sight, this contrasts with
previous reports (43, 44, 46, 118), especially with the observation of Potter et al.,
which showed a decrease in phagocytosis of apoptotic cells in premorbid (age 8–12
weeks) lupus-prone mice compared to the control strain BALB/c and C57Bl/6.
However, we also observed a lower phagocytic clearance of apoptotic cells using
10% FCS, in lupus strains compared to BALB/c both at 6–12 weeks and >20 weeks.
This is possibly related to the use of BALB/c mice as control, since we found a
similar, lower phagocytic clearance of apoptotic cells in normal CBA mice, which is
a H-2 haplotype identical strain for MRL mice (42). We did not test C57Bl/6 mice
in this study. This suggests that the difference in phagocytic efficacy of premorbid
lupus mice, as observed by others (43, 44, 46, 118), is due to the intrinsic higher
efficacy in some (BALB/c) but not all (CBA) normal strains. 
An apoptosis induced decrease of the number of macrophages ingesting
apoptotic cells has been put forward as a possible explanation for the decrease in
phagocytic clearance (43, 44, 46, 118). In contrast to these reports, we did not find
a decrease in the percentage of macrophages ingesting apoptotic cells. We observed
a shift of the distribution curve of apoptotic cells per macrophage towards zero (data
not shown). We also found no decrease in the recovery of macrophages from the
peritoneal cavity for lupus strains compared to control strains. In a previous study in
pre-morbid lupus mice, we also found no evidence for a constitutive defect in the
phagocytosis of apoptotic cells (42). 
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The observed decrease in apoptotic cell phagocytosis is more likely related
to one or more factors residing in the serum. This could be due to an increase of
some inhibitory factor(s), or alternatively result from a decreased concentration of a
serum factor required for phagocytosis. The decrease could be due to either a
defective binding or internalisation of apoptotic cells by macrophages. In a previous
study, we could show that uptake and binding are different processes (142).
However, only the uptake of apoptotic cells by macrophages is critically dependent
of serum. Therefore, we can conclude that the internalisation becomes impaired.
There are several putative candidates whose increased presence could lead to a
decrease in apoptotic cell phagocytosis. First, nucleosomes have been shown to be
able to inhibit phagocytosis of apoptotic cells (182) This would be in line with our
recent data showing that diseased SLE mice indeed have nucleosomes in their
circulation (51). However, there appears to be no correlation between the amount of
nucleosomes in the serum and the phagocytic capacity. We found that the amount of
nucleosomes is high in the NZB and MRL/+ background strains, and lower in the
NZBxNZW(F1) and MRL/lpr strains (51). These two latter strains show decreased
phagocytic efficacies, while MRL/+ mice do not. Moreover, young mice from both
SLE and control strains have nucleosomes in their circulation (51), but they do not
have a decreased phagocytic capacity. Therefore, circulating nucleosomes are
probably not responsible for the observed impairment of phagocytosis of apoptotic
cells in NZB, NZBxNZW(F1) and MRL/lpr mice. 
A second candidate responsible for the observed decrease in phagocytosis
could be the presence of autoantibodies against several structures expressed on
apoptotic cells like the β2-glycoprotein-1/phophatidylserine complex. Indeed,
antibodies to phosphatidyl-serine have been implicated in the modulation of
apoptotic cell clearance (183, 184). However, to our knowledge autoantibodies
against phosphatidylserine have not been reported in NZB mice, yet serum from
these mice also induces a decrease in phagocytosis. We defined disease in lupus
strains by the presence of anti-DNA antibodies, but we did not find a correlation
between the anti-DNA titer and the clearance of apoptotic cells by macrophages.
Further studies are needed to determine whether autoantibodies are involved, and if
so which antibody specificity would then be responsible for inhibition of
phagocytosis in diseased lupus mice.
Recently, several soluble factors have been shown to be required for the
disposal of cellular and chromatin debris, and deficiencies in such factors can
directly be linked to the etiology of SLE (13, 103). Targeted disruption of IgM (132,
134, 187) or C1q (124) leads to the development of antinuclear antibodies and
glomerulonephritis. Disease development in these cases has been contributed to
defective removal of apoptotic cells. Especially, complement has been shown to play
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an important role, since C1q could bind to apoptotic cells and apoptotic cells could
activate both the classical and the alternative pathway (125, 188). Also, impaired
clearance of nucleosomes resulting from induced deficiency of DNaseI (131) or
serum amyloid P (SAP) (129) causes SLE-like phenotypes characterised by
antinucleosome antibodies and glomerulonephritis. Furthermore, thrombospondin
(121), C-reactive protein (189), pentraxin (190), serum-derived protein S (191) and
prothrombin (192) have also been implicated in the phagocytic clearance of
apoptotic cells. Further studies are required to determine if any of the molecules
mentioned above play a role in the decreased phagocytic efficacy of macrophages
that we observed in diseased SLE mice. These studies could help to reveal which
receptors and ligands are involved in the phagocytic clearance of apoptotic cells.
This might suggest a number of targets (ligands, soluble bridging molecules, or
receptors) that could be modulated to control exacerbations in SLE patients.
72
Decreased phagocytosis of apoptotic cells in diseased lupus mice
Chapter 5.
A prospective study of anti-nucleosome and anti-
C1q auto-antibodies in patients with
proliferative lupus nephritis treated with
cyclophosphamide and azathioprine
Jürgen Dieker, Cecile Grootscholten, Fabian McGrath,
Gerry Ligtenberg, Ron Derksen, Johan van der Vlag, Moh Daha & 
Jo Berden, on behalf of the Dutch Working Party on SLE
To be published
73
74
Abstract
The nucleosome is the major autoantigen in systemic lupus erythematosus
(SLE). Anti-nucleosome autoantibodies, which comprise anti-DNA, anti-histone and
nucleosome-specific autoantibodies, are specific for SLE and correlate with disease
activity. Moreover, complexes of anti-DNA and anti-nucleosome autoantibodies with
nucleosomes play an important role in the development of lupus nephritis, since they
can bind to heparan sulfate in the glomerular basement membrane (GBM). Anti-C1q
autoantibodies, which also correlate with disease activity, can bind to deposited C1q
and via this mechanism can also bind to the GBM. We measured autoantibody levels
in patients with proliferative lupus nephritis, who were treated with cyclo-
phosphamide pulses, the standard treatment, or azathioprine in combination with
methylprednisolone pulses. During the first year of treatment we found no difference
between the two treatments for the levels of anti-nucleosome, anti-DNA, anti-histone
and anti-C1q autoantibodies. We found a prevalence before starting treatment of 81%,
96%, 23% and 62% for anti-nucleosome, anti-DNA, anti-histone and anti-C1q
autoantibodies, respectively. Anti-nucleosome correlated with anti-DNA and anti-
histone, but not with anti-C1q levels. We found a correlation of anti-nucleosome, anti-
DNA and anti-histone, but not anti-C1q, with disease activity measured by the
SLEDAI. We found no significant differences for any of the antibodies between
patients with high antibody reactivity or low antibody reactivity, for treatment
efficacy, serological markers or renal function parameters. We conclude that almost all
patients with proliferative lupus nephritis are positive for anti-nucleosome and/or anti-
DNA autoantibodies, with no clinical differences between patients with high or low
antibody titers. Treatment with cyclophosphamide or azathioprine induced a
comparable decline in the levels of anti-nucleosome, anti-DNA and anti-C1q
autoantibodies. 
Systemic lupus erythematosus (SLE) is an autoimmune disease in whichthe autoimmune response is autoantigen driven and T cell dependent.
Historically, anti-double stranded (ds) DNA autoantibodies are the serological
hallmark of the disease. However, dsDNA is not immunogenic by itself. Only bound
to proteins, like histones or microbial proteins, dsDNA can induce an autoimmune
response (9, 10). Therefore, the nucleosome has been proposed as the major
autoantigen (13, 64). Nucleosomes are the basic structure of chromatin, which
enable the dense packing of dsDNA in the nucleus. Each nucleosome consists of 146
bp of dsDNA wrapped twice around an octamer of pairs of the four core histones
H2A, H2B, H3 and H4. Nucleosomes are the exclusive product of apoptosis, when
chromatin is cleaved by DNases into individual nucleosomes. A defective removal
of apoptotic cells leads to the release of (modified) nucleosomes, which can induce
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an autoimmune response. Indeed, nucleosomes can be found in the circulation of
SLE patients (49, 50). Moreover, histone- and nucleosome-specific T cells have
been identified (54-56, 58). Anti-nucleosome autoantibodies can be divided into
antibodies that recognize one of the components of the nucleosome, i.e. DNA or
histones, and autoantibodies that preferentially recognize the intact nucleosome
(nucleosome-specific antibodies). In lupus mice nucleosome-specific autoantibodies
arise before anti-DNA autoantibodies (84). Anti-nucleosome are found in the vast
majority of SLE patients (40-90%), especially in patients with lupus nephritis (193).
High anti-nucleosome and also anti-DNA reactivity has been associated with disease
activity and flares of lupus nephritis, one of the most serious manifestations of SLE
(68, 70, 71, 75, 76, 79). The proportion of SLE patients which have anti-nucleosome
antibodies, but no anti-DNA reactivity, which means the presence of nucleosome-
specific antibodies, has been estimated around 12-30%, (71, 72, 79, 194).
Especially, anti-nucleosome autoantibodies are specific for SLE, although some
studies also report anti-nucleosome autoantibodies in patients with mixed
connective tissue disease and scleroderma (68, 195). However, there are indications
that the mucleosome preparation used in these studies, was contaminated with
topoisomerase I, which might explain this reactivity (67). Anti-histone
autoantibodies are less frequently found in SLE patients, but more often in patients
with drug-induced lupus. However, their clinical relevance is still not clear (80). We
regard the binding of anti-nucleosome/nucleosome complexes to the basement
membrane in the glomerulus as a major event in the initiation of lupus nephritis (11).
These complexes can bind to negatively charged heparan sulfate in the basement
membrane via the positively charged histone tails, especially when anti-DNA or
nucleosome-specific autoantibodies mask the negative charges on the nucleosomes
(82). 
Clearance of immune complexes involves the classical pathway of the
complement system. Indeed, deficiency of members of the classical pathway, like
C1q, C3 and C4, results in the development of anti-nuclear autoimmunity and
glomerulonephritis in mice (124, 196). In patients deficient for C1q, SLE-like
disorders are often found and about one third of the patients develop
glomerulonephritis (197). Paradoxically, anti-C1q autoantibodies are also found
frequently in SLE patients (30-45%) (198). Moreover, anti-C1q autoantibodies are
especially found in patients with lupus nephritis and are predictive for renal flares
(199, 200). Binding of anti-C1q/C1q complexes to the GBM can induce
glomerulonephritis in mice (201), but is dependent on the presence of other IgG
molecules (202). Moreover, anti-C1q autoantibodies might interfere with the
function of C1q and thereby amplify the disease. Apart from its effect on the
clearance of immune complexes, C1q is also involved in the removal of apoptotic
cells, since mice with a targeted disruption of C1q  have an impaired removal of
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apoptic cells and develop anti-nucleosome reactivity and lupus-like
glomerulonephritis (124). 
Various studies, mainly conducted at the National Institute of Health (NIH)
have indicated that treatment of lupus nephritis with a combination of
corticosteroids and a cytotoxic immunosuppressive (either cyclophosphamide or
azathioprine) provides better renal survival than treatment with corticosteroids alone
(99). However, which cytotoxic immunosuppressive treatment should be given is
still under debate. Intravenous cyclophosphamide pulses combined with oral
steroids has been the standard treatment for proliferative lupus nephritis for many
years, but side effects, in particular gonadal toxicity, are profound. Since most SLE
patients are young females, an effective therapy associated with a reduced risk of
infertility is warranted. Therefore, the Dutch Working Party on SLE initiated in 1995
a prospective randomized controlled trial to compare cyclophosphamide pulses with
azathioprine and methylprednisolon pulses. Inclusion ended in 2001 and recently the
first results after a minimum follow-up of 2 years were published (203). 
The aim of this study is to assess the anti-nucleosome, anti-DNA, anti-
histone and anti-C1q reactivity in these patients with proliferative lupus nephritis,
treated with either cyclophosphamide combined with oral prednisone or
azathioprine combined with methylprednisolone pulses and oral prednisone, during
their first year of treatment. Autoantibody levels were analysed for their association
with several serological markers, such as complement C3 and C4, disease activity
and renal function parameters.
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Materials & Methods
Patients
Eighty-seven patients with proliferative lupus nephritis were enrolled in the
first Dutch Lupus Nephritis Study. All patients met the following criteria: presence
of at least 4 American College of Rheumatology (ACR) criteria (61), age 18 to 60
years, creatinine clearance (Cockcroft-Gault formula (204)) >25 ml/min, and biopsy
proven proliferative lupus nephritis according to the WHO-criteria (205). Patients
were stratified according to center, serum creatinine (<150 µmol/l or >150 µmol/l),
WHO-class III or IV, and previous treatment with cytotoxic immunosuppressive
medication for lupus nephritis. Cyclophosphamide-treated patients (CY) were given
six pulses of cyclophosphamide (750 mg/m2) every 4 weeks, followed by seven
pulses every 12 weeks, combined with oral prednisone, initially 1 mg/kg/day,
tapered to a final dose of 10 mg daily after six months. Azathioprine-treated patients
(AZA) started with azathioprine (2 mg/kg/day) at day one, combined with
methylprednisolone intravenously (1000 mg) on three consecutive days. This cycle
of three pulses was repeated after two and six weeks. In addition, oral prednisone
(20 mg/kg/day) was given for five months and then tapered to 10 mg/day. 
Plasma samples were collected before treatment and during the first year of
treatment and stored at -80°C until use. Levels of complement components C3, C4
and anti-DNA titer (Farr assay and/or Crithidia test (206)) were measured. Overall
disease activity was assessed by means of the SLE Disease Activity Index
(SLEDAI) (207). A relapse was defined as doubling of the lowest obtained serum
creatinine so far and/or development of either a nephrotic syndrome (proteinuria
>3.5 g/day and serum albumin <30 g/l), while the lowest protein excretion so far had
been >2.0 g/day repeatedly, or proteinuria >1.5 g/day without other causes, in a
previously non-proteinuric patient. Complete remission was defined as proteinuria
<1.0 g/day and a serum creatinine <130% of the lowest serum creatinine since start
of treatment. 
Anti-DNA, anti-histone and anti-nucleosome ELISA
All ELISA tests for autoantibody reactivity were repeated in a central
laboratory. For the anti-nucleosome ELISA H1-stripped chromatin (kindly provided
by Dr. R. Burlingame) was diluted 1:500 in PBS and 100 µl was coated overnight at
4°C in Maxisorb® 96-well plates (Nunc, Roskilde, Denmark). In the DNA ELISA,
100 µl of calf thymus dsDNA (Roche, Almere, The Netherlands) was coated
overnight at 4°C in Maxisorb® 96-well plates at a concentration of 20 µg/ml in PBS.
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In the histone ELISA 100 µl of calf thymus histones (Roche) were coated overnight
at 4°C in a concentration of 2.5 µg/ml in 0.1 M glycine buffer at pH 9. The wells
were washed with PBS/0.05% (v/v) Tween-20 (PBS-T) and blocked with 150 µl
blocking reagent for 2 h at room temperature, i.e. 5% fetal calf serum (FCS) for the
anti-DNA and anti-nucleosome ELISA and for the anti-histone ELISA 5% milk,
which was treated with DNaseI, as previously described (97). After washing with
PBS-T, 100 µl of the patient plasmas and positive and negative control plasmas were
added at a starting dilution of 1:50 in blocking reagent and were incubated for 2 h at
room temperature. After washing with PBS-T, 100 µl horseradish peroxidase-
conjugated goat anti-human Ig(H+L) (Southern Biotechnology Associates,
Birmingham, U.S.A.) diluted 1:10,000 in PBS-T was added and incubated for 1 h at
room temperature. The plates were washed again with PBS-T and developed for 30
min using 100 µl 3,5,3’,5’-tetramethylbenzidine (TMB) (SFRI Diagnostics, Saint
Jean d’Ilac, France). The reaction was stopped by the addition of 100 µl 2 M H2SO4
and the optical density at 450 nm was measured in a microplate reader (Biorad). The
titer (in arbitrary units (AU)) was defined as the dilution of the patient serum that
yielded an absorbance of 0.5 at 450 nm. A standardized positive and negative patient
plasma was used as standard in each experiment.
Anti-C1q ELISA
The anti-C1q ELISA was performed as described earlier (208). Briefly,
Maxisorb® plates were coated with purified C1q at a concentration of 3 µg/well for
2 h at 37°C. After washing with PBS-T, a-specific binding was blocked with
PBS/0.01% gelatin for 1 h at 37°C. After washing with PBS-T, samples were diluted
in PBS-T with 1% fetal calf serum (FCS) and 1 M NaCl, added to the wells and
incubated for 1 h at 37°C. Wells were washed with PBS-T and an DIG-labeled anti-
human IgG diluted 1:10,000 in PBS-T/FCS was added. After washing with PBS-T,
an HRP-conjugated anti-DIG antibody (Dako, Roche) diluted 1:8,000 in PBS-
T/FCS was added. Plates were washed again with PBS-T and developed with 2,2’-
Azino-bis-(3-ethylbenziazoline-6-sulfonic acid (ABTS)/H2O2 for 30 min. Optical
density was measured at 415 nm in a microplate reader. Aserum positive for anti-
C1q was used as a standard in each assay, plate reactivity was assessed as relative to
the standard serum set at 100 aU/ml.
Statistics
Statistical analysis was performed using the Statistical Pack for Social
Sciences version 12.0.1 (SPSS; Chicago, IL, USA). Comparisons of patient groups
were performed by repeated measurements mixed model tests. The correlations
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were determined by Spearman’s rank correlation or chi-square test where
appropiate. A p-value,  after Bonferroni correction for multiple comparisons, of
<0.01 was regarded statistically significant,
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Results
Autoantibodies during first year of treatment
Autoantibodies were measured in ELISA in plasma’s from patients with
proliferative nephritis before treatment and during treatments after 4, 12, 26 and 52
weeks. Anti-nucleosome reactivity above the cut-off value (negative control+3xSD:
18.5 AU) was present in 81% of all the patients before treatment with no significant
difference between the CY and AZA groups (80% vs 82%). Before starting
treatment, anti-DNA and anti-histone reactivity above cut-off values (negative
control+3xSD: 26.5 AU and 17.5 AU, respectively) were found in 96% and 23% of
the patients, respectively, with also no significant difference between the CY and
AZA groups. Anti-C1q reactivity (above 75 AU) was present in 62% of all patients
before treatment. During treatment the median anti-nucleosome, anti-DNA and anti-
histone reactivity showed no significant difference between both treatment groups
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Figure 1. Autoantibody reactivity in CY and AZA-treated patients during the first year of treatment.
Anti-nucleosome (A), anti-DNA (B), anti-histone (C) and anti-C1q (D) reactivity. Results are
expressed as medians, AU=arbitrary units. The cut-off value for the different assays is indicated by
the dashed lines.
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(Fig. 1). The reactivity against nucleosomes and dsDNA declined rapidly after
treatment (Fig. 1, A and B). However, anti-histone reactivity was initial low and did
not change during treatment (Fig. 1C). The anti-C1q reactivity decreased
significantly during treatment, with no significant difference between the treatment
protocols (Fig. 1D). Although the reactivity for anti-nucleosome, anti-DNA and anti-
C1q declined during the first year of treatment, reactivity at 52 weeks stayed above
the cut-off value in most patients. Since the two treatment regimens might have a
different effect on the kinetics of the antibody titers, we compared the decrease of
the titer of anti-nucleosome antibodies during the first 4 weeks of treatment (Fig. 2).
We could not demonstrate a significant difference in the rate of decline between the
CY and AZA treatment groups. We found comparable results for the decline of anti-
DNA and anti-C1q titers (data not shown).
Correlation between autoantibodies
Since no significant differences were observed in titers and time course of
the autoantibodies in CY and AZA treated patients, all patients were considered
together for correlative calculations. Before treatment, anti-nucleosome reactivity
showed a significant correlation with anti-DNA reactivity (r=0.629, Table I). We
also found a significant correlation of anti-nucleosome and anti-DNA with anti-
histone autoantibodies (r=0.583 and r=0.495, respectively). This underlines the fact
that chromatin is the driving autoantigen in the formation of these autoantibodies. In
contrast, anti-C1q reactivity showed no significant correlation with any of the anti-
chromatin autoantibodies. 
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Figure 2. Decrease of anti-nucleosome antibody titers in CY (A) and AZA-treated (B) patients
during the first 4 weeks of treatment. No statistically significant differences were found between the
two treatment groups. AU=arbitrary units.
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Correlation of  autoantibodies with other serological markers and
disease activity
We analysed the correlation between the autoantibody titers before treatment
measured in ELISA with the results of the Farr assay, which is often used as the
standard assay to determine anti-DNA autoantibodies in these patients (Table II).
Anti-nucleosome, anti-DNA and anti-histone reactivity showed a significant
correlation (p<0.0001) with anti-DNA reactivity measured in the Farr assay. Anti-
C1q reactivity showed no such correlation. Complement C4 levels showed no
correlation with any of the autoantibodies, while C3 showed only a significant
correlation with anti-DNA autoantibody levels (Table II). Finally, disease activity as
assessed by the SLEDAI, correlated with anti-nucleosome, anti-DNA and anti-
histone reactivity. We found no significant differences for the SLEDAI and anti-
DNA measured by the Farr assay, when we compared patients with high (above the
median) or low (below the median) anti-nucleosome, anti-DNA, anti-histone or anti-
C1q antibody levels in ELISA (Tabel III). 
We observed during the first year, an increase of anti-nucleosome and/or
anti-nucleosome titers of more than 100%, in 8/52 patients. Only one of these 8
patients experienced a clinical renal relapse. Interestingly, in 6 of these 8 patients the
doubling of the antibody titer occurred directly after induction of remission (data not
shown). In the 2 other patients remission occurred after 56 weeks, while the increase
on antibody titers was observed after 12 weeks. High anti-DNA and anti-
83
Chapter 5
84
0-
6 >6 0-
6 >6 0-
6 >6 0-
6 >6
1
100
10000 anti-DNA anti-NUCL anti-HIST anti-C1q
A
nt
ib
od
y 
tit
er
s
Figure 3. Antibody
titers in patients with
remission within 6
months or remission
after 6 months. No sta-
tistical significant dif-
ferences were found.
A prospective study of anti-nucleosome and anti-C1q auto-antibodies in SLE patients 
nucleosome titers at the start of  treatment, were predictive for the doubling of
antibody titers later on during ther first year (7 out of 8 and 6 out of 8 respectively;
Table III).     
Association with renal function parameters
We compared renal function parameters in patients with high levels (above
the median) of anti-nucleosome, anti-DNA, anti-histone or anti-C1q autoantibodies
with those in patients with low (below the median) levels (Table III). We found no
significant difference between patients with high or low autoantibody levels for the
calculated GFR, serum creatinine or proteinuria. We compared the course of the
disease in patients with high versus low antibody titers and found no significant
difference for the occurrence of failure, relapse, death, or complete remission.
Moreover, we could not demonstrate a significant difference in the time to complete
remission. In addition, we compared antibody titers in patients with remission
within 6 months or remission after 6 months (Fig. 3). No significant difference could
be demonstrated. We also looked at patients for whom this was the primary nephritis
compared to patients who were already experienced nephritis before. We found no
significant difference in antibody levels (data not shown), but patients with primary
nephritis tended to have higher anti-DNA and lower anti-histone autoantibody
reactivity, but this difference did not reach statistical significance (Table III).
Although the SLEDAI was for all autoantibody specificities numerically higher in
the high titer group, this difference was not statistically significant. 
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Discussion
In experimental animal models complexes of anti-nucleosome or anti-DNA
with nucleosomes, possibly in combination with anti-C1q/C1q complexes, play a
decisive role in the development of lupus nephritis (82). Moreover, these
autoantibodies are correlated with the occurence of lupus nephritis (70). Although
many studies have described the prevalence, sensitivity and specificity of these
autoantibodies in SLE patients (68, 70, 193), not much is known about the
characteristics of these autoantibodies and their relation to clinical parameters in
patients with a proliferative lupus nephritis. We showed a high prevalence of anti-
DNA and anti-nucleosome autoantibodies in these patients (96% and 81%,
respectively). The prevalence of anti-DNA and anti-nucleosome was higher than is
found on average in unselected SLE patients. This can be expected since the
presence of these autoantibodies correlates with the occurrence of lupus nephritis
(72, 76). Remarkably, in our cohort the prevalence of anti-DNA autoantibodies is
higher than the presence of anti-nucleosome autoantibodies. This has been found
before (71, 209). SLE patients which are only positive for anti-DNA autoantibodies
have been described (72, 194). Based on our results we can not prove the anticipated
superiority of anti-nucleosome testing in these patients.  
We found a correlation between anti-DNA and anti-nucleosome, which is
comparable to values found in the total group of SLE patients (70, 71, 75, 76, 210).
Prevalence of anti-histone autoantibodies was low (23%). Moreover, anti-histone
reactivity was low in the majority of the patients. Indeed, anti-histone autoantibodies
are more often found in drug-induced lupus (80), and do not correlate with renal
disease (193). Studies in mice showed that complexes of monoclonal anti-histone
autoantibodies and nucleosomes bound less efficient to the glomerular basement
membrane (GBM), possibly by masking of the positive histone charges involved in
the GBM-binding by the antibody (82). 
Anti-C1q autoantibodies are also associated with lupus nephritis (198). We
found that 66% of the patients showed positieve anti-C1q reactivity, which is
comparable to reported prevalences in patients with lupus nephritis (198, 211). No
correlations were reported between anti-chromatin antibodies and anti-C1q
autoantibodies before treatment, which can be explained by a different inducer
(nucleosomes and C1q) of the immune responses. 
We compared the standard treatment of proliferative lupus nephritis with
cyclophosphamide to an alternative treatment with azathioprine/
methylprednisolone. No differences were found in the induction of remission
although relapses occurred more frequently in the AZA treated patients (203). In
addition, we found in this study no differences on the course of autoantibody titers
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during the first year of treatment between the two treatment groups. Autoantibody
titers declined very fast after start of treatment, although anti-DNA tended to
declined somewhat faster than anti-nucleosome autoantibodies. To evaluate this in
more detail we compared the kinetics of this decline, from week 0 to week 4 for both
treatments. However, this revealed no  difference for these autoantibody
specificities. 
Anti-nucleosome and anti-DNA autoantibodies have been associated with
disease activity and renal function in SLE patients (70, 193).  However, these
correlations were investigated in patients with and without lupus nephritis. Anti-
nucleosome, anti-DNA and anti-histone autoantibodies showed a positive
correlation with the SLEDAI, comparable to the literature (70, 71, 79). Remarkable
was the absence of such a correlation with anti-C1q reactivity. Although anti-
nucleosome and anti-C1q autoantibodies have been shown by others to correlate
with the presence of lupus nephritis (68, 71, 193, 211), we could not observe in our
patient cohort a direct correlation between anti-nucleosome and anti-C1q
autoantibody titers and markers for renal function (i.e. GFR, serum creatinine,
proteinuria). In addition, we found no difference in renal function parameters
between patients with high autoantibody titers compared to patients with low
autoantibody titers. The absence of these correlations might be due to the fact that
all our patients had a biopsy proven lupus nephritis with more or less comparable
disease manifestations. Significant increases in autoantibody titers (i.e. anti-
nucleosome and/or anti-DNA) during the first year of treatment were more frequent
observed in patients with high anti-nucleosome or anti-DNA at the start of treatment.
We also looked whether patients who were only positive for one autoantibody
specificity (either anti-nucleosome of anti-DNA) were different for clinical
parameters from  patients who were  positive  for both specificities.  However, this
showed comparable results (data not shown).
In conclusion, we have shown here that treatment of proliferative lupus
nephritis with azathioprine does not result in significant differences in anti-
chromatine or anti-C1q autoantibody kinetics compared to patients treated with
cyclophosphamide. In addition, the vast majority of lupus nephritis patients are
positive for anti-nucleosome, anti-DNA and/or anti-C1q autoantibodies. Their titers
correlate with disease activity, but not with renal function parametes or disease
course. These findings imply that measurement of these autoantibody specificities
are important tools for diagnosis of lupus nephritis but not for monitoring treatment.
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Abstract
Autoantibodies against chromatin are the most characteristic serological
feature in SLE patients. Anti-DNA and nucleosome-specific antibodies are associated
with glomerulonephritis, the most serious manifestation of SLE. Identification of
peptides mimicking conformational epitopes (so-called mimotopes) on the nucleosome
recognized by these antibodies is of considerable interest. Using an approach similar
to that used previously to characterize mimotopes for anti-DNA autoantibodies, we
have selected and identified a mimotope for a nucleosome-specific autoantibody (#32)
by screening a random peptide phage display library. However, the reactivity of
monoclonal antibody (mAb) #32 with the selected mimotope (MIMO#0) in ELISA was
dependent on the blocking reagents used. Using nonfat dry milk (5%), mAb #32
clearly bound to MIMO#0, but using fetal bovine calf serum (FCS) (5%), there was no
binding. Furthermore, again dependent on the blocking reagent used in ELISA, the
selected mimotope MIMO#0 was not only recognized by the selecting antibody mAb
#32, but also by a large number of other monoclonal anti-DNA, anti-histone and
nucleosome-specific autoantibodies (NSA). We could demonstrate that the selected
mimotope was able to bind directly to nucleosomal material (DNA/histone complexes)
and labeled DNA. This finding was extended to other previously identified mimotopes
for anti-DNA autoantibodies. We conclude that nucleosomal material (DNA/histone
complexes), derived from reagents used during the mimotope selection procedure,
resulted in the selection of DNA-binding peptides from the phage display library,
rather than mimotopes. In addition, we could demonstrate that blocking reagents
greatly influence the reactivity of anti-DNA, anti-histone and nucleosome-specific
autoantibodies in ELISA. Development of blocking reagents devoid of nucleosomal
material (DNA/histone complexes) is urgently needed for assay systems in which anti-
nuclear autoantibodies are tested.
Systemic lupus erythematosus is an autoimmune disease, in which theautoimmune response is T cell dependent and autoantigen-driven (99).
Autoantibodies detected in lupus patients are directed against a variety of
autoantigens, particularly against chromatin. Basically, chromatin consists of a chain
of nucleosomes, which are octamers of the histones H2A, H2B, H3 and H4, around
which 146 base pairs of double stranded DNA (dsDNA) are wrapped, while histone
H1 is bound to the linker DNA between the nucleosomes. Anti-chromatin
autoantibodies can be divided into those antibodies directed against one of the
subcomponents of the nucleosome, either DNA or histones, and those antibodies
which only recognize the intact nucleosome (so-called nucleosome-specific
antibodies). Historically, the serological hallmark of SLE was considered to be the
presence of anti-DNA autoantibodies (100), but now the presence of nucleosome-
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specific antibodies appears to be a better marker (12, 13). Nucleosome-specific
antibodies have been found in 88% of SLE patients, and correlate with disease
activity (64). Initially, it was claimed that they were lupus specific (70), but later it
has been reported that they can also be found in other autoimmune diseases, such as
mixed connective tissue disease and systemic sclerosis (68). Identification of the
conformational epitopes recognized by nucleosome-specific autoantibodies could
provide more insight into the pathogenesis of SLE. This approach may also reveal
important tools for both diagnostic and therapeutic applications. Several epitopes for
anti-histone autoantibodies and histone-specific T cells have been identified (58,
212-214). However, the identification of epitopes for anti-DNA or nucleosome-
specific antibodies requires another approach, since these epitopes also encompass
non-protein structures (i.e. DNA). Screening of random peptide phage display
libraries, in which random peptides are expressed on one of the coat proteins of the
phage, with monoclonal antibodies (mAb) against non-protein structures such as
DNA has revealed peptides, so called mimotopes, which mimic the non-protein
structures recognized by the antibody, such as anti-DNA antibodies (87-89, 215). 
In this study, we identified a nucleosome-specific mimotope by screening a
10-mer random peptide phage display library with a nucleosome-specific
monoclonal autoantibody. Surprisingly, this mimotope appeared not to be specific
and, depending on the applied blocking reagent in the ELISA, it was not only
recognized by the selecting antibody, but also by many other anti-chromatin
autoantibodies. More importantly, the reactivity in ELISA of the antibody used for
selection with the mimotope peptide was dependent of the blocking reagent used.
We found in ELISA the same blocking-dependent variation in reactivity of anti-
chromatin antibodies with a previously identified DNA mimotope peptide and a
histone peptide. Further analysis revealed that this blocking-dependent variation in
poly-reactivity with the three peptides was caused by nucleosomal material present
in the blocking reagents used in the ELISA procedure. Due to the presence of
nucleosomal material derived from reagents used during selection of phages, DNA
binding peptides rather than nucleosome-specific mimotopes were selected.
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Materials & Methods
Antibodies
The anti-chromatin monoclonal autoantibodies used in this study are listed
in Table I. All antibodies were purified on a protein A Sepharose (Amersham
Pharmacia Biotech, Uppsala, Sweden) under high salt conditions after DNaseI
treatment of the culture supernatant (94). Free histones and histone-complexed
antibodies were removed on a DNA-cellulose column (Amersham Pharmacia
Biotech) as described previously (94). The purity of the antibodies (i.e. absence of
histones and DNA) was checked by SDS-PAGE analysis followed by silver staining
(Bio-Rad Laboratories, Veenendaal, The Netherlands). The presence of DNA was
identified by extraction with phenol chloroform, separation and analysis on a 1%
agarose gel using ethidium bromide staining. Other monoclonal control antibodies
used in this study were WT-32, an IgG2a anti-CD3 antibody (216), and anti-MYC
(Invitrogen, Breda, The Netherlands). Human sera used in this study were collected
from SLE patients at the National University Hospital, Singapore, and tested for the
presence of antibodies to dsDNA as described earlier (89).
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Blocking reagents
Blocking reagents used in this study were: 5% nonfat dry milk (Bio-Rad
Laboratories), 5% fetal bovine calf serum (FCS) (Invitrogen), 1% bovine serum
albumin (BSA) purity 96%, 98% and 99%, 1% casein, 1% fish gelatin (all from
Sigma, Zwijndrecht, The Netherlands) and 1% Aurora Blocking Reagent (Perbio
Science, Etten-Leur, The Netherlands).
Biopanning of peptide library by nucleosome-specific antibody #32
The L100 library, displaying a 10-mer random peptide on phage coat-protein
III, kindly provided by Dr. M. Scharff (Einstein College, New York), was screened
with nucleosome-specific mAb #32. Library screening was performed as described
previously (217). Briefly, in the first panning round 1 µM of mAb #32 (belonging to
the IgG2a subclass) and 2 µM of biotin-labeled goat anti-mouse IgG2a (Southern
Biotechnology Associates, Birmingham, USA) were incubated and subsequently
added to 50 µl streptavidin-coated magnetic beads (Qiagen, Hilden, Germany). The
antibody-coated streptavidin beads were incubated for 4 h with an aliquot of the
phage library containing 1012 transducing units (TU) in 100 µl of biopanning buffer
(150 mM NaCl/10 mM Tris–HCl pH 7.4/0.1% (v/v) Tween-20/0.1% (w/v) BSA).
Beads were collected by a magnet (Polysciences, Warrington, USA), and unbound
phages were removed by washing with biopanning buffer. Phages were eluted with
100 µl of 0.1 M glycine-HCl (pH 2.2) for 10 min and directly neutralized with 16 µl
2 M Tris–HCl pH 8.0. Eluted phages were amplified overnight in Escherichia coli
K91kan in LB medium with 20 µg/ml tetracycline and 100 µg/ml kanamycin.
Amplification of phages, PEG purification and phage titration were performed as
described previously ((218). For the second and third round of panning, either 1 µM
and 10 nM or 10 nM and 100 pM of mAb #32, respectively, were incubated for 4 h
with phages from the previous round containing 107–1010 TU. Next, the
phage/antibody complexes were captured shortly for 10 min by 50 µl (1 µM
antibody) or 10 µl (other concentrations) streptavidin-coated magnetic beads
saturated with biotin-labeled goat-anti mouse IgG2a antibody. Individual clones
were picked after three rounds of selection and grown overnight in LB medium
containing 20 µg/ml tetracycline and 100 µg/ml kanamycin. Phage ssDNA was
isolated with the Qiaprep Spin M13 kit (Qiagen), according to the protocol supplied
by the manufacturer, and sequenced according to the Sanger method by the BigDye
Terminator (Applied Biosystems), using an 22-base fUSE5 anti-sense primer (5’-
gtaacgatctaaagttttgtcg-3’).
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Peptides
Peptides were synthesized by Genemed Synthesis (San Francisco, USA) on
an eight-branched multi-antigen peptide (MAP) backbone. The purity was >70%, as
checked by HPLC. The MAP-peptides were dissolved in DMSO at a concentration
of 100 mg/ml. MAP-peptides used for this study were: MAPMIMO#0 (MAP-
GSGGNRKDWIERTLGAPS), a mimotope for nucleosome-specific monoclonal
autoantibody #32; MAP-DNAmimic (MAP-RLTSSLRYNP), a mimotope for
polyclonal anti-DNA autoantibodies, and variants of this peptide used for the alanine
scanning (MAP-ALTSSLRYNP, MAPRATSSLRYNP, MAP-RLASSLRYNP, etc.);
MAP-H3(21-37) (MAP-ATKAARKSAPATGGVKK), recognized by anti-histone
antibody #34, and MAP-MYC (MAP-GSGGEQKLISEEDLGAPS), containing a
MYC-tag sequence. MAP-MIMO#0 and MAP-MYC contained the recognized
motif (underlined) and four flanking residues derived from the phage coat-protein.
Biotin labeling of DNA
Calf thymus DNA was labeled with biotin using the nick translation mix
(Roche). Briefly, 10 µg of DNA were incubated with 4 µl nick translation mix in a
total volume of 20 µl for 1 h at room temperature. The reaction was stopped by
adding EDTA to a final concentration of 15 mM.
Peptide ELISA
Maxisorb® 96-well plates (Nunc, Roskilde, Denmark) were coated with 100
µl of peptide at a concentration of 25 µg/ml in 50 mM carbonate buffer pH 9.6
overnight at 4°C. The wells were washed with PBS/0.05% (v/v) Tween-20 (PBS-T)
and blocked with 150 µl blocking reagent for 2 h at room temperature. After
washing with PBS-T, 100 µl of monoclonal antibody were added at a concentration
of 100 ng/ml in PBS-T and incubated for 2 h at room temperature. After washing
with PBS-T, 100 µl horseradish peroxidaseconjugated goat anti-mouse Ig(H+L)
(Southern Biotechnology Associates) diluted 1:7500 in TBS-T were added and
incubated for 1 h at room temperature. The plates were washed again with PBS-T
and developed for 15 min using 100 µl 3,5,3’,5’-tetramethylbenzidine (TMB) (SFRI
Diagnostics, Saint Jean d’Ilac, France). The reaction was stopped by the addition of
100 µl 2 M H2SO4 and the absorbance at 450 nm was measured in a microplate
reader (Biorad). The results for the various types of anti-chromatin autoantibodies
(i.e. anti-DNA, anti-histone and nucleosome-specific) are depicted for each class of
autoantibodies as mean (±S.D.) of the absorbance. For the binding of biotin-labeled
DNA, 0.5 µg of biotin-labeled DNA was added in 100 µl PBS-T after the blocking
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step and incubated for 30 min at room temperature. After washing with PBS-T, 100
µl of horseradish peroxidase-conjugated streptavidin (Amersham Pharmacia
Biotech) diluted 1:500 in PBS-T were added for 1 h at room temperature.
Development and measurement of the absorbance was performed as described
above.
DNaseI treatment of blocking reagents
Blocking reagents were incubated with 20 µg/ml of grade II DNaseI (Roche)
and 1 mM MgCl2 for 30 min at 37°C. The reaction was stopped by adding EDTA to
a final concentration of 15 mM.
SDS-PAGE and immunoblotting
A range of dilutions of blocking reagent dissolved in PBS was added to 2
volumes of 3x Laemmli buffer (62.5 mM Tris–HCl pH 6.8, 25% glycerol, 2% SDS,
0.01% Bromophenol Blue, 5% β-mercaptoethanol), and was heated for 5 min at
95°C and resolved by 18% SDS-PAGE gel electrophoresis using the Protean III
System (Bio-Rad Laboratories). The resolved proteins were transferred to a 0.45 µm
nitrocellulose membrane (Bio-Rad Laboratories) in blotting buffer (125 mM
glycine, 25 mM Tris, 0.02% SDS and 20% methanol). The blots were washed in
PBS and blocked in 1%(w/v) blocking reagent (Roche) for 1 h. After washing with
PBS (3x) and phosphate buffered solution containing Tween/fish gelatin
(Sigma)/sodium (PBTGNa) (0.1% (w/v) gelatin, 0.5% (w/v) BSA, 0.05% (v/v)
Tween-20 and 300 mM NaCl in PBS) (1x), blots were incubated for 2 h with
monoclonal anti-histone antibody KM-2, diluted 1:100 in PBTGNa. After washing
with PBS (3x) and PBTGNa (1x), blots were incubated for 1 h with a horseradish
peroxidase-conjugated goat anti-mouse Ig(H+L) (Southern Biotechnology
Associates), diluted 1:7500 in PBTGNa. After washing three times with PBS, blots
were developed using LumiLight® (Roche) and exposed to Hyperfilm ECL X-ray
films (Amersham Pharmacia Biotech).
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Results
Selection of a mimotope for a nucleosome-specific antibody
The nucleosome-specific mAb #32 was used to screen a 10-mer random
peptide phage display library. Three rounds of selection were performed using a
decreasing concentration of antibody during the panning rounds (1 µM, 10 nM and
100 pM, respectively). Positive clones were selected after the third round of panning
with 100 pM antibody and the common amino acid motif NRKDWIERTL was
deduced from the DNA sequence of 10 separate clones. To confirm in vitro binding
of mAb #32 in ELISA, a peptide containing the motif NRKDWIERTL (MAP-
MIMO#0) was synthesized on an eight-branched multiantigen peptide (MAP)
backbone with four flanking amino acids of the pIII phage coat-protein, which
resembles the amino acid context during selection. Antibody #32 showed reactivity
with this MAP-synthesized MIMO#0 in ELISA (Fig. 1A).
Poly-reactivity of anti-chromatin autoantibodies
Surprisingly, other nucleosome-specific autoantibodies (NSA), but also anti-
DNA and anti-histone autoantibodies showed reactivity with the MAP-MIMO#0
peptide (Fig. 1B). The poly-reactivity of a wide range of anti-chromatin
autoantibodies was not unique to the mimotope we identified for the nucleosome-
specific autoantibody #32, since a similar broad reactivity was found with a
previously described DNA mimicking MAP-peptide (RLTSSLRYNP, hereafter
designated as the MAP-DNAmimic). This DNA mimicking peptide was selected by
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Figure 1. (next page) A. Reactivity of nucleosome-specific autoantibody #32 with MAP-MIMO#0,
selected with this antibody, and anti-histone autoantibody #34 with MAP-H3(21-37) in ELISA. (B,
C) Poly-reactivity of anti-chromatin autoantibodies. Nucleosome-specific (NSA: i.e. NZA2, LG10-
1 and PL2-3), anti-histone (i.e. KM-2) and anti-DNA (i.e. #36 and #42) autoantibodies, nucleosome-
specific autoantibody #32, anti-histone autoantibody #34 or control antibodies (WT-32 and anti-
MYC) were tested at a concentration of 100 ng/ml with MAP-MIMO# 0, MAP-DNAmimic, MAP-
H3(21-37) and control peptide MAP-MYC, using nonfat dry milk (B)or FCS as blocking reagent (C)
All anti-chromatin antibodies showed reactivity with MAP-MIMO#0, MAP-DNAmimic and MAP-
H3(21-37) using milk as blocking reagent. When FCS was used, only reactivity of the anti-DNA
autoantibodies with these three peptides, and reactivity of anti-histone autoantibody #34 with MAP-
H3(21-37) was observed. No reactivity of the anti-chromatin antibodies was found with the control
peptide MAP-MYC. Coating of the MAP-peptide was appropriate as seen with the anti-MYC
antibody. The control monoclonal antibody WT-32 did not bind to any of the peptides.
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Figure 2. Effect of DNaseI treatment of the blocking reagent on the binding of anti-chromatin
antibodies. A. DNaseI treatment of milk resulted in a dramatic decrease of the reactivity of all anti-
chromatin antibodies with the MAP-DNAmimic, MAP-MIMO#0 and MAP-H3(21-37). Interactions
of anti-histone autoantibody #34 with MAP-H3(21-37) and anti-MYC with MAP-MYC were not
affected by the DNaseI treatment. Results are expressed as percentage residual reactivity calculated
by dividing the reactivity after DNaseI treatment by the reactivity without DNaseI treatment, x100.
B. Addition of biotin-labeled DNA to coated MAP-peptides after blocking with DNaseI-treated milk
shows binding of dsDNA to MAP-MIMO#0, MAP-DNAmimic and MAP-H3(21-37). No DNA-
binding was observed with the control peptide MAP-MYC. Results are expressed as absorbance
values at 450 nm.
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screening a 15-mer pVIII phage library with polyclonal anti-DNA antibodies
isolated from SLE patient sera via a DNA-Sepharose column (89) (Fig. 1B). In
addition, a histone peptide was also recognized by the set of anti-DNA, anti-histone
and nucleosome-specific autoantibodies tested (Fig. 1B). This histone peptide,
comprising the histone H3 amino acids 21–37 synthesized on a MAP backbone
(MAP-H3(21-37)), contains the epitope of antibody #34 as shown before (221). The
monoclonal anti-histone H3 autoantibody #34 showed a high reactivity with this
peptide (Fig. 1A). The control antibodies WT-32 and anti-MYC showed no
reactivity with either MAP-MIMO#0, MAP-DNAmimic or MAP-H3(21-37) (Fig.
1B). To exclude reactivity with the MAP backbone, all antibodies were tested with
a control MAP-peptide, containing an MYC-tag sequence (Fig. 1B). None of the
anti-chromatin autoantibodies bound to this control peptide. This was not due to
insufficient coating of the MAP-MYC peptide, since an anti-MYC antibody showed
good reactivity (Fig. 1B). Furthermore, coating of MAP backbone alone did not
reveal binding of any of the antibodies tested (data not shown).
Influence of the blocking reagent
Since we could not directly explain the polyreactivity of our anti-chromatin
autoantibodies with MAP-MIMO#0, MAP-DNAmimic and MAP-H3(21-37), we
applied a different ELISA protocol using FCS instead of nonfat dried milk as
blocking reagent. Surprisingly, completely different results were obtained when
FCS was used as blocking reagent (Fig. 1C). Under these conditions, the poly-
reactivity with the MAP-MIMO#0, MAP-DNAmimic and MAPH3(21-37) was
restricted only to the anti-DNA autoantibodies, while the reactivity of the
nucleosome-specific and anti-histone autoantibodies disappeared. Compared to the
ELISA using milk as blocking reagent (Fig. 1B), the reactivity of the anti-MYC
antibody with the MAP-MYC and the reactivity of anti-histone H3 autoantibody
#34 with MAP-H3(21-37) were not affected by the presence of FCS (Fig. 1C). At
first glance, this would suggest that MAP-MIMO#0 and the MAP-DNAmimic were
mimicking DNA; but this does not explain why anti-DNA antibodies were found
bind to the histone peptide MAP-H3(21-37). We also analyzed other blocking
reagents, including BSA, casein, fish gelatin and Aurora Blocking reagent, and we
found a comparable poly-reactivity with MAP-MIMO#0, MAP-DNAmimic and
MAP-H3(21-37), as when using FCS as blocking reagent (data not shown). Most
importantly, the reactivity of the selecting mAb #32 with its mimotope, MAP-
MIMO#0, was dependent on the blocking reagent, i.e. positive binding using milk
(Fig. 1B) and no binding using FCS (Fig. 1C).
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Effects of DNaseI treatment
Since the antibodies that showed poly-reactivity were all anti-chromatin
autoantibodies, the influence of the blocking reagent on the reactivity of these
autoantibodies suggests that components of the nucleosome, i.e. DNA and/or
histones, were present in the blocking reagent. We therefore performed a DNaseI
treatment of nonfat dry milk, to determine what effect this had on the binding of
anti-chromatin autoantibodies to the MAP-peptides (Fig. 2A). The poly-reactivity of
anti-DNA, and also of nucleosome-specific and anti-histone autoantibodies, was
completely lost after DNaseI treatment. Note that the reactivity of the antibody used
for selection, i.e. #32, with MAP-MIMO#0, was almost completely lost upon
DNaseI treatment of milk. The binding of autoantibody #34 with MAP-H3(21-37),
and anti-MYC with MAP-MYC was not affected by DNaseI treatment of the
blocking reagent.
Next, we added DNA, histones or nucleosomes to the DNaseI-treated
blocking reagent to see if the poly-reactivity could be reconstituted. Indeed, the
poly-reactivity of anti-DNA antibodies reappeared by the addition of 12 ng/ml calf
thymus dsDNA after the blocking step. Furthermore, the addition of nucleosomes
(concentration of 10 ng/ml dsDNA) after the blocking step could also restore the
binding of anti- DNA, anti-histone and nucleosome-specific autoantibodies to the
MAP-bound epitopes/mimotopes (data not shown).
Direct binding of DNA
The effect of DNaseI treatment on the binding of anti-DNA, and also anti-histone
and nucleosome-specific autoantibodies to the MAP-peptides, suggested that DNA,
present in nonfat dry milk, caused the binding of anti-chromatin autoantibodies. To
show direct binding of dsDNA to all these peptides, i.e. MAP-MIMO#0, MAP-
DNAmimic and MAP-H3(21- 37), we added biotin-labeled calf thymus dsDNA to
the incubation medium (Fig. 2B). Biotin-labeled dsDNA was able to bind dose-
dependently to all three MAP-peptides, but not to the MAP-MYC control peptide
(Fig. 2B). Furthermore, the addition of biotin labeling mix without DNA resulted in
no binding to any of the MAP-peptides (data not shown).
Presence of nucleosomal material in blocking reagents
The dependency of the poly-reactivity of anti-chromatin autoantibodies with
MAP-peptides on the blocking reagent, and the effect of DNaseI treatment of the
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Figure 3. Histones and DNA are present in blocking reagents. A. Histones were identified in milk
by SDS-PAGE and immunoblotting using anti-histone autoantibody KM-2, recognizing histone H2A
and H4. Therefore, only two out of the four bands are visible (lane 1: 0.5 mg milk). Calf thymus
histones were used as a marker (lane 2). Histones could not be detected in FCS and could barely be
detected in BSA (data not shown). B. DNA was directly identified in 10 µl of 10% milk, 100% FCS
and 25% BSA (lanes 1, 2 and 3, respectively).
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blocking reagent on the reactivity can only be explained by the presence of
nucleosomal material in the blocking reagent. Indeed, we directly identified histones
in milk on immunoblots probed with anti-histone autoantibody KM-2, which
recognizes both histone H2A and H4 (Fig. 3A). The amount of histones present in
nonfat dry milk was estimated to be 1.5 µg/mg milk, by comparison of the intensity
of the histone bands to a standard of calf thymus histones. We found no histones in
FCS and a barely detectable amount in 99% pure BSA (data not shown). We also
identified the presence of DNA in milk, FCS and BSA (Fig. 3B).We estimated this
to be 1000 ng/ml in milk, 150 ng/ml in FCS and 70 ng/ml 99% in pure BSA. The
isolated DNA from all three blocking reagents was sensitive to DNaseI treatment
(data not shown).
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Figure 4. The motif within the MAP-DNAmimic was involved in binding to dsDNA as determined
by alanine scanning. The effect of replacing each amino acid by alanine on binding is compared to
the reactivity with the unsubstituted MAP-DNAmimic (=100%) as determined in a direct ELISA
using milk as the blocking reagent containing DNA. The results are expressed as mean reactivity
(±S.D.) of the positive anti-chromatin autoantibodies (i.e. #32, NZA2, LG10-1, PL2-3, #34, KM-2,
#36 and #42) and three anti-DNA positive sera from SLE patients. The arginine residues at positions
1 and 7 and the serine residue at position 4 are critical for dsDNA binding.
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Identification of the DNA-binding motif of the ‘DNAmimic’
We performed an alanine scan to identify the motif in the ‘MAP-
DNAmimic’ involved in the binding of DNA. MAP-peptides, which had one of the
amino acids of the RLTSSLRYNP motif substituted by an alanine residue, were
tested with the panel of anti-chromatin autoantibodies in a direct ELISA (Fig. 4).
The reactivity for all the anti-chromatin autoantibodies was decreased by 40% or
more compared to the unmodified MAP-DNAmimic, when the arginines on
positions 1 and 7 or the serine on position 4 were substituted. The substitution of the
other residues by an alanine had no effect on the binding of DNA as revealed by the
binding of the anti-chromatin autoantibodies. Since the initial results with the MAP-
DNAmimic were found with anti-DNA positive sera from SLE patients (89), we
also performed the alanine scanning with some of the original SLE patient sera used
for selection of the DNAmimic. These anti-DNA positive sera from SLE patients
showed a similar decrease of binding with alanine substitutions in positions 1, 4 and
7 (Fig. 4).
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Discussion
A mimotope for the nucleosome-specific antibody #32 was selected using a
10-mer random peptide phage display library. The motif NRKDWIERTL contains
several positively and negatively charged amino acids, which might mimic,
respectively the positively charged histones and the negatively charged DNA within
the nucleosome. Surprisingly, besides antibody #32, a panel of other nucleosome-
specific, anti-DNA and anti-histone antibodies also showed reactivity. The poly-
reactivity of these anti-chromatin autoantibodies was not restricted to the mimotope
we selected, but was also observed with a previously identified DNA mimotope (89)
and a histone H3 peptide. We previously reported that the binding of DNA/histone
complexes to anti-chromatin antibodies, generated during hybridoma cell culture,
causes a similar poly-reactivity (94). Since this latter finding, we have extensively
purified our anti-chromatin autoantibodies, until we cannot detect any complexed
histones or dsDNA. The use of these noncomplexed purified anti-chromatin
autoantibodies excluded the antibody preparation as a source for histones or dsDNA. 
One of the explanations of the observed poly-reactivity may be the presence
of DNA and histones in the blocking reagents used in the ELISA. Indeed, we were
able to demonstrate that DNaseI treatment of the blocking reagents prevented the
poly-reactivity of anti-chromatin autoantibodies, with MAP-MIMO#0, the MAP-
DNAmimic and MAP-H3(21-37). Importantly, the reactivity of the nucleosome-
specific antibody #32, used for the selection of MIMO#0, completely lost its
reactivity with MAP-MIMO#0 in ELISA, when DNaseI treated milk was used as
blocking reagent. DNaseI treatment of the blocking reagent resulted in complete
degradation of the DNA (data not shown). Moreover, we found that dsDNA was able
to bind directly to these peptides. The presence of DNA and/or histones in milk and
bovine serum has been described previously (222, 223). In agreement with these
results, we identified DNA and/or histones in bovine nonfat dry milk and FCS, and
additionally also in BSA (purity 99%). Since we found no reactivity with any of the
anti-chromatin autoantibodies after direct coating of the  blocking reagents (data not
shown), the effect of histones and dsDNA in the blocking reagents is only observed
when a DNA- or histone-capturing molecule, i.e. the mimotope or histone peptide,
is coated.
The identification of these DNA-binding peptides from the peptide phage
display library and the blocking reagent-dependent reactivity in ELISA of the
nucleosome-specific antibody, used for selection of MIMO#0, with the MAP-
MIMO#0 peptide suggests that DNA or DNA/histone complexes were also present
during the selection of phages. By their presence, this reagent-derived chromatin
may mediate the binding of DNA- or histone-binding phages to the antibody used
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for selection. Practically, it is almost impossible to determine which reagent has
provided this chromatin bridge between the selected phage and the antibody used for
selection. In addition to the blocking reagents, the chromatin-bridge may have
originated from phages, bacteria or the yeast extract, which all contain DNA and/or
histones by definition. The two mimotopes for two anti-DNA antibodies that have
been reported by Sibille et al. (88) were selected in the absence of blocking reagents,
but other sources of chromatin were still present (i.e. bacteria, phages, yeast extract).
Furthermore, these mimotopes were not only recognized by the antibody used for
selection, but also by the other antibody. 
Although the selection of phages in the complete absence of chromatin
seems impossible by definition, the characterization of mimotopes for anti-
chromatin antibodies in ELISA should only be performed with blocking reagents
devoid of DNA, histones or nucleosomes. However, to the best of our knowledge
such blocking reagents are not available and should be developed. We identified the
motif necessary for binding of dsDNA in the DNAmimic by performing an alanine
scan. The arginines on positions 1 and 7 and the serine on position 4 of the
DNAmimic were crucial for DNA binding. A motif containing two arginines,
separated by four or five other amino acids, has been shown to be directly involved
in the binding of DNA in several DNA-binding proteins (224). We did not perform
an alanine scanning of the MIMO#0 peptide, but compared to the DNAmimic, it
also contains the two arginines (positions 2 and 8) separated by five other amino
acids. This motif, in combination with the asparagine on position 3 of MIMO#0, has
been found in the DNA-binding domain of zinc finger proteins (225). Moreover,
binding of proteins, containing this motif, to non-immunogenic DNA could help to
induce an autoimmune response against DNA and other DNA-binding proteins such
as histones (226). However, we did not observe any effect when we immunized
normal and lupus-prone mice with the MIMO#0 peptide (data not shown). Binding
of dsDNA to MAP-H3(21-37) might be expected, since this peptide is part of the N-
terminal tail of histone H3. Selection of mimotopes for anti-DNA and nucleosome-
specific antibodies does not always have to result in the identification of DNA-
binding peptides since we could not show binding of labeled DNA to the mimotope
peptide D/E-W-D/E-YS/G (87) (not shown), but the possibility remains that this
particular peptide specifically binds histones and/or nucleosomes. In conclusion, our
results show that the presence of reagent-derived nucleosomal material is a serious
problem when anti-chromatin antibodies are used for both screening of random
peptide phage display libraries and the subsequent characterization of
epitope/mimotope peptides in ELISA. Preliminary results also indicate that the
reactivity of SLE patient sera with DNA, histones and nucleosomes greatly depends
on the blocking reagent used (data not shown). The influence of chromatin present
in the blocking reagent on the reactivity of anti-chromatin autoantibodies may also
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play a role in commercially available tests that rely on the use of conventional
blocking reagents. Efforts should be made to develop blocking reagents totally
devoid of chromatin. Since such a blocking reagent does not yet exist, we
recommend at this stage that FCS be used for general serological testing when anti-
DNA responses are measured, and that DNaseI-treated milk be used when anti-
histone reactivity is analyzed.
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Abstract
Anti-nucleosome autoantibodies are most frequently found in patients with the
autoimmune disease systemic lupus erythematosus (SLE). Nucleosomes are the basic
structure of chromatin and consist of 146 base pairs of dsDNA wrapped around an
octamer of the core histones H2A, H2B, H3 and H4. Several epitopes targeted in lupus
by T cells and autoantibodies have been identified in the core histones. Here we
mapped the epitope of a monoclonal anti-histone histone autoantibody, mAb #34,
derived from the MRL/lpr lupus mouse, by screening several random peptide phage
display libraries. We identified the common motif S/G-A-P-A-S/T-G, which
corresponds to amino acid residues 28-33 in the N-terminal region of histone H3.1.
Within this N-terminal region the single amino acid difference between the histone H3
variants H3.1 and H3.3 is located, i.e. at position 31 a serine residue in H3.1 versus an
alanine residue in H3.3, respectively. We demonstrated that #34 was specific for H3.1
both in direct and inhibition ELISA. Compared to the unmodified H3.1 peptide, we
found in ELISA a less pronounced inhibitory effect of the H3.3 peptide and H3.1
peptides phosphorylated at S28 and/or acetylated at K18 and K23. A H3.1 peptide di-
methylated at K27 showed an inhibitory effect comparable to the unmodified H3.1
peptide. In conclusion, we identified #34 as an anti-histone autoantibody specific for
(unmodified) histone H3.1.
Systemic lupus erythematosus (SLE) is an autoimmune disease driven byautoantigens, of which the nucleosome has been identified as a major
autoantigen (13). Nucleosomes are the basic structure of chromatin, which enables
the compact folding of DNA in the nucleus. Each nucleosome consists of 146 base
pairs of double stranded (ds) DNA wrapped around an octamer of the core histones
H2A, H2B, H3 and H4. For a long time, anti-DNA autoantibodies have been
regarded as the serological marker for SLE, however DNA itself is not
immunogenic. When DNA is bound to histones or microbial proteins, it can induce
an anti-nucleosome and anti-DNA response (9, 10). Indeed, nucleosome- and
histone-specific T and B cells have been identified (54-59, 214, 227-229). By using
overlapping histone H3 peptides B- and T cells epitopes have been identified in
histone H3, i.e. amino acids 53-85, 85-119 and 111-130 (55, 58, 227). In addition,
reactivity of sera from lupus mice and patients with the N-terminal tail of histone H3
has been found (212, 230). However, the exact amino acid sequences recognized by
some anti-histone autoantibodies are unknown. Previously, Smeenk and co-workers
characterized several monoclonal autoantibodies (mAb) derived form lupus mice
(81), including anti-histone mAb #34 derived from the MRL/lpr lupus mouse. We
already  demonstrated that this antibody showed a high reactivity with nucleosomes
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and histones, and a low reactivity with a histone H3 peptide, i.e. amino acids 18-32
(94, 221).
In this study, we identified the exact epitope of mAb #34 by screening
several random peptide phage display libraries. The epitope of mAb #34 was found
in the N-terminal tail of histone H3, as S/G-A-P-A-S/T-G (amino acids 28-33).
Using synthetic peptides we could demonstrate that mAb #34 is specific for the
histone variant H3.1 and not for the H3.3 variant, which differs in the N-terminal
region of H3 at amino acid position 31 from the H3.1 variant (A->S). Furthermore,
we demonstrated that mAb #34 preferentially binds to the unmodified H3.1 peptide
(amino acids 18-37) compared to the corresponding peptides acetylated and/or
phosphorylated at K18, K23 and/or S28, respectively. However, mAb #34 showed a
comparable reactivity with a H3 peptide that was di-methylated at  K27. We
conclude that mAb #34 is a histone-specific autoantibody that primarily recognizes
(unmodified) H3.1.
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Figure 1. Histone H3 peptides tested in ELISA. The N-terminal tail of histone H3 (amino acid 1-44)
is depicted, which can be modified by either acetylation of lysine, methylation of lysine or arginine
and phosphorylation of serine or threonine residues. We tested H3 peptides with the H3.1 or H3.3
sequence, or modified residues, i.e. acetylated at K18 and K23 and/or phosphorylated at S28. The
black shaded region corresponds to the identified epitope (28-33) for mAb #34.
A lupus-derived anti-histone autoantibody specific for histone variant H3.1
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Materials & Methods
Random peptide phage display
Antibody #34 is a monoclonal anti-histone autoantibody, derived from the
(NZBxNZW)F1 lupus mouse model, and was purified as described previously (94).
The epitope recognized by antibody #34 was determined by screening a 10-mer
(kindly provided by Dr. C. Putterman), a 12-mer (New England Biolabs) and a 15-
mer (kindly provided by dr. G. Smith) random peptide phage display library with
mAb #34, as described previously (97, 217). 
Direct and inhibition ELISA
The reactivity of mAb #34 was analyzed in a direct and an inhibition ELISA
with the H3(18-32) and H3(30-45) peptides, and several H3(18-37) peptides,
containing  either the H3.1 or H3.3 sequence, or one or more modified residues (i.e.
acetylated and/or phosphorylated at K18, K23 and/or S28, respectively), and the
H3(23-34) peptide di-methylated at  K27 (Abcam, Cambridge, U.K.). All peptides
were synthesized in the peptide synthesis facility of the CNRS in Strasbourg, except
for the H3.3(18-37) peptide  (Eurosequence, Groningen, The Netherlands). For
direct ELISA, Maxisorb® 96-well plates (Nunc, Roskilde, Denmark) were coated
with 100 µl of peptide at a concentration of 2 µM in 50 mM carbonate buffer pH 9.6
overnight at 4°C. The wells were washed with PBS/0.05% (v/v) Tween-20 (PBS-T)
and blocked with 150 µl 1% BSA for 2 hours at room temperature. After washing
with PBS-T, 100 µl of mAb #34 starting at a concentration 10 µg/ml were added in
PBS-T and incubated for 2 hours at room temperature. After washing with PBS-T,
100 µl horseradish peroxidase-conjugated goat anti-mouse Ig(H+L) (Southern
Biotechnology Associates, Birmingham, U.S.A.) diluted 1:7500 in PBS-T were
added and incubated for 1 hour at room temperature. The plates were washed again
with PBS-T and developed for 15 minutes using 100 µl 3,5,3’,5’-
tetramethylbenzidine (TMB) (SFRI Diagnostics, Saint Jean d’Ilac, France). The
reaction was stopped by the addition of 100 µl 2 M H2SO4 and the optical density at
450 nm was measured in a microplate reader (Biorad, Veenendaal, The
Netherlands). 
For inhibition studies, 0.5 µg/ml of mAb #34 diluted in PBS-T was pre-
incubated in a 96-wells plate (Greiner, Alphen a/d Rijn, The Netherlands) with a
series of dilutions of a competitor peptide, and added to a Maxisorb® 96 plate
coated with (unmodified) H3.1(18-37) peptide.
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Results
To map the epitope of mAb #34, we first screened a 10-mer random peptide
phage display library. This resulted into the consensus motif: S/G-A-P-A-S/T-G,
which was deduced from clones obtained after 3 rounds of selection with a
decreasing concentration of mAb #34 (i.e. 1 µM, 10 nM and 100 pM) (Table I). We
could deduce the same motif from clones selected after screening a 12-mer and a 15-
mer library (not shown). The sequence of the selected motif corresponded to amino
acid residues 28-33 of the N-terminal region of histone H3.1. Previously, we
observed a low reactivity of mAb #34 with a histone H3(18-32) peptide (221). Here
we found that mAb #34 had a high reactivity with the H3(18-37) peptide, while no
reactivity with the H3(1-21), H3(30-45) and H3(18-32) peptides could be observed,
although this latter peptide contained almost the entire identified S/G-A-P-A-S/T-G
sequence (data not shown). Since mAb #34 shows a high reactivity with
nucleosomes (94), which initially led to the assumption that it was a nucleosome-
specific autoantibody, we tested the effect of adding DNA to a coated H3(18-37)
peptide. However, the binding of mAb #34 to H3(18-37) was not affected by the
addition of DNA (not shown). These results suggested that mAb #34 is actually a
histone-specific antibody.
Within the identified epitope (amino acids 28-33) for mAb #34 resides the
single N-terminal amino acid difference between the H3 variants H3.1 and H3.3, i.e.
at position 31 an alanine versus a serine residue, respectively (Fig. 1). We
demonstrated in direct ELISA that mAb #34 exclusively binds to the histone
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H3.1(18-37) peptide and not to the H3.3(18-37) peptide (Fig. 2A). Moreover, the
H3.3 peptide was not able to inhibit the binding of mAb #34 to the H3.1 peptide in
an inhibition ELISA (Fig. 2B). 
Modifications of amino acid residues close to or in the S/G-A-P-A-S/T-G -
motif have been described to occur in vivo (see Fig. 1) (14). We tested in a direct and
an inhibition ELISA the influence of some of these modifications on the reactivity
of mAb #34.  H3 peptides acetylated at lysine 18 and 23 and/or phosphorylated at
serine 28, showed a decreased binding of mAb #34 and an about 5-fold lower
inhibitory effect compared to the unmodified H3.1 peptide (Fig. 2, A and B).
However, this effect was much less pronounced when compared to the H3.3 peptide.
We were not able to demonstrate direct binding of #34 to a H3.1 (23-34) peptide di-
methylated at lysine 27, but this could be explained by inefficient coating of this
shorter peptide. However, in the inhibition ELISA the di-methylated H3(23-34)
peptide showed an inhibition comparable to the unmodified H3.1 peptide (Fig. 2, A
and B). 
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Figure 2. Reactivity of mAb #34 with (modified) histone H3.1 and H3.3 peptides in ELISA. A.
Reactivity of #34 was tested with directly coated peptides. The reactivity is calculated as the
reciprocal of the concentration of #34 that yields an absorbance of 0.5 at 450 nm. B. Inhibition of the
binding of #34 to unmodified H3.1(18-37) by (modified) H3.1 and  H3.3 peptides. The inhibitory
concentration (IC) of the peptide that yields a 50% decrease of reactivity of #34 with H3(18-37) is
given as the IC50.
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Discussion
In this study, we have identified the epitope of a monoclonal anti-histone
autoantibody, mAb #34, in the N-terminal tail of histone H3, i.e. amino acids 28-33.
In the past, we have shown that after extensive purification, mAb #34 showed a high
reactivity with nucleosomes, a lower reactivity with histones and a very low
reactivity with a histone H3(18-32) peptide (94, 221). Since for the H3(18-37)
peptide a much higher reactivity was observed than for the H3(18-32) peptide, and
the di-methylated H3(23-34) peptide showed an inhibition comparable to the
unmodified H3(18-37) peptide, we conclude here that mAb #34 requires  amino acid
residues 28-33 for optimal binding.
Four different variants of histone H3 have been reported: H3.1, H3.2 and
H3.3, which have a similar amino acid sequence, and the completely different
centromeric histone H3 variant, CENPA (231). Recently, H3.3 has been associated
with transcriptionally active sites in chromatin, while H3.1 is tightly coupled to
DNA replication and transciptionally silent chromatin regions (232, 233). The full
sequence of H3.1 and H3.3 differs only at four amino acid residues, the three
different residues in the globular domain (i.e. position 87, 89 and 90) which are
crucial for the distinctive function of the H3.3 variant (232), and a single amino acid
difference in the N-terminal tail, for which no clear role has been designated yet. The
N-terminal amino acid difference between the histone H3 variants H3.1 and H3.3,
i.e. at position 31 an alanine residue in H3.1 and a serine residue in H3.3, resides in
the epitope we identified for mAb #34. We showed that mAb #34 is specific for
histone H3.1, since a peptide corresponding to the N-terminal H3.3 sequence was
not recognized by mAb #34 and could not inhibit the binding of the antibody to the
H3.1 peptide. Additionally, we tested several modifications, i.e. acetylation,
phosphorylation and methylation, which have been described in or close to the
identified epitope. The phosphorylation of S28 has been associated with apoptosis,
and could be an apoptosis-induced modification targeted by autoantibodies in SLE
(21, 25, 234, 235). We found that acetylation and/or phosphorylation resulted in a
decreased binding of mAb #34, while methylation had a minor effect on the binding.
However, the inhibitory effect of these modifications was much less pronounced
compared to the inhibitory effect of the single amino acid substitution at position 31
in the H3.3 peptide. Since antibodies specific for histone H3 variants are rare, the
particular specificity of mAb #34 led to the successful application in a study
concerning the presence of histone H3 variants in the early mouse zygote (98). In
this study asymmetry for histone H3 variants in the pre-S-phase zygote was
demonstrated for the paternal and maternal derived nucleus, since staining with
mAb #34 showed that H3.1 is virtually absent from the paternal chromatin, while
localization of the histone H3.3/H4 assembly factor HIRA with the paternal
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chromatin indicated the presence of histone H3.3. Moreover, double staining of
early zygotes with mAb #34 and antibodies specific for modifications in or nearby
the epitope of #34 (i.e. acetylation of K18 or K23, mono-/di-/tri-methylation of K27
and phosphorylation of S28) never revealed a co-localization between mAb #34 and
the mAb specific for H3 phosphorylated at S28, while staining with antibodies
specific for the other modified forms of H3 sometimes revealed a partial co-
localization with mAb #34. Combining all results, we conclude that antibody #34
primarily recognizes (unmodified) histone H3.1.
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Abstract
Objectives: To evaluate the binding of lupus-derived autoantibodies, dsDNA and
nucleosomes to the positively charged SmD1(residues 83-119) peptide.  
Methods: Binding of lupus-derived monoclonal antibodies, SLE patients' sera, dsDNA
and nucleosomes to the SmD1(83-119) peptide was determined using different ELISA
methods. 
Results: Anti-dsDNA antibodies and SLE patients' sera reacted with the SmD1(83-119)
peptide, while DNaseI treatment of the applied reagents led to a decreased reactivity.
Purified dsDNA and nucleosomes bound to the peptide.
Conclusions: The SmD1(83-119) peptide is able to bind dsDNA and nucleosomes, and
dsDNA/nucleosomes in applied reagents can lead to an apparent reactivity of anti-
dsDNA, anti-histone or nucleosome-specific antibodies with the SmD1(83-119) peptide. 
In systemic lupus erythematosus (SLE) a variety of autoantibodies againstnuclear components such as nucleosomes (histones and dsDNA) and
spliceosomal proteins (e.g. SSA/Ro, SSB/La, snRNP, Sm and hnRNP antibodies)
exist. The autoantibody production appears to be antigen driven and T cell
dependent. Recently, the glycine-arginine-rich C-terminal part (residues 83-119) of
the spliceosomal SmD1 protein has been identified as a major autoepitope targeted
by sera from 36-70% of SLE patients (236, 237). The reactivity with the SmD1(83-
119) peptide correlates to the anti-dsDNA reactivity and disease activity (236, 237,
243). Furthermore, SmD1(83-119)-reactive T cells can stimulate the production of
pathogenic anti-dsDNA antibodies and administration of the SmD1(83-119) peptide
to NZB/NZW lupus mice strongly accelerates the progression of the disease (238,
239). 
Anti-Sm reactivity has been included as one of the classification criteria for
SLE by the American College of Rheumatology and at present the anti-SmD1(83-
119) reactivity in ELISA is routinely measured. The binding of dsDNA to the
positively charged C-terminal tail of the SmD1 protein may play a role in the
development of the anti-chromatin immune response in SLE (226, 239), but may
also interfere with ELISA measurements (97). Therefore, we evaluated the binding
of lupus-derived monoclonal anti-dsDNA, anti-histone, nucleosome-specific
antibodies (NSA), SLE patients' sera, dsDNA and nucleosomes to the SmD1(83-
119) peptide using different ELISA methods.
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Materials & Methods
Monoclonal antibodies and patient sera
Monoclonal anti-dsDNA (#36, #42, #56), anti-histone (KM-2 and #34) or
NSA (PL2-3, #32 and LG10-1) were derived from (NZBxNZW)F1 lupus mice,
except PL2-3 (MRL/+ lupus mice) and KM-2 and LG10-1 (MRL/lpr lupus mice)
(97). Following DNaseI treatment of the hybridoma culture supernatants, the
monoclonal antibodies were thoroughly purified as described (82). WT-32 (anti-
CD3 antibody) was used as a control. A rabbit anti-SmD1(83-119) peptide antiserum
was described (237). SLE patients' sera were collected at the Radboud University
Nijmegen Medical Centre and the Charité University Hospital, and approved by the
local ethical committees.
Anti-SmD1(83-119) peptide and anti-dsDNA ELISA
Anti-SmD1(83-119) reactivity was determined in ELISA essentially as
described (237). Coated SmD1(83-119) peptide was blocked with PBS/0.05% (v/v)
Tween-20 (PBS-T) with 1% blocking reagent, i.e. non-fat dry milk (Bio-Rad
Laboratories, Veenendaal, The Netherlands), casein (Sigma, Zwijndrecht, The
Netherlands) or BSA for 2 hours at room temperature (RT). Wells were incubated
with serially diluted (in PBS-T) monoclonal antibody, starting with a concentration
of 5 µg/ml, or 1:100 diluted SLE patients' serum for 2 hours at RT. For detection
horseradish peroxidase-conjugated goat anti-mouse IgG diluted 1:30,000 or goat
anti-human IgG diluted 1:15,000 (Southern Biotechnology Associates, Birmingham,
U.S.A.) in PBS-T was used. Anti-dsDNA ELISA and DNaseI treatment of reagents
were performed as described (97). 
Binding of dsDNA, biotin-labeled dsDNA or nucleosomes to the SmD1 (89-119)
peptide
dsDNA was labeled with biotin according to the manufacturer's instructions
(Roche). Coated SmD1(83-119) peptide was blocked with DNaseI-treated milk or
casein, or BSA (1%) and incubated with serially diluted (in PBS-T) dsDNA (Roche),
biotin-labeled dsDNA or nucleosomes (quantity based on the absorbance at 260 nm)
for 30 minutes at RT. The remainder of the ELISA was performed as described (97).
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Results
Apparent reactivity of anti-dsDNA antibodies and binding of
dsDNA and nucleosomes to the SmD1(83-119) peptide 
The reactivity of lupus-derived monoclonal anti-dsDNA, anti-histone and
NSA with the SmD1(83-119) peptide was determined in ELISA. Using milk or
casein as blocking reagent, all anti-dsDNA antibodies showed a high reactivity with
the peptide, while the anti-histone and NSA hardly reacted (Fig. 1A). With BSA as
blocking reagent only a very low reactivity of anti-histone antibodies could be
observed (Fig. 1A). Recently, it appeared that the application of different blocking
reagents led to different reactivities of SLE patients' sera with the SmD1(83-119)
peptide (240), while we showed that the presence of nucleosomal material in
common blocking reagents interfered with the reactivity of anti-chromatin
autoantibodies in ELISA (97). Therefore, we also tested the effect of DNaseI
treatment of the applied blocking reagent, i.e. milk and casein, which indeed
abolished the reactivity of all monoclonal anti-dsDNA antibodies with the
SmD1(83-119) peptide (Fig. 1A). The addition of purified dsDNA (Fig. 1B) or
nucleosomes (Fig. 1C) to the coated SmD1(83-119) peptide not only restored the
reactivity of anti-dsDNA antibodies, but also revealed reactivity of NSA and anti-
histone antibodies with the peptide (Fig. 1, B and C). We could also demonstrate
direct binding of biotin-labelled dsDNA to the SmD1(83-119) peptide (Fig. 1D).  
DNaseI treatment of blocking reagent and/or serum abolishes anti-
SmD1(83-119) reactivity
We now questioned whether the dsDNA and nucleosomes present in
blocking reagents could also interfere with the reactivity of SLE patients' sera with
the SmD1(83-119) peptide. Indeed, DNaseI treatment of the blocking reagent, i.e.
123
Figure 1. (next page) Binding of lupus-derived monoclonal anti-dsDNA, anti-histone, or
nucleosome-specific antibodies (NSA) with the SmD1(83-119) peptide. The reactivity of the
antibodies was determined in ELISA with milk or casein, either or not treated with DNaseI, or BSA
(1%) as blocking reagent. WT-3 served as a control antibody (A). Reactivity of anti-dsDNA, anti-
histone and NSA with the SmD1(83-119) peptide, using BSA (1%) as blocking reagent, after addition
of dsDNA, starting at 100 ng/ml (B), or nucleosomes, starting at 74 ng/ml (C). Binding of biotin-
labelled DNA to the SmD1(83-119) peptide determined in ELISA with DNaseI-treated milk (1%) as
blocking reagent (D). All results are expressed as absorbance values at 450 nm. The mean (±SD) of
six experiments is shown.
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1% milk, resulted on average in a 90% decreased reactivity of 6 (designated group
I) out of 8 tested sera, while two sera (designated group II) retained about 60% of
their original reactivity. The reactivity of the rabbit anti-SmD1(83-119) peptide
antiserum was not affected (Fig. 2). DNaseI treatment of sera resulted on average in
a 20% decreased reactivity, while the reactivity of the rabbit serum was not altered
(Fig. 2). A combination of DNaseI treatment of both the blocking reagent and the
sera almost completely abolished the reactivity of 6 out of 8 sera (group I), while
two sera (group II) retained about 60% of their original reactivity (Fig. 2). All 8 sera
showed a high reactivity with dsDNA, while the rabbit serum showed no reactivity
(data not shown). In contrast to the anti-SmD1(83-119) reactivity, DNaseI treatment
of reagents did not change the reactivity of the sera with dsDNA (data not shown).
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Figure 2. The reactivity of SLE patients' sera with the SmD1(83-119) peptide and the effect of
DNaseI treatment. The reactivity of the sera from 8 SLE patients, either or not treated with DNaseI,
was determined in ELISA with milk (1%), either or not treated with DnaseI, as blocking reagent. A
rabbit anti-SmD1(83-119) peptide antiserum served as a control. Results are expressed relative to the
reactivity obtained with untreated blocking reagents and sera, which is set to 100%. The mean (±SD)
of six experiments is shown.
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Discussion
We demonstrate that lupus-derived monoclonal anti-dsDNA antibodies can
bind to the spliceosomal SmD1(83-119) peptide when milk or casein were used as
blocking reagents, while anti-histone and NSA hardly reacted with the SmD1(83-
119) peptide. Apparently dsDNA/nucleosomes, which were present in the applied
blocking reagents, mediated the SmD1(83-119) reactivity of anti-dsDNA antibodies,
since DNaseI treatment abolished the reactivity. In line with these findings we
recently showed that nucleosomal material present in blocking reagents could
interfere with the binding of lupus-derived anti-chromatin antibodies in ELISA (97).
The SmD1(83-119) peptide was able to bind purified dsDNA and nucleosomes,
which in addition to the reactivity of anti-dsDNA antibodies, revealed reactivity of
anti-histone and NSA. Taken into account the presence of 16 (out of 37) positively
charged residues in the SmD1(83-119) peptide and the negative charges abundantly
present in dsDNA and nucleosomes, the binding of dsDNA and nucleosomes to the
peptide was not unexpected and previously it has been shown that ss/dsDNA can
bind to Sm proteins (245). Also the reactivity of 6/8 SLE patients' sera with the
SmD1(83-119) peptide was completely abolished after DNaseI treatment of the
reagents, while 2 sera retained their reactivity. These data may explain that the use
of different ELISA methods may lead to great differences (36-70%) in the
prevalence of anti-SmD1(83-119) reactivity in SLE patients (236, 237). Using other
methods the binding of anti-dsDNA antibodies to the intact SmD1 protein and
binding of anti-SmD1 antibodies to ss/dsDNA has also been demonstrated (241-243,
245, 246, 289). The in vivo formation of dsDNA/SmD1 complexes and other
dsDNA/protein complexes may play an important role in the development of the
anti-dsDNA response in SLE (226, 239) and anti-SmD antibodies mainly target the
positively charged structures within spliceosomal proteins (247). Most importantly,
it has been demonstrated that SmD1(83-119)-specific T cells provide help for the
production of anti-dsDNA antibodies (239). Whether SmD1(83-119)-specific T cells
also provide help for anti-histone or NSA remains to be investigated, but our present
findings do point to the formation of nucleosome/SmD1(83-119) complexes.
In conclusion, the measurement of reactivity of sera with the SmD1(83-119)
peptide in ELISA can lead to overestimation of the anti-SmD1 reactivity, since anti-
dsDNA antibodies can also react. Therefore, to distinguish anti-dsDNA reactivity
from genuine anti-SmD1(83-119) reactivity in ELISA, we recommend DNaseI
treatment of all reagents and/or to use BSA as blocking reagent. Nevertheless,
recognition of the dsDNA/SmD1(83-119) complex by anti-dsDNA antibodies, and
of the nucleosome/ SmD1(83-119) complex by anti-dsDNA, anti-histone and NSA,
is a novel finding, which may play a role in the development of the anti-chromatin
immune response in SLE.
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Introduction
Systemic lupus erythematosus (SLE) is an autoimmune diseasecharacterized by the formation of autoantibodies directed against various
autoantigens. These autoantibodies are often specific for antigens located in the
nucleus, such as nucleosomes, histones and double stranded (ds) DNA, but also
RNA-associated proteins, like SS-A, SS-B and Sm. Historically, antibodies against
dsDNA are considered as a hallmark of the disease. Antibodies specific for dsDNA
can be detected in about 70% of SLE patients and in about 96% of SLE patients with
active disease (247). Increasing anti-DNA antibody levels also precede
exacerbations of the disease (100). First, polyclonal B cell activation was regarded
as the mechanism behind the formation of anti-DNA antibodies. Later, it became
clear, however, that SLE is a T cell-dependent and autoantigen-driven autoimmune
disease. Since naked DNA is a poor immunogen, the nucleosome, the basic structure
of chromatin that consists of DNA and proteins, has been proposed as the major
autoantigen (11). The significance of the nucleosome as a major autoantigen in SLE
has been further substantiated by the identification of nucleosome-specific T helper
cells (60) and the high prevalence of anti-nucleosome autoantibodies (12). In
addition, nucleosomes have been detected in the circulation of SLE patients (49) and
lupus mice (51). During apoptosis nucleosomes are clustered in apoptotic blebs at
the surface of apoptotic cells (36). When the removal of apoptotic cells is impaired,
nucleosomes may be released in the circulation due to the instability of these cells.
Indeed, there is increasing evidence that apoptosis is disturbed in SLE (102).
Apoptosis-induced modifications of autoantigens targeted in SLE may make them
more immunogenic (152). This becomes particularly relevant if the removal of
apoptotic cells is insufficient. 
Often no distinction is made between anti-DNA and anti-nucleosome
antibodies, which is confusing. Anti-DNA and anti-histone antibodies are specific
for respectively DNA and histones, but also recognize nucleosomes. Anti-
nucleosome antibodies are defined by their much higher specificity/reactivity
towards the complete nucleosome compared to isolated histones or naked DNA. The
total group of antibodies reacting with nucleosomes, histones and DNA are referred
to as anti-chromatin antibodies. The prevalence of anti-nucleosome antibodies is
even higher than that of anti-DNA antibodies. These anti-nucleosome antibodies are
not exclusively found in SLE, but also in scleroderma and mixed connective tissue
disease (68), although this latter finding was not confirmed in another study (70).
Anti-nucleosome antibodies are detected before anti-DNA antibodies are present in
the circulation, which indicates that they most likely are responsible for the
subsequent induction of both the anti-DNA and the anti-histone antibody responses
via antigen spreading (64). 
129
Chapter 9
Apart from their role as autoantigen, nucleosomes also play a role in
mediating tissue lesions, especially glomerulonephritis (99). Nephritis is one of the
most serious manifestations of SLE and develops in 40-50% of the SLE patients.
Granular deposits of immunoglobulins and complement factors can be found in
glomeruli in renal biopsies of SLE patients, which suggests an immune complex-
mediated pathogenesis. Renal manifestations of the disease are often preceded by a
rise in the level of anti-chromatin antibodies in the circulation, while these
antibodies are also detected in immune deposits in the glomerulus (248). Apparently,
anti-chromatin antibodies play an important role in the development of renal disease
during SLE. However, the mechanism that explains the induction of nephritis by
antichromatin is still under debate. Until now two different models have been
formulated. The first model explains the deposition of anti-chromatin antibodies in
the kidney by direct interaction of these antibodies with molecules present in the
glomerular basement membrane (GBM). The second, in our opinion more favorable
model, attributes the glomerular pathology to nucleosome-mediated deposition of
immune complexes either formed in situ or originating from circulating immune
complexes. Both models will be discussed in more detail in the next sections.
Reactivity of anti-chromatin antibodies with glomerular
components
The causal relationship between autoantibody formation and nephritis in
SLE has intrigued many investigators. A variety of autoantibody specificities has
been assigned a pathogenic role in the development of lupus nephritis. Antibodies
specific for known components of the GBM are not commonly found in SLE, but
most sera are reactive towards the GBM, which led to the idea of cross-reactive
recognition of glomerular components (249). In particular, the observation that
murine and human monoclonal antibodies specific for dsDNA showed a cross-
reactivity to several proteins, has been the basis to explain the binding of
autoantibodies to glomerular components, especially in the GBM (250). This cross-
reactivity has even been used to distinguish pathogenic anti-DNA antibodies in SLE
sera from nonpathogenic anti-DNA antibodies present in normal sera (251). The
cross-reactivity of anti-DNA autoantibodies has been described for various
biomolecules, such as membrane structures like cardiolipin (252-255) and
phosphocholin (256), ribosomal protein P1 (257), A and D snRNP (241), nuclear
proteins like nuclear envelope proteins (258) and the transcription factor EF-2 (259). 
The various in vitro and in vivo studies showing reactivity of anti-DNA
antibodies with glomerular components or the GBM are listed in Tables I and II.
Immunoglobulins in serum from lupus mice and patients show reactivity with
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isolated glomeruli (260), which could be inhibited by the addition of DNA, but not
by DNaseI treatment of the glomeruli. This finding may implicate that DNA shares
epitopes with GBM constituents, but does not mediate the glomerular binding.
Monoclonal anti-DNA antibodies derived from several mouse models for human
SLE, such as the MRL-lpr/lpr, (NZWxNZB)F1 and graft-versus-host (GVH) mouse,
have been shown to react in vivo with isolated glomeruli (261-266). As with the
human sera, DNA could in most cases inhibit the antibody binding to isolated
glomeruli, while DNaseI treatment did not affect this binding. These in vitro results
are summarized in Table I. To approach a more in vivo situation of antibody binding
to the glomerulus, perfusion studies have been performed in which monoclonal
antibodies were directly perfused via the renal artery after which glomerular binding
could be determined by immunofluorescence (Table II). Several mouse monoclonal
anti-DNA antibodies, indeed, could bind to the glomerulus (264). When anti-DNA
antibodies that were complexed with DNA were perfused, no binding could be
observed. Also these more in vivo experiments revealed that human anti-DNA
antibodies could bind to the GBM. After perfusion of IgG, isolated from human SLE
sera by protein A-Sepharose, glomerular binding also could be observed (264).
Interestingly, IgG from SLE patients with nephritis resulted in a higher intensity of
glomerular binding, than IgG from SLE patients without nephritis. The binding to
the GBM could be inhibited by pre-incubating the isolated IgG fraction with DNA,
but not by pre-treatment with DNaseI. A different in vivo approach is intraperitoneal
injection in im-mune-deficient mice of hybridoma cells producing a monoclonal
anti-DNA antibody. This procedure leads to circulating monoclonal antibodies,
which can bind to the GBM. Indeed the injection of anti-DNA hybridomas derived
from MRL-lpr/ lpr (261, 265-268), (NZWxNZB)F1 (261, 264, 268) and SNF1 mice
(266) resulted in glomerular deposits in the capillary wall and in the mesangium. In
some cases the staining of the mesangium was more intense than the staining of the
capillary walls. In another study, i.v. injection of a mouse anti-DNA monoclonal
antibody also resulted in a glomerular staining pattern (265). 
In conclusion, monoclonal anti-DNA antibodies, either from lupus mice or
SLE patients, seem to bind to the GBM both in vitro and in vivo. However, not all
antibodies are able to react with the GBM and the exact features of the antibodies,
which are responsible for the GBM-associated `cross-reactivity’ still remain un-
known. The molecules, to which the anti-DNA antibodies bind, have been identified
in some cases only. 
A major component of the GBM is heparan sulfate (HS), which is the
negatively charged glycosaminoglycan side chain of HS proteoglycan (HSPG). HS
is responsible for the majority of the anionic sites in the GBM, which are the most
important determinants for the charge-selective permeability of the GBM. Loss of
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anionic sites leads to proteinuria, while injection of antibodies specific for HS in rats
instantly induces an acute selective albuminuria (271). In both human and murine
SLE sera anti-HS reactivity has been found (270). In an early report anti-HS
reactivity has been demonstrated in 30 out of 33 SLE patients that were positive for
anti-DNA antibodies in the Farr assay and the anti-DNA ELISA. The observed HS
binding in ELISA could not be attributed to a much higher IgG concentration in the
SLE patients because the IgG concentration was only 2-fold higher compared to the
control sera, while the reactivity towards HS was about 100-fold higher. To exclude
any possible DNA contamination of the HS, which could easily explain the apparent
binding of anti-DNA antibodies, the reactivity of human SLE sera has also been
tested with HS that was pre-treated with DNaseI. However, no difference in
reactivity towards HS could be observed with or without DNaseI pre-treatment
(270). The titers of anti-HS-reactive antibodies showed a significant correlation with
the titers of anti-DNA antibodies both in sera from SLE patients and MRL-lpr/lpr
mice (270). To obtain additional evidence that the binding of anti-DNA antibodies
to the GBM was mediated by HS, ELISA blocking experiments with DNA and HS
have been performed (261). The binding of sera from SLE patients and MRL-lpr/lpr
mice to DNA in ELISA could be inhibited by the addition of either HS or DNA. Vice
versa, the HS reactivity in ELISA could also be inhibited in a dose-dependent
manner by the addition of either HS or DNA. The degree of inhibition varied from
60 to 100% (261). In addition, antibodies eluted from MRL-lpr/lpr kidneys and from
a kidney of a SLE patient showed reactivity towards HS, which again could be
inhibited by the addition of DNA. The observed HS binding is very unlikely caused
by entrapment of serum IgG in the eluate, because the reactivity was much higher in
the eluates than in the corresponding serum (261). Murine monoclonal anti-DNA
antibodies, that are able to bind to the GBM, also showed reactivity to HS or HSPG
in ELISA. Again this could be inhibited dose dependently with DNA or HS,
respectively (261). Binding of anti-DNA antibodies to isolated GBM loops also
could be completely prevented by pre-incubation of the GBM loops with cationic
ferritin, while pre-treatment with heparitinase (i.e. enzymatic removal of HS chains)
reduced the binding considerably, but not completely. The remaining HS might be
responsible for the residual binding of anti-DNA antibodies, but the result might also
indicate that other anionic molecules than HS within the GBM, such as laminin, can
serve as binding sites for anti-DNA antibodies (269). The glomerular binding was
also not due to non-specific charge interaction, since a non-related monoclonal
antibody with a high isoelectric point (above 9.0) did not bind to the GBM. The anti-
DNA antibodies that resulted in glomerular deposits and showed reactivity in
ELISA towards HS, were used for in vivo studies. Hybridomas that produced non-
HS-binding anti-DNA antibodies only resulted in deposits in the mesangium.
Injection of HS-binding anti-DNA producing hybridomas also led in most cases to
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proteinuria in normal mice. This was not the case when non-relevant antibody-
producing hybridomas were used (261). Similar experiments with hybridomas that
produce human monoclonal anti-DNA antibodies did result also in a capillary wall
and mesangial staining and proteinuria (272). All in vivo results that relate anti-DNA
antibodies to glomerular deposition are summarized in Table II. All previously
discussed results seem to support the theory that the most prominent autoantibody
in SLE, anti-DNA, can cross-react with the negatively charged component of the
GBM, HS (261). As will be outlined further this ‘cross-reactivity’ of anti-DNA with
HS was not due to a direct binding, but mediated via nucleosomes bound to the
antibody. 
Screening of a random peptide phage display library is a more recent
approach to identify structural motifs (2) that can explain the reactivity of anti-DNA
antibodies with the GBM. This technique can be used to find mimotopes for anti-
DNA (or anti-nucleosome) antibodies, which are peptide motifs that mimic the
epitopes which are recognized by the antibody. The random peptide phage display
technology has proven to be a powerful technique, especially for antibodies that by
definition do not recognize a protein-based epitope, such as anti-DNA autoanti-
bodies (87, 217). Briefly, the autoantibody is coated on a carrier (i.e. a plate or
beads) and subsequently incubated with a phage library, which contains numerous
different phages that display a short random peptide fused with a phage coat protein.
Finally, the phages that bind to the anti-DNA autoantibody with the highest affinity
are selected. In silico, the selected motifs of course can be compared to all known
proteins sequences, including GBM proteins. A positive match between the
sequence of the selected motif and the sequence of a GBM protein then readily
explains the observed reactivity of the anti-DNA antibody with the GBM. 
Several DNA mimotopes with a motif that mimics the epitope of anti-DNA
autotoantibodies have been selected so far with this random peptide phage display
(87-89). In one study anti-DNA antibodies from sera of SLE patients, which were
positive in the Farr assay, have been purified by a γ-bind Sepharose column followed
by a DNA-Sepharose column (89). The purified antibodies have been used for the
screening of a phage library with a random sequence of 12 amino acids fused to the
pVIII phage coat protein. After several rounds of screening a common motif (amino
acid sequence: RLTSSLRYNP) could be deduced from the selected sequences.
Despite the negative charge of DNA, this motif surprisingly contained some positive
charges. The motif showed only homology with a chromosome-associated
polypeptide. The peptide that was synthesized on the basis of the motif did react
with 88% of the anti-DNA+ SLE patient sera. The reaction of the IgG used for the
selection with the peptide could be inhibited by the addition of dsDNA, native RNA,
denatured DNA, and most efficiently with ssDNA. Apparently, the peptide mimics
a common epitope present in dsDNA, ssDNA and RNA (89). 
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Random peptide phage display has also been applied to several monoclonal
anti-DNA antibodies. Screening of a 16-mer random peptide phage display library
with three anti-DNA antibodies derived from (NZBxNZW)F1 mice did result in
mimotopes for two antibodies (88). The motif obtained by one of the antibodies
(F14.6) contained two cysteines, which could form a loop, negatively charged ami-
no acids and some aromatic residues. The motif selected by the other antibody was
different, but also contained two cysteines, negatively charged and aromatic amino
acids. No significant homology could be found with any other proteins (88).
Screening of a 10-mer pIII phage library with a mouse monoclonal anti-DNA
antibody (R4A) that causes glomerular deposits in non-autoimmune mice, did also
result in a mimotope (87). This mimotope contains a net negative charge, like DNA,
and has two aromatic amino acids, which may mimic the sugar backbone structure
or one of the base pairs. It was evaluated whether the mimotopebased synthetic
peptide could inhibit the deposition of the R4A antibody to the GBM in vivo.
Administration of only the anti-DNA antibody caused deposits in the glomerulus in
SCID mice. Administration of both the mimotope-based peptide and the R4A
antibody reduced the deposits in the glomerulus. Binding of the antibody to the
GBM seems likely, because of the inhibition of glomerular binding by the
mimotope-based peptide. Therefore, one could expect or argue that the mimotope
should mimic a GBM component or structure. However, on the protein level only
homology with collagen XIII could be found (C. Putterman, personal
communication), a molecule that is normally not present in the GBM. The DWEYS
peptide on a MAP backbone has been used to immunize 4-to 6-week-old BALB/c
mice (90). The immune response resulted in antibodies against DNA, histones and
cardiolipin. Most importantly, the mice developed a SLE-like disease with
glomerular deposits of IgG and complement C3 (90). In a recent study the reactivity
of R4A with the NR2 glutamate receptor was found (92). 
Comparison of the amino acid sequences of the different DNA mimics that
have been identified thus far (87-89) reveals that there is no homology between the
mimotopes at all. At first, this finding may seem rather unexpected because the basic
structure of naked DNA, i.e. without associated proteins, is a double helix. The
differences between the several reported DNA mimics may be explained by different
characteristics of the original DNA autoantigen such as different higher-order
structures of DNA (supercoils) or just differences in the nucleotide sequence. Most
importantly, on the amino acid level the DNA mimotopes do not show homology
with any known protein in the GBM. However, it cannot be excluded that the DNA
mimotopes mimic a structural feature of the GBM that cannot be easily deduced
from the amino acid sequences of known proteins. In summary, several studies
suggest that certain anti-nuclear antibodies can bind to glomerular components and
induce glomerular deposits. However, from these studies it is difficult to conclude
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which characteristics of the antibody determine glomerular binding. After a decade
of research by several groups, the ligands in the glomerulus that could serve as
cross-reactive epitopes for anti-nuclear antibodies still have not been identified. So
the direct binding of anti-DNA antibodies to the GBM cannot yet be explained by a
look-a-like of DNA present in the GBM. 
After our initial observation that anti-DNA antibodies could cross-react with
HS and GBM loops (270), we showed that this binding was mediated by
nucleosomes bound to the anti-DNA antibodies (93). As will be outlined in the
subsequent section, removal of these nucleosomal components completely
abrogated the binding to HS in vitro and to the GBM in vivo (99). A similar
observation has been made with respect to other cross-reactive molecules (263,
273). Given these results, in our opinion, it is likely that the majority of the observed
cross-reactions, as discussed above, are mediated by nucleosomal components
bound to the antibodies. Let us assume that this is the case, is it possible to explain
the results described in Tables I and II. A common feature of all these experiments,
summarized in Tables I and II, is that DNA can block the binding to the GBM and
DNaseI treat ment has no effect. This led to the conclusion that binding of DNA to
the antigen binding sites of the antibody prevents cross-reactive recognition of the
GBM ligand. The lack of effect of DNaseI treatment was regarded as proof for the
absence of DNA in the antigen binding site. However, these findings can be ex-
plained differently. When an anti-DNA antibody is complexed to nucleosomes, ad-
dition of DNA to these complexed antibodies will lead to binding of DNA to the
positively charged histone tails, thereby neutralizing these positive charges. This
masking will lead to the abrogation of binding to HS in the GBM. Addition of
DNaseI to the antibodies complexed to nucleosomes will lead to the removal of
DNA from the nucleosome, but will not remove the bound histone part, as we have
documented (94). These remaining histone molecules are still able to bind HS in the
GBM.
The nucleosomes as mediator of autoantibody binding to the GBM 
The nucleosome, the fundamental unit of chromatin, is defined as the total
of compacted DNA and DNA-associated biomolecules in the eukaryotic cell
nucleus. In the nucleosome two superhelical turns of 146 base pairs of DNA are
complexed to the pairs of four different core histones that form an octamer (Fig. 1).
The core histones are histones H2A, H2B, H3 and H4, while histone H1 is bound
outside of the nucleosome. The core histones have a molecular weight that ranges
from about 11 to 15 kDa, a positive charge and an isoelectric point of about 11. The
basic residues are clustered in the flexible N-terminal parts of the core histones,
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which are located outside of the histone
octamer. Nucleosomes are exclusively
formed during apoptosis by enzymatic
cleavage of the linker dsDNA regions of
chromatin. The observation that apoptosis
is disturbed in SLE makes the nucleosome
an important candidate autoantigen. The
antigenicity of nucleosomes can probably
be enhanced by modifications of the
histones or DNA during apoptosis. Several types of modifications associated with
apoptosis and/or chromatin condensation have been described so far. These include
(1) phosphorylation or dephosphorylation of specific sites on the N-terminus of the
core histones (143), (2) methylation of certain amino acids on the N-terminus of the
core histones, (3) hyperacetylation or deacetylation of histones (23, 28), (4)
ubiquitination so far described for topoisomerase II and histone H2A (148), (5)
citrullination, the selective deamination of arginine to citrullin (149), and (6)
transglutaminase-facilitated crosslinking of proteins like histone H2B (150). In
addition to protein modifications, (nucleosomal) DNA can be altered by
methylation. 
As outlined in the introduction there is now convincing evidence that the nu-
cleosome is the driving autoantigen in SLE. Nucleosomes are not only important in
the induction phase of SLE, but they also play an important role in the development
of tissue lesions. Several studies provided the evidence that nucleosomes can act as
a mediator for the binding of autoantibodies to the GBM. As outlined before we
found that certain anti-DNA monoclonal antibody derived from MRL lpr/lpr,
(NZBxNZW)F1 and GVH mice bound to HS isolated from bovine kidney in ELISA
(270). The majority of these HS+ anti-DNA antibodies also showed reactivity with
HSPG isolated from human kidneys. The antibodies showed no ‘crossreactivity’
with other GBM components such as fibronectin, laminin or collagen IV. However,
when the culture supernatants of the anti-DNA antibody-producing hybridomas
were treated with DNaseI, the binding to HS or HSPG was strongly reduced in both
ELISA and Western blot. This could mean that DNA mediates the binding of anti-
DNA antibodies to HS or HSPG. The residual binding then might be explained by
the insufficient removal of DNA form the antibody preparations by DNaseI
Figure 1. Composition of the nucleosome. The
core particle consists of an octamer of four pairs of
core histones H2A, H2B, H3 and H4, and around
146 bp of dsDNA, histone H1 is attached to the
nucleosomes.
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treatment, therefore further purification of the antibodies on a protein A-Sepharose
column under dissociating high salt conditions was carried out. Strikingly, after this
extended purification procedure all previously HS+ anti-DNA antibodies lost their
ability to bind to HS as could be determined in the anti-HS ELISA, whereas they
showed an unaltered anti-nuclear antibody reactivity in immunofluorescence on rat
liver sections. The reactivity of these purified antibodies with HS and HSPG could
be restored by the addition of the effluent of the protein A-Sepharose column. Figure
2A depicts a representative experiment with the monoclonal antibody clone #32,
which later appeared to be a genuine anti-nucleosome antibody. The purified anti-
DNA antibody was used for immunoprecipitation of the component that could
restore the binding to HS, from the protein A effluent. After SDS-PAGE, the
precipitated material clearly showed multiple bands with a molecular weight
between 10 and 15 kDa, which were identical to calf thymus histones (Fig. 2B). In
addition, the presence of DNA in the unpurified antibody preparation could be
detected by agarose gel electrophoresis after DNA isolation (Fig. 2C). DNaseI
treatment of the protein A-Sepharose column effluent abolished the reconstitutive
effect of the effluent with respect to HS binding of purified anti-DNA antibodies,
which provided additional evidence for the presence of bound DNA in unpurified
anti-DNA antibodies. The presence of both DNA and histones was required for the
binding of anti-DNA antibodies to HS because the separate addition of histones or
DNA to the purified antibody could not restore the HS binding. Apparently, a DNA-
histone complex was already bound to the unpurified anti-DNA antibody. Indeed,
during hybridoma culture nucleosomes are released (274). We therefore concluded
that the binding of anti-DNA antibodies to HS and HSPG is mediated by DNA-
histone complexes bound to the anti-DNA antibody (93). 
In addition to the ELISA studies, in vitro binding studies have been
performed with isolated GBM loops (275). Anti-DNA antibodies extensively
purified as described above did not bind in vitro to the GBM loops isolated from
human kidney. Pre-incubation of the anti-DNA antibodies with both DNA and
histones led to a strong granular binding. Addition of histones or DNA alone to the
anti-DNA antibodies did not lead to binding to GBM loops. Pre-incubation of GBM
loops with cationic ferritin prevented subsequent binding of histone-DNA-antibody
complexes, which indicated that anionic sites like HS in the GBM were important
for this binding. 
To analyze whether this binding to HS could also take place in vivo, renal
perfusion studies in normal rats have been performed. In this approach histones,
DNA and purified antibody were subsequently perfused via the renal artery (Fig. 2,
D and E). Perfusion of non-complexed purified antibodies did not lead to glomerular
binding, however, after successive perfusion of histones, DNA and several anti-
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Figure 2. Reactivity with HS and the GBM of anti-nucleosome antibody #32. The purification
procedure included DNaseI treatment and Protein A-Sepharose chromatography under dissociative
high salt conditions. A. Clone #32 binds in the HSPG ELISA before purification (sup); after
purification under dissociative condition on a Protein A column this reactivity is lost (pur), while
addition of the Protein A column effluent to the purified monoclonal antibody restores the binding
activity (pur + eff). B. SDS-PAGE followed by silver staining of antibody fractions before
purification (lane 3) and after purification (lane 1 and 2). Before purification histone bands are
visible. Marker (M) is a protein marker (in kDa). C. Agarose gel electrophoresis after DNA extraction
of antibody fractions before (lane 1) and after purification (lane 2). Marker (M) is a DNA marker (in
bp). The gel is stained with ethidium bromide. D. Immunofluorescence (stained with FITC-labeled
anti-IgG) of rat kidney sections. After successive renal perfusion of histones, DNA and purified
monoclonal antibody #32 into the left kidney. A strong staining of glomeruli can be detected. E.
Similar to (D), but now histones, DNA and a non-relevant antibody (WT32) have been successively
perfused. No glomerular staining is seen (glomeruli indicated with arrow). Note that due to prolonged
exposure auto-fluorescence of the tubuli is observed. 
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DNA antibodies, immunofluorescence analysis revealed an intense staining of the
glomeruli, arteries and peritubular capillaries. Immunoelectron microscopy analysis
showed large deposits at the cell membranes of glomerular endothelial cells and
smaller complexes in the GBM. In the case of a high-avidity anti-DNA monoclonal
antibody, perfusion of only DNA and subsequently an anti-DNA antibody did only
result in mesangial deposits, but not in deposits in the capillary loop. 
A completely different glomerular deposition pattern could be observed
when the high avidity anti-DNA antibody was administered into the tail vein 1 h
after the perfusion of histones and DNA into the left kidney via the renal artery and
subsequent restoration of the renal circulation (275) Deposits now could be detected
along the capillary wall in a membranous pattern, while variable amounts were
present in the mesangium. Immunoelectron microscopy revealed the presence of
immune deposits in the GBM located in the slit pores and under the foot processes
of the podocytes. In contrast to the direct perfusion method, no binding to the
endothelial cells could be observed. Most likely the 1 h time interval between
intrarenal perfusion of histones-DNA and the intravenous administration of the anti-
DNA antibody allows for the penetration of DNA-histones into the glomerular
capillary wall, where they then serve as planted antigens for the monoclonal anti-
DNA antibody. The direct perfusion method also resulted in an increased urinary
excretion of albumin, which suggests a damaged glomerular filter. Control
experiments with non-related monoclonal antibodies of the same isotype and at the
same concentration did not result in any glomerular binding. In conclusion, anti-
DNA antibodies can bind via complexes of histones and DNA to the GBM, which
results in subendothelial or subepithelial deposits and proteinuria. Only in the case
of high-avidity anti-DNA antibodies was the presence of DNA alone sufficient for
glomerular binding, which, however, was exclusively localized in the mesangium.
These studies revealed that the DNA-histone complex served as a planted antigen in
the GBM for anti-DNA antibodies (275). Histones alone can also act as planted
antigens for artificially prepared DNA-anti-DNA complexes as has been shown in a
study in rats, in which prior to the administration of DNA-anti-DNA complexes,
histones were perfused through the renal artery (276). 
In vivo histone-DNA complexes exist as nucleosomes, therefore, the
perfusion experiments described above were repeated with antibodies complexed
with nucleosomes (94). The applied monoclonal antibodies were partially purified
from the hybridoma culture supernatant by protein A-Sepharose under physiological
salt conditions, which yields antibodies still complexed to nucleosomes. Control
perfusions were performed with purified antibodies free of nucleosomes (see also
Fig. 2, B and C). This latter purification method included DNaseI treatment of the
hybridoma culture supernatant, a protein A-Sepharose column under high salt
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conditions and in some cases a DNA-cellulose column, which removes antibodies
still bound to histones. The purity of the antibody fractions was analyzed by SDS-
PAGE and agarose gel electrophoresis for the presence of histones and DNA,
respectively. In contrast to unpurified antibodies and antibodies purified under
physiological conditions, all extensively purified antibodies did not contain DNA
and/or histones. The purified antibodies have been tested in ELISA for their
reactivity towards DNA, histones and nucleosomes. It then turned out that only
some anti-DNA antibodies reacted with nucleosomes. Most likely, the reactivity
with dsDNA of the formerly classified anti-DNA antibodies was due to histones
within the nucleosome bound to the antibody. The `genuine’ anti-DNA antibodies
reacted after purification with both DNA and nucleosomes. The reactivity of `anti-
DNA antibodies’, which were in fact anti-nucleosome antibodies, with HS in ELI-
SA could only be demonstrated when these antibodies were not purified. In agree-
ment with this latter finding, the purified anti-nucleosome antibodies did not show
glomerular binding, while unpurified anti-nucleosome antibodies did show
glomerular binding, as could be seen by immunofluorescence after renal perfusion
experiments. As expected, reconstitution of purified anti-nucleosome antibodies
with purified calf thymus nucleosomes restored glomerular binding. In conclusion,
both immune complexes consisting of anti-DNA-nucleosome and anti-nucleosome-
nucleosome are able to bind to the glomerulus in vitro and in vivo (94). To
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Figure 3. Effect of heparin and non-coagulant heparinoids on binding of nucleosome/anti-
nucleosome complexes to HS or the GBM. In vitro experiments: inhibition of the binding of the
complexed anti-nucleosome antibody #34 to coated HS (A) or DNA (B) in the inhibition ELISA.
Binding of complexed #34 to both HS (A) and DNA (B) was inhibited dose dependently by heparin
(HEP), N-desulfated/acety-lated heparin (DSA-HEP) and low-molecular-weight
desulfated/acetylated heparin (LMW-DSA-HEP). Dextran could not inhibit the binding. In vivo
experiments: C. Direct immunofluorescence (with FITC-labeled anti-IgG) of glomeruli of BALB/c
mice after perfusion of complexed anti-nucleosome #34 mixed with dextran (1) or heparin (2). After
perfusion of complexed antibody #34 mixed with dextran clear binding of the complex to the
glomerulus was observed (1). However, the addition of heparin to the complexed antibody #34 could
completely prevent this binding (2). D. Cumulative incidence of albuminuria in the various groups
of MRL-lpr/lpr mice. Starting at the age of eight weeks MRL-lpr/lpr mice were treated once daily
with either 50 µg HEP, DSA-HEP, LMW-DSA-HEP or with PBS as control. Each group consisted of
15 animals. Albuminuria was considered to be present when the urinary albumin excretion exceeded
300 µg/18 h (mean +2 SD of albuminuria in non-SLE normal control mice). This mean value is 100
µg/18 h, P < 0.05. E. Representative examples of the immunofluorescence findings of glomeruli of
MRL-lpr/lpr mice either treated with PBS (1) or HEP (2). PBS-treated mice show extensive
deposition of IgG, mainly along the capillary wall. In HEP-treated animals the deposits were confined
to the mesangium. Thus, HEP treatment prevented deposition in the capillary loop. F. Severity of
glomerular lesions in MRL-lpr/lpr mice treated with phosphate-buffered saline (PBS), HEP, DS-HEP
or LMWHEP. The severity of the glomerulus was scored as normal (no), mild glomerulonephritis or
severe glomerulonephritis. 
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investigate the significance of HS in the GBM for glomerular binding of
nucleosome-complexed autoantibodies, heparinase was perfused intrarenally prior
to administration of the immune complexes. After heparinase perfusion the staining
of HS side chains of HSPG within the GBM almost disappeared completely, while
the staining of the HSPG core protein was not affected. Staining of other GBM
components, like laminin and collagen IV also was not affected by heparinase per-
fusion. Perfusion of nucleosome-autoantibody complexes after the heparinase
treatment did result in a decreased binding to the GBM, but this binding did not
disappear totally (94). This observation suggested that HS is not the only ligand that
is responsible for the binding of anti-nucleosomes-nucleosome immune complexes
to the GBM. The binding of nucleosome-containing immune complexes to other
GBM components has indeed been reported (277). In this latter study, the binding of
sera from MRL-lpr/lpr mice to GBM could be competitively inhibited by DNA or
histones and collagenase treatment of the GBM. The binding of the antibodies could
only be restored after the addition of collagen IV. With purified GBM components
coated in ELISA antibody binding could only be observed when DNA was coated
on collagen I; however, no or little binding was observed when DNA was coated on
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collagen IV, laminin or fibronectin. Coating of histones prior to DNA coating on
collagen IV resulted in a positive binding of the MRL/lpr sera. These latter findings
suggested that nucleosomes can bind to collagen IV via their histone parts,
analogous to the situation with HS (277).
Other evidence that HS is the major target in the GBM for nucleosome-
mediated autoantibody binding came from our studies in which we used heparin,
which is structural very similar to HS (174). We hypothesized that heparin could
bind to the positively charged N-terminal parts of the core histones within the nu-
cleosomes, thereby preventing histone binding to HS. Indeed, in ELISA heparin and
non-coagulant heparinoids could inhibit dose-dependently the binding of
nucleosome-complexed autoantibodies to HS or DNA (Fig. 3, A and B). Similarly,
in renal perfusion experiments heparin could prevent glomerular binding of
nucleosome-complexed autoantibodies, while dextran showed no effect (Fig. 3C). In
vivo in MRL-lpr/lpr mice daily subcutaneous administration of heparin or non-
coagulant heparin derivatives prevented the development of proteinuria and glo-
merular lesions (Fig. 3, D and F). Immunohistology of the kidneys revealed that in
heparin(oid)-treated mice only mesangial deposits were present and in 80% of the
heparin(oid)-treated animals no glomerular lesions could be observed (Fig. 3E)
(174). These results support that immune complex deposition in lupus mice is
mediated for the greatest part by the interaction of cationic histones with anionic HS.
To further document that the N-termini of the core histones are important for the
binding to HS, we performed in vivo inoculation studies with hybridoma cells in
BALB/c nude mice (82). We hypothesized that anti-histone producing hybridomas
would generate less nephritogenic nucleosome-autoantibody complexes than anti-
nucleosome or anti-DNA antibodies. Our hypothesis was based on the fact that the
epitopes for anti-histone antibodies reside within these N-termini. Binding of anti-
histone antibodies to the cationic tails would reduce the ability of histones to bind to
the anionic HS in the GBM, i.e. because of masking of the positive charges on these
N-termini. Binding of anti-nucleosome or anti-DNA antibodies would hardly
influence these charges. Inoculation of the different hybridoma cells led to
detectable levels of antibodies in ascites only against the part of the nucleosome, to
which the antibody produced by the hybridoma was directed (Fig. 4A). Antibody
reactivities in plasma samples were comparable to those obtained in ascites
indicating that the antibodies were transferred to the systemic circulation. Indeed,
inoculation of mice with three different anti-histone hybridomas induced only in
15% of the animals glomerular deposits, while with three different anti-nucleosome
and three anti-DNA antibodies 60% of the animals had GBM deposits (Fig. 4, C and
D) (82). Apparently, the differences in glomerular binding between the antibodies
were not due to differences in the levels of nucleosome-autoantibody complexes,
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Figure 4. Glomerular binding
after intraperitoneal inoculation
of hybridomas producing anti-
nuclear antibodies. A. Reactivity
of ascites of mice inoculated with
anti-DNA, anti- histone, anti-
nucleosome or control hybridoma
(producing CD7) in ELISA
towards the different nuclear
antigens: histones, DNA and
nucleosomes. The titer in ELISA
was defined as the reciprocal of
the dilution giving an OD of 1.0
at 450 nm and expressed per mg
of Ig. The results show that the
appropriate specificity was
detected in the ascites. 
B. Nucleosome-IgG complex
assay performed on as cites from
mice inoculated with anti-DNA
(n =3), anti-histone (n =3), anti-
nucleosome toneal (n =3) or CD7
control hybridomas (n =3).
Values are given as mean ± SEM.
No statistically significant
difference was found between the
amounts of complexes formed for
the different anti-nuclear
antibodies. C. Immuno-
fluorescence analysis of kidney
sections of mice inoculated with
anti-DNA (n =15), anti-histone (n
=13), anti-nucleosome (n =13) or
control hybridomas (n =6). The
results are expressed as
percentage of mice with GBM
deposits. D. Representative
examples of kidney sections of
mice inoculated with anti-DNA
#42 (1) or anti-nucleosome #32
(2).
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since these were not different (Fig. 4B). 
These latter observations may seem in contrast with previous results that
show direct binding of anti-DNA antibodies to the GBM, which were explained by
cross-reactivity. However, there is a good explanation for this apparent contradic-
tion. A major point of concern is the purity of the antibody fractions that have been
used in the experiments as outlined earlier. During the culture of hybridoma cells
apoptosis occurs spontaneously and of the hybridoma cells nucleosomes are
released (274). This material will subsequently bind to the monoclonal antibodies
that are present in the supernatant and which are directed against nucleosomes. This
undoubtedly leads to the formation of nucleosome-antibody complexes (94, 278). In
studies describing cross-reactivity mostly unpurified antibodies from culture
supernatants or only partial purified antibodies by protein A/G-Sepharose columns
are used. However, this latter purification step under physiological conditions does
not dissociate the bound DNA and especially the bound histones from the antibody,
as we have shown (94). Sometimes a DNaseI treatment of the culture supernatant is
used, but in most cases not in combination with high salt-p rotein A/G-Sepharose.
In our experience anti-nucleosome and anti-DNA antibodies have to be purified by
DNaseI treatment, high salt-protein A/G-Sepharose and a DNA cellulose column
(which removes residual histone-containing complexes). Many reports do not show
or discuss the purity of the applied anti-DNA, anti-histone or anti-nucleosome
antibody preparations, which is of prime importance for studies that aim to unravel
the mechanism of glomerular deposition in SLE.
Evidence for nucleosome-mediated binding in lupus nephritis 
So far, we have presented experimental data for the role of nucleosomes as
mediators for autoantibody binding to the GBM. However, if this concept is true,
nucleosomes and anti-nucleosome antibodies should be present in the glomeruli of
patients and mice with spontaneous lupus nephritis. We therefore set up a number of
studies to investigate whether these proteins and antibodies were present in the glo-
merulus in lupus nephritis. First, we searched for the presence of
nucleosomes/nucleosomal antigens in glomerular deposits. A polyclonal anti-
histone H3 serum which reacts with the N-terminal amino acids 1-21 was used to
probe histones in kidney biopsies of 11 SLE patients with diffuse proliferative
glomerulonephritis (DPGN) and six patients with lupus membranous
glomerulonephritis (MGN) (95). Histones could be detected in all of the eleven SLE
patients with DPGN and two out of the six SLE patients with MGN (Fig. 5A). A
histone monoclonal antibody (KM-2), which reacts with the N-terminal parts of both
histone H2A and H4, only demonstrated the presence of histones in three patients
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with DPGN and none of the patients with MGN. In addition a nucleosomal staining
could be detected by using three different nucleosome-specific antibodies (LG10-1,
LG8-1 and #34) in five patients with DPGNand two patients with MGN(the same
two patients that stained positively for histones). Anti-DNA antibodies (#36, #42
and #56) did not reveal DNA in glomerular deposits. This latter finding seems
remarkable since nucleosomes (that contain DNA per definition) could be detected
by anti-nucleosome antibodies. We assume that all epitopes within DNA recognized
by the probing anti-DNA antibodies were masked by autoantibodies present within
the glomerular deposits. This also explains why the histone epitopes were much
more easily to detect, because when these epitopes are covered by anti-histone
antibodies the complex will not bind to the GBM as outlined above. In non-SLE
glomerulonephritis none of the applied monoclonal antibodies could stain
glomerular deposits. However, the presence of DNA in immune deposits associated
with human lupus nephritis has been demonstrated at the electron microscopy level
by an anti-DNA antibody labeled with protein A-gold and DNaseI-gold complexes
(279). Histones and nucleosomes have also been detected in immune deposits in two
models of murine SLE (NZBxNZW)F1 and GVH mice (280). 
In order to evaluate the sequence of deposition of the different autoantibody
specificities in MRL-lpr/lpr mice, we eluted glomeruli from 18-to 24-week-old mice
with either no proteinuria, short duration proteinuria (within 1 week of onset) or
heavy proteinuria (for more than 3 weeks) (248). The onset of proteinuria was
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Figure 5. Presence of nucleosomes and
anti-nuclear antibodies in glomerular
deposits in lupus nephritis. A. Presence of
nucleosomal antigens in GBM deposits in
kidney biopsies of SLE patients with
either DPGN or MGN and non-SLE
controls with either mesangiocapillary
glomerulonephritis (MCGN) or
idiopathic MGN. Staining of histones
with polyclonal rabbit anti-H3 1-21
serum, staining of nucleosomes with
monoclonal antibody #34, LG8-1 and
LG10-1, staining for DNA with antibody
#42 was negative in all biopsies. 
B. Immunoglobulin concentration and
titers towards nucleosomal antigens of
glomerular eluates from MRL-lpr/lpr
mice. The 18-to 24-week-old mice either
had no albuminuria, short albuminuria of
less than 7 days or prolonged albuminuria
for 14-21 days. 
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accompanied by a 3-fold higher IgG content of the eluate, which did not increase
further in mice with heavy proteinuria. The analysis of the antigen specificities in
the eluates showed that anti-nucleosome antibodies deposited first, while the highest
reactivity for anti-DNA antibodies was found in mice with heavy proteinuria. Anti-
histone reactivity was low and did not increase further when proteinuria developed
or progressed (Fig. 5B). 
Evidence for the presence of nucleosome-immune complexes in lupus
nephritis was obtained rather indirectly. Using monoclonal antibodies against HS
and HSPG core protein (271, 281) we found an almost complete absence of HS
staining in the GBM in renal biopsies from patients with lupus nephritis, while the
staining for the core protein remained unaltered (282). Since MRL/lpr mice also
showed this decrease in HS staining at advanced states of nephritis (283), we could
study the responsible mechanisms in more detail. In these lupus mice the decrease
in HS staining correlated inversely with the amount of immunoglobulin deposits in
the GBM. The pathophysiological significance of the reduction of HS staining was
underlined by the inverse correlation with albuminuria. Also in human lupus
nephritis an inverse correlation was found between HS staining and the amount of
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Figure 6. Schematic representation of the binding of nucleosome-anti-nucleosome complexes to the
GBM. (Left to right) No binding will occur of non-complexed anti-nuclear antibodies (1) or free
nucleosomes (2). Binding of anti-nucleosome (3) or anti-DNA (4) will decrease the density of
negative charges of the nucleosome - this will enhance binding of the complex to the negatively
charged GBM. In contrast to this, binding of anti-histone antibodies (5) to the nucleosome will
decrease the amount of positive charges, which reduces the capacity to bind to HS in the GBM.
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histone deposits in the GBM (95). The decrease in HS staining was not due to
decrease in HS content since the amount of HS within the GBM was normal (283).
Together, these data suggest that the decrease in HS staining is due to masking of
HS by nucleosome-immune complexes. Indeed, nucleosome autoantibody
complexes were able to inhibit dose dependently the binding of the anti-HS
monoclonal antibody JM403 to HS in ELISA, whereas non-complexed autoanti-
bodies had no effect (283). As outlined above, heparin treatment in MRL/lpr mice
prevented formation of deposits in the GBM. In these heparin-treated animals a
decrease in HS staining was not observed (174). Therefore, in SLE nephritis HS is
masked by deposited nucleosome-autoantibody complexes. This masking may have
the same functional consequences as reduction of HS, since it may lead to an
enhanced permeability of the GBM as shown by the induction of albuminuria by the
anti-HS monoclonal (271).
Conclusion
Nucleosome-mediated autoantibody binding to HS in the GBM is
responsible for the formation of immune deposits in the GBM in lupus nephritis. As
outlined in this review, a large part of the evidence for direct binding of
autoantibodies to the GBM due to `cross-reactivity’ is questionable and is explained
by the use of unpurified autoantibodies, more specifically the use of autoantibodies
already complexed with nucleosomes. In our model, detailed in Fig. 6, autoantibody
binding or deposition to the anionic GBM is mediated by the binding of the cationic
and protruding N-termini of the histones to the GBM. Furthermore, the binding of
anti-nucleosome or anti-DNA antibodies to the nucleosome will mask its negative
charge and will facilitate the binding of the positively charged N-terminal histone
tails to the GBM, which ultimately leads to the deposition of immune complexes.
On the other hand the binding of anti-histone antibodies to the N-terminal histone
parts will mask their positive charge, which will lead to reduction of deposition of
immune complexes (see Fig. 6 for details). 
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The autoimmune disease systemic lupus erythematosus (SLE) ischaracterized by autoantibodies that target about 100 sofar identified
targets (8). The nucleosome has been suggested as a major player in this complex
autoimmune response (39). Nucleosomes are the basic structure of chromatin, which
enables the dense packing of DNA in the nucleus. Each nucleosome consists of 146
base pairs of dsDNA wrapped twice around an octamer of pairs of the core histones
H2A, H2B, H3 and H4. Chromatin is cleaved into nucleosomes during apoptosis
and clusters together with other autoantigens at the cell surface of apoptotic cells.
During apoptosis, nucleosomes can be modified by the addition or removal of
covalently linked moieties. Therefore, we appointed a central role to the nucleosome
which links an impaired apoptosis or removal of apoptotic cells and the subsequent
release of modified apoptotic material to the initiation of an anti-chromatin
autoimmune response and the development of lupus nephritis (see also Chapters 1
and 2). In this thesis, we have further evaluated the role of the nucleosome within
this proposed model.
Apoptosis-induced histone modifications: the driving force for the
anti-chromatin response in SLE
Apoptotic cells are the unique source of nucleosomes, which are formed
through the cleavage of chromatin by endonucleases. Apoptosis, or programmed cell
death,  involves cleavage and modification of numerous proteins. Remarkebly, many
of these modified non-histone proteins are targeted by SLE autoantibodies.
Although, apoptosis-induced histone modifications have been described, these
modifications have never been identified as targets for SLE-derived autoantibodies.
In chapter 3, we have identified apoptosis-induced acetylation of histones as a
target for SLE autoantibodies. We mapped the epitope of KM-2, a monoclonal anti-
histone autoantibody derived from the MRL/lpr lupus mouse, by random peptide
phage display in the N-terminal region of histone H4. For this region acetylation of
lysines at positions 5, 8, 12 and 16 has been described. We found that KM-2
preferentially recognized H4 peptides acetylated at lysine 8,12 and/or 16. Moreover,
we assessed the binding of KM-2 to histones from cells treated with a histone
deacetylase inhibitor (Trichostatin A, TSA), which induces hyperacetylation of
histones, and cells treated with camptothecin (CPT, an inhibitor of DNA
topoisomerase I) or anti-Fas antibody, which both induce apoptosis. Cells treated
with TSA, CPT or anti-Fas all revealed a stronger nuclear staining with KM-2. This
was also confirmed by Western blot analysis of the resolved extracts, which revealed
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an enhanced reactivity of KM-2 with histone H4 and H2A. In addition to these
findings with the monoclonal autoantibody KM-2, we also found that polyclonal
autoantibodies in plasmas from SLE mice and patients showed an increased
reactivity with at least one of the acetylated H4 peptides compared to the unmodified
H4 peptide. In addition, Western blot analysis revealed a higher reactivity of these
plasmas with histones H4, H2A, H2B, H3 (and H1) extracted from cells treated with
CPT or TSA. Acetylation and deacetylation of histones is a dynamic process, which
involves histone acetyltransferases (HATs) and histone deacetylases (HDACs). The
apoptosis-induced hyperacetylation of histones appeared to be mediated by an
increased histone acetyltransferase activity and a decreased histone deacetylase
activity as measured by a fluorescence-based assay in (apoptotic) cell extracts. From
these results we concluded that histones acetylated during apoptosis are a target of
autoantibodies in SLE. 
To asses the effect of a tri-acetylated histone H4 peptide on the development
of disease in MRL/lpr mice, we treated these mice with either a histone H4 peptide
tri-acetylated at lysine residue 8, 12 and 16, an unmodified H4 peptide or PBS.
Treatment of MRL/lpr mice with the tri-acetylated H4 peptide, compared to
treatment with unmodified H4 peptide or PBS, significantly accelerated disease as
measured by proteinuria and the progression of skin lesions. The titers of the anti-
chromatin autoantibodies were not different between the different treatment groups,
but the delayed type hypersensitivity (DTH) response against the tri-acetylated H4
peptide was significantly higher than against the unmodified H4 peptide in all
groups, irrespective of the treatment. Therefore, in the MRL/lpr lupus mice a T cell
response is  mounted against these histone modifications.
These novel observations indicate a crucial role of apoptosis-induced histone
modifications in the pathogenesis of SLE. Apoptosis-induced autoantigen
modifications are normally not encountered by the immune system. However, an
impaired removal of apoptotic cells leads to the release of modified nucleosomes
(see next section). This may then lead to the disruption of the balance between
tolerance and autoimmunity. 
Removal of apoptotic cells: release of modified nucleosomes
Normally, phagocytes (mainly macrophages) swiftly remove apoptotic cells
to prevent exposure of their contents to the environment. Accumulating evidence
shows that in SLE a defective removal of apoptotic cells leads to the release of
apoptotic material, including modified nucleosomes and histones. Mice deficient for
molecules involved in the complex process of apoptotic cell removal, develop anti-
nuclear autoantibodies and in some cases glomerulonephritis. In SLE patients, it
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been demonstrated phagocytosis of apoptotic cells is impaired. However, in lupus
mice, like the MRL/lpr and (NZWxNZB)F1 models, there is no clear evidence for
an impaired phagocytosis of apoptotic cells. Previously, work from our lab has
demonstrated that a defective removal of apoptotic cells is not an intrensic defect
already present in lupus mice before disease development (42). In chapter 4, we
describe a decreased removal of apoptotic cells in diseased SLE mice. We analysed
the ability of resident peritoneal macrophages from pre-diseased and diseased
MRL/lpr and (NZWxNZB)F1 mice to phagocytose apoptotic cells in an in vitro
assay. The in vitro assay was carried out with autologous macrophages and apoptotic
thymocytes in the presence of autologous serum. Macrophages isolated from
diseased MRL/lpr and NZBxNZW(F1) SLE mice, and from age-matched NZB mice
showed a decreased phagocytic capacity. The decreased phagocytosis was due to a
factor present or absent in the serum of diseased SLE mice, since the addition of
serum from diseased mice to macrophages from normal or pre-diseased lupus mice
led to a decreased of phagocytosis. In contrast to another report (43), we could not
demonstrate a constitutive phagocytic defect in the macrophages of pre-diseased or
diseased SLE mice. However, we did find a difference in phagocytic capacity for
apoptotic cells when we compared macrophages from several control mice strains.
This may explain the results described in the studie of Potter and co-workers, which
used macrophages BALB/c mice as a control, which appeared to possess a higher
phagocytic capacity compared to other control and SLE strains.
We concluded that during disease progression in murine lupus apoptotic cell
clearance deteriorates due to a factor present or absent in the serum, which may play
an inportant role in disease progression. This serum factor may be a critical
component required for the phagocytosis or an inhibitor of phagocytosis. However,
further research is needed to identify this serum factor. Several candidates involved
in the removal of apoptotic cells are of potential interest (40), such as IgM,
complement, DNaseI, serum amyloid P (SAP), thrombospondin, C-reactive protein,
C1q, nucleosomes (39). An alternative explanation could be the presence of certain
autoantibodies which influence this process. 
Anti-nucleosome & anti-C1q autoantibodies in patients with lupus
nephritis
Anti-nucleosome autoantibodies are most frequently found in SLE patients.
The level of anti-nucleosome autoantibodies appears to be correlated with disease
activity and the presence of lupus nephritis, the most severe manifistation in SLE
patients (41). Moreover, anti-nuclear autoantibodies can be detected in the sera of
patients already up to 10 years before onset of the disease (164). Anti-nucleosome
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autoantibodies can be divided into three categories: 1) antibodies that recognize
DNA (anti-DNA); 2) antibodies that recognize histones (anti-histone); and 3)
antibodies that exclusively or predominantly recognize nucleosomes or
subnucleosomal structures (nucleosome-specific). Within the Dutch Working Party
on SLE, we have studied the anti-nucleosome, anti-DNA and anti-histone response
in SLE patients with proliferative lupus nephritis (chapter 5). These patients were
enrolled in the first Dutch lupus nephritis trial and were either treated with
cyclophosphamide and prednison (CY) or azathioprine, methylprednisolon and
prednison (AZA). This latter treatment was compared to the standard CY/P
treatment, since cyclophosphamide often results in infertility in these young female
lupus patients. We analysed autoantibody profiles in these patients during their first
year of treatment. We could demonstrate that there was no significant difference in
the anti-nucleosome, anti-DNA, anti-histone or anti-C1q responses between the two
treatment groups. We observed anti-nucleosome, anti-DNA, anti-histone anti-C1q
reactivity in 81%, 96% , 23% and 62% of the patients, respectively. Antibody titres
rapidly decreased for all autoantibodies shortly after start of the treatment. We found
a correlation between anti-nucleosome, anti-DNA and anti-histone reactivity, but not
with anti-C1q reactivity. Anti-nucleosome and anti-DNA antibodies correlated with
disease activity. We conclude that almost all patients with proliferative lupus
nephritis are positive for anti-nucleosome and/or anti-DNA autoantibodies, with no
clinical differences between patients with high or low antibody titers. Treatment
with cyclophosphamide or azathioprine induced a comparable decline in anti-
nucleosome, anti-DNA and anti-C1q autoantibodies.  
Mimotopes for nucleosome-specific autoantibodies: nucleosomes
interfere in in vitro assays
Although nucleosome-specific autoantibodies already are present early in
disease, even before anti-DNA autoantibodies arise, and are involved in the
initiation if lupus nephritis, their specific detection is very complex, since the use of
nucleosomes as coating results also in the detection of anti-DNA and anti-histone
autoantibodies. Therefore, mimopes for nucleosome-specific autoantibodies, i.e.
peptides micking conformational nucleosomal epitopes, could be very usefull for
this purpose. Analogous to mimotopes for anti-DNA autoantibodies identified
previously, we have selected and identified a mimotope for a monoclonal lupus-
derived nucleosome-specific autoantibody (mAb #32) by screening a random
peptide phage display library (chapter 6). The sequence NRKDWIERTL (called
MIMO#0) contained both negatively (D,E) and positively (R,K) charged residues,
possibly mimicking DNA and histones, respectively. To our surprise and regret the
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identified mimotope turned out to be a DNA-binding motif instead of the epitope for
mAb #32. Firstly, in ELISA we discovered that reactivity of mAb #32 to the
MIMO#0 peptide was dependent on the blocking reagent. Secondly, we encountered
that in addition to mAb #32, most monoclonal nucleosome-specific, anti-DNA and
anti-histone autoantibodies recognized the MIMO#0 peptide, which again was
dependent on the applied blocking reagent. Thirdly, DNaseI treatment of the
blocking reagent totally abolished the reactivity of all monoclonal antibodies.
Fourthly, we could directly demonstrate that DNA and histones were present in
several blocking reagents. Finally, the MIMO#0 peptide could directly bind
nucleosomal material (i.e. DNA /histones) and labelled DNA. Importantly, we
obtained similar results for a DNA mimotope previously identified by Sun and co-
workers (89). So nucleosomal material, present in experimental reagents, such as
blocking reagents and bacterial growth media, that are used during the selection and
characterization of the mimotopes, prevent the identification and proper
characterization of mimotopes for anti-DNA and nucleosome-specific antibodies.
Besides the reactivity of monoclonal antibodies, we found that nucleosomal material
in blocking reagents not only affected the reactivity of patients sera with mimotopes,
but also with DNA, histones and nucleosomes. So far, based on our results specific
blocking reagents without nucleosomal material should be used when these anti-
nuclear autoantibodies are measured. Although such a blocking reagent does not yet
exist, we found that for analysis of anti-DNA and anti-nucleosome autoantibodies,
FCS is an acceptable blocking reagent, while for anti-histone Dnase-treated milk can
be used. However, the use of these blocking reagents in these assays will not
completely solve the problem. Therefore, the search for blocking reagents without
DNA and histones should be continued.  Moreover, it is questionable whether with
the random peptide phage display technique mimotopes for anti-chromatin
autoantibodies can be identified, despite the fact that with this technique mimotopes
were identified for non-nucleosomal non-protein structures (215).
An anti-histone autoantibody specific for histone variant H3.1
In contrast to the identification of mimotopes for nucleosome-specific
autoantibodies described in chapter 6, the random peptide phage display technique
appeared to be succesfull for the identification of the epitopes of monoclonal anti-
histone autoantibodies. In addition to the epitope of KM-2 described in chapter 3,
we also identified the epitope of mAb #34 (chapter 7). This resulted into the
common motif S/G-A-P-A-S/T-G, which corresponds to amino acid residues 28-33
of the N-terminal region of histone H3. Four different isoforms of histone H3 have
been reported: H3.1, H3.2 and H3.3, which have similar sequences, and the
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completely different centromeric histone H3 variant, CENPA (231). Recently, the
H3.3 variant has been linked to transcriptionally active chromatin regions, while the
H3.1 variant is tightly coupled to DNA replication (232, 233). The single amino acid
difference between the histone H3 variants H3.1 and H3.3 in the N-terminal tail
resides within the epitope we identified for mAb #34, i.e. at position 31 an alanine
residue in H3.1 and a serine residue in H3.3. We demonstrated that mAb #34 was
specific for H3.1 both in direct and inhibition ELISA using synthetic H3 peptides.
Additionally, we tested several modifications, i.e. acetylation, phosphorylation and
methylation, which have been described within or close to the identified epitope. We
found that acetylation and/or phosphorylation resulted in a decreased binding of
mAb #34, while di-methylation had little effect on the binding. However, the effect
of the H3.1 modifications on the binding of mAb #34 was much less pronounced
when compared to the single amino acid substitution at position 31 in H3.3. Since
antibodies specific for histone H3 variants are rare, the specificity of mAb #34 for
the H3.1 variant was applied in a study to demonstrate the presence or absence of
histone H3 variants in the early mouse zygote (98). 
Binding of anti-nucleosome/nucleosome complexes to the C-
terminal peptide (83-119) of the SmD1 autoantigen
Anti-nucleosome/nucleosome complexes can bind to both negatively
charged (via positively charged histones) and positively charged molecules (via
negatively charged DNA). Direct binding of anti-DNA autoantibodies has been
described for many proteins, such as alpha-actinin, alpha-enolase, myosin and the
glutamate receptor (92, 284-286). However, contamination of the anti-DNA
antibody (94) or applied reagents (see also chapter 6) with nucleosomal material
easily can lead to misinterpretation of data. In chapter 8, we showed that the
reactivity with the C-terminal part of the SmD1 autoantigen (SmD1 83-119) is not
only due to direct binding of specific anti-SmD1 autoantibodies, but also to indirect
binding of anti-DNA antibodies complexed to DNA and/or nucleosomes. DNaseI
treatment of both the applied blocking reagent and the patient serum tested resulted
in an almost complete abolishment of reactivity with the SmD1(83-119) peptide in
several sera from SLE patients, as measured in ELISA. Since the SmD1(83-119)
peptide contains about 50% positively charged amino acid residues, anti-DNA/DNA
complexes could bind to this peptide via the negatively charged DNA. In fact, we
could demonstrate binding of DNA and nucleosomes to the SmD1(83-119) peptide.
It has been reported that immunisation with the SmD1(83-119) peptide induces the
development of anti-DNA antibodies, which was explained by antigen-spreading
(238). In addition, recent results revealed that the SmD1(83-119) peptide can induce
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tolerance in SLE mice via the activation of regulatory T-cells (287). Our data
suggest that nucleosomes bound to SmD1 may be able to initiate and modulate the
autoimmune response to nucleosomes.
Binding of anti-nucleosome/nucleosome complexes to the GBM
Anti-DNA and nucleosome-specific antibodies play a decisive role in the
development of lupus nephritis, since complexed to nucleosomes they can bind to
the glomerular basement membrane (GBM) and cause local inflamation. In the past,
our group has identified and studied this phenomenon extensively (summarized in
chapter 9). It was found that intrarenal perfusion of autoantibodies complexed to
nucleosomes led to glomerular binding and albuminuria, in contrast to perfusion of
the same autoantibodies in non-complexed form. In these studies, anti-nucleosome
autoantibodies were eluted from glomeruli of diseased lupus mice, and nucleosomes
(i.e. histones and DNA) were identified in glomerular depositis in lupus mice. A
decrease in staining of heparan sulfate (HS) along the GBM was found in lupus mice
with albuminuria. This decreased staining for HS revealed an inverse correlation
with immunoglobulin (Ig) deposits in the GBM. This indicated masking of
negatively charged HS by Ig complexes. The interaction of anti-
nucleosome/nucleosome complexes with heparan sulfate (HS) in the GBM was
most likely due to the interaction of cationic residues in the histone tails with anionic
residues of  HS. Nucleosome/Ig complexes were induced in vivo in nude BALB/c
mice by intraperitoneal injection of hybridomas producing monoclonal anti-DNA,
anti-histone or nucleosome-specific autoantibodies. Immunoglobulin deposits were
found much more frequently in mice injected with anti-DNA or nucleosome-specific
hybridomas then mice injected with anti-histone hybridomas. This indicated, that
especially anti-DNA and nucleosome-specific autoantibodies were nephritogenic.
We postulated that especially these autoantibodies by binding can mask the negative
charge of the nucleosome, which leads to a more positively charged nucleosome,
thus facilitating deposition in the GBM.
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Future direction of research
Work from this thesis raised many interesting questions about the role ofnucleosomes and anti-nucleosome autoantibodies in the pathogenesis
of SLE. Primarily, the identification of apoptosis-induced histone modifications as
targets for autoantibodies in SLE definitely proves that nucleosomes released from
apoptotic cells are able to drive the anti-chromatin immune response as originally
was proposed in our model. Future research should be aimed at the identification of
additional apoptosis-induced histone modifications that are targeted by SLE
autoantibodies. Furthermore, the effect of modified nucleosomes on the maturation
of dendritic cells, the processing and presentation by dendritic cells to T cells and
the direction of the T and B cell responses to nucleosomes, histones and DNA,
should be evaluated. The possible role of these apoptotic modified nucleosomes in
binding to the GBM also requires additional research. Since autoantibodies against
modified histone peptides were already found in young, pre-diseased lupus mice, a
possible diagnostic application of these modified peptides should be further
investigated in plasmas from SLE patients. Indeed, autoantibodies that recognize
citrullinated proteins, another covalent modification (which has also been described
for histones), are specific and predicitive for another autoimmune disease, i.e.
rheumatoid arthritis. Importantly, histone peptides containing apoptosis-induced
modifications may be used for the induction of tolerance and in this way may offer
new therapeutical tools for the treatment of SLE. Promising results have already
been obtained with another lupus autoantigen, a phosphorylated U1-70K peptide,
which could prevent the development of SLE in MRL/lpr mice (288). 
Selection and characterization of mimotopes for nucleosome-specificautoantibodies seemed to be a mission impossible using the current
technology. However, the identification of these mimotopes still remains important
for diagnostic and therapeutic purposes. Future research should be directed to the
development of techniques that circumvent the use of reagents that contain
interfering nucleosomal material. 
Finally, the binding of anti-nucleosome/nucleosome complexes to otherproteins probably has an important pathophysiological role in the
induction of the autoimmune response in SLE and the induction of tissue damage.
Although, many scientists still strongly believe in the direct binding of anti-DNA
autoantibodies to various non-nucleosomal proteins, the binding of anti-
nucleosome/nucleosome complexes is an attractive alternative for this binding that
should be acknowledged. As we have shown in the past and in this thesis the use of
anti-chromatin autoantibodies complexed to nucleosomes and/or reagents that
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contain nucleosomal material should be circumvented in future experiments
studying anti-chromatin autoantibodies. Althoug it was not the intention of our
research at the first phase, the identification of mimotopes for nucleosome-specific
and anti-DNA autoantibodies as DNA- and nucleosome-binding peptides could lead
to a better insight in the pathological effect of these complexes.
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Iedere dag is ons lichaam in een strijd gewikkeld met binnendringendemicroorganismen, waaronder bacteriën, schimmels and virussen. Gelukkig
is ons lichaam uitgerust met een verdedigingsmechanisme tegen deze indringers. Dit
afweersysteem (of immuunsysteem) is getraind om allerlei structuren te herkennen,
echter alleen van indringers, niet van het lichaam zelf. Helaas is dit systeem feilbaar.
Systemische lupus erythematodes (SLE) is het gevolg van een falen van ons
afweersysteem. SLE is een autoimmuunziekte, wat wil zeggen dat het
immuunsysteem eigen structuren herkent en hiertegen antistoffen maakt. Aangezien
autoantistoffen circuleren in het bloed, kunnen ze leiden tot ontstekingen door het
hele lichaam, ondermeer in de huid en de gewrichten, maar ook in organen zoals de
nieren, het centrale zenuwstelsel, het hart, de longen en de bloedvaten. Deze
ontstekingsreacties veroorzaken de ziekteverschijnselen in SLE, die echter per
patient zeer verschillend kunnen zijn. SLE komt vooral voor bij vrouwen (90%) en
kan ontstaan op elke leeftijd, maar meestal tussen de 20-40 jaar. De exacte oorzaak
van SLE is nog niet bekend. Waarschijnlijk spelen meerdere factoren een rol,
waaronder omgevings- (zonlicht), hormonale en genetische factoren en infecties.
Aangezien de oorzaak nog niet bekend is kan de ziekte zelf niet genezen worden, de
symptomen kunnen wel onderdrukt worden door diverse medicijnen. 
Ondanks decennia onderzoek blijft de oorzaak van SLE een puzzel. Tot nu
toe zijn er 100 verschillende autoantigenen bekend. Het nucleosoom wordt echter
gezien als het belangrijkste autoantigeen in deze complexe autoimmuunrespons.
Nucleosomen zijn de basisstructuur van chromatine. Chromatin is de structuur
waardoor 2 meter DNA in een celkern van ongeveer 20 micrometer kan worden
opgevouwen. Een nucleosoom bestaat uit 146 baseparen dubbelstrengs (ds) DNA
tweemaal gewikkeld rond een octameer gevormd door paren van de histonen H2A,
H2B, H3 en H4. Histonen kunnen op vele manieren gemodificeerd worden,
bijvoorbeeld door het aanzetten of verwijderen van een acetyl ((de)acetylering), een
fosfaat ((de)fosforylering) of een methylgroep ((de)methylering). Deze modificaties
spelen normaal een belangrijke rol in de regulatie van de chromatinestructuur en het
activeren en inactiveren van genen.
Wij hebben de afgelopen jaren een hypothese ontwikkeld voor het ontstaan
van SLE, waarin het nucleosoom een belangrijke rol speelt (zie hoofdstuk 1 en 2).
In het kort gaat dit model als volgt: het lichaam gebruikt apoptose, of
geprogrammeerde celdood, als mechanisme om cellen die niet meer nodig zijn op te
ruimen zonder hun inhoud vrij te laten komen. Dit is zeer belangrijk, aangezien
bestanddelen van de cel toxisch kunnen zijn en er tijdens apoptose veranderingen
optreden van zowel DNA als allerlei eiwitten. Het immuunsysteem zou deze
veranderde, of gemodificeerde, eiwitten kunnen herkennen en antistoffen gaan
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maken tegen deze gemodificeerde eiwitten. Normaliter worden apoptotische cellen
direct opgeruimd door macrofagen, de vuilnissmannen van ons lichaam. Er zijn de
laatste jaren vele aanwijzigingen gevonden dat apoptose en/of de opruiming van
apoptotische cellen is verstoord in zowel lupusmuizen als SLE patienten. Wanneer
apoptotische cellen niet adequaat opgeruimd worden, vallen ze uit elkaar en komt
hun inhoud vrij. Het idee is dat het immuunsysteem antistoffen gaat maken tegen
deze gemodificeerde eiwitten, waaronder nucleosomen. In bijna alle SLE patienten
worden antistoffen gevonden tegen nucleosomen, bovendien hebben deze patienten
ook de vrijgekomen nucleosomen in hun bloed. De anti-nucleosoom antistoffen
binden aan nucleosomen en vormen daardoor immuuncomplexen. Deze
immuuncomplexen kunnen binden aan allerlei moleculen, waaronder heparansulfaat
(dat voor de negatieve lading in het nierfilter zorgt) in de nier. Hierdoor ontstaan er
plaatselijk een nierfilterontsteking, een zogenaamde glomerulonefritis. In dit
proefschrift hebben we de rol van chromatine en anti-chromatine autoantistoffen in
dit model verder geëvalueerd.
Apoptose-geïnduceerde histonmodificaties zijn de drijvende kracht
in de ontwikkeling van een anti-chromatine respons in SLE
Nucleosomen kunnen alleen ontstaan tijdens apoptose, waarbij ze gevormd
worden door het knippen van chromatin door specifieke enzymen (endonucleases).
Apoptose, of geprogrammerde celdood, gaat gepaard met het knippen en
modificeren van vele eiwitten. Het is opmerkelijk dat vele van deze gemodificeerde
eiwitten in SLE herkend worden door autoantistoffen. Hoewel apoptose-
geïnduceerde modificaties op histonen beschreven zijn, is nog nooit aangetoond dat
deze gemodificeerde histonen specifiek worden herkend door SLE autoantistoffen.
In hoofdstuk 3 laten we voor het eerst zien dat histonen die tijdens apoptose worden
geacetyleerd, specifiek worden herkend door SLE autoantistoffen. We hebben het
epitoop van KM-2, een monoklonaal autoantilichaam gericht tegen histonen en
afkomstig uit de MRL/lpr muis (een model in de muis voor SLE), gekarakteriseerd
door als het ware te ‘vissen’ in een faagbank, waarin iedere faag een willekeurig kort
stukje eiwit (peptide) tot expressie brengt. Wij identificeerden het epitoop op de N-
terminale staart van histon H4, maar vonden echter de lysineresiduen op positie 8,
12 en 16 niet terug in het epitoop. De acetylatie van lysines op positie 5, 8, 12 en 16
is beschreven voor histon H4. In de enzyme-linked immunosorbent assay (ELISA)
vonden we dat KM-2 de H4 peptides geacetyleerd op positie 8, 12 en/of 16 beter
herkent dan het niet geacetyleerde peptide. Vervolgens hebben we de binding van
KM-2 bepaald aan histonen afkomstig uit cellen die behandeld zijn met een remmer
van histondeacetylases (Trichostatine A, TSA), hetgeen leidt tot een hyperacetylatie
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van histonen, en cellen behandelt met camptothecine (CPT, een remmer van DNA
topoisomerase I) of een anti-Fas antilichaam die beide leiden tot apoptose van de
behandelde cel. Zowel behandeling met trichostatine A, camptothecine als anti-Fas
zorgde voor een sterkere binding van KM-2 in de celkern. Dit vonden we ook via
analyse in Western blot van celextracten van de behandelde cellen, die een
verhoogde reactiviteit van KM-2 met histon H2A en H4 onthulde. Dit betekende dat
KM-2 specifiek histon H4 en H2A geacetyleerd tijdens apoptose herkende. Deze
resultaten vonden we niet alleen met het monoklonale antilichaam KM-2, maar ook
met plasma’s van lupusmuizen en SLE patienten. In ELISA bleek dat autoantistoffen
in deze plasma’s ten opzichte van het ongemodificeerde peptide een verhoogde
reactiviteit lieten zien met minimaal een van de geacetyleerde peptides. Bovendien
bleek in een analyse met Western blot dat deze autoantistoffen in SLE plasma’s een
hogere reactiviteit hadden met de histonen H4, H2A, H2B, H3 (en H1) geëxtraheerd
uit cellen die behandeld waren met CPT of TSA. Acetylatie en deacetylatie van
histonen is een dynamisch proces, waarbij enzymen betrokken zijn die de histonen
acetyleren (histonacetyltransferases of HAT’s) en enzymen die de histonen
deacetyleren (histondeacetylases of HDAC’s). De apoptose-geïnduceerde
hyperacetylatie van histonen bleek via een verhoogde activiteit van
acetyltransferases en een verlaagde activiteit van histondeacetylases te gaan. Uit
deze resultaten concludeerden we dat histonen geacetyleerd worden tijdens apoptose
en vervolgens het doelwit zijn van autoantistoffen in SLE.
Om het effect van een histon H4 peptide tri-geacetyleerd op de
lysineresiduen 8, 12 en 16 (het epitoop van KM-2) op de ontwikkeling van SLE in
MRL/lpr muizen te bepalen, hebben we deze muizen ingespoten met een tri-
geacetyleerd H4 peptide, een ongemodificeerd H4 peptide of fysiologisch zout
(PBS). Behandeling van MRL/lpr muizen met een tri-geacetyleerd H4 peptide leidde
tot een duidelijke versnelling van de ontwikkeling van de ziekte, gemeten aan het
ontstaan van een eiwitlek in de urine en de ontwikkeling van huidafwijkingen. De
behandeling met het ongemodificeerde H4 peptide of PBS versnelde de
ontwikkeling van de ziekte niet. Niveaus van anti-chromatine autoantistoffen waren
niet verschillend tussen de verschillende behandelingen, maar er was wel sprake van
een verhoogde DTH (delayed type hypersensitivity) reactie tegen het tri-
geacetyleerde H4 peptide in alle groepen, onafhankelijk van de behandeling. Dit
duidt erop dat ook T cellen specifiek het getriacetyleerde H4 peptide kunnen
herkennen.
Deze vernieuwende resultaten duiden op een cruciale rol voor apoptose-
geïnduceerde histonmodificaties in de pathogenese van SLE. Apoptose-
geïnduceerde modificaties van autoantigenen worden normaal niet gezien door het
immuunsysteem. Een verstoorde opruiming van apoptotische cellen leidt echter tot
het vrijkomen van deze gemodificeerde nucleosomen (zie ook volgende sectie). Dit
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kan vervolgens leiden tot een verstoring van de balans tussen tolerantie en
autoimmuniteit.
Opruiming van apoptotische cellen: het vrijkomen van
gemodificeerde nucleosomen
Normaal gezien worden apoptotische cellen direct opgeruimd door
fagocyten (zoals macrofagen), voordat hun inhoud, waaronder (gemodificeerde)
nucleosomen en histonen, vrijkomt in het omringende milieu. In toenemende mate
wordt de laatste jaren gevonden dat een verstoorde opruiming van apoptotische
cellen belangrijk is voor het ontstaan van SLE. Muizen die deficiënt zijn voor
moleculen betrokken in het complexe proces van de opruiming van apoptotische
cellen, ontwikkelen anti-nucleosoom antistoffen en in sommige gevallen een
ontsteking aan de nierfilter (glomerulonefritis). In SLE patiënten zijn er ook
aanwijzingen gevonden dat de fagocytose van apoptotische cellen verstoord is. Maar
het bewijs voor een verstoorde opruiming van apoptotische cellen in lupus muizen,
zoals de MRL/lpr en de (NZWxNZB)F1 modellen, is echter nog onduidelijk. Eerder
is al door ons laboratorium gevonden dat de een verstoring van de opruiming van
apoptotische cellen niet al aanwezig is in lupusmuizen voor de ontwikkeling van de
ziekte. In hoofdstuk 4 laten we zien dat de opruiming van apoptotische cellen in
zieke lupusmuizen verlaagd is. Gebruik makende van een in vitro fagocytose-assay
hebben we de opname van apoptotische cellen door peritoneale macrofagen
gemeten in lupusmuizen voor en na het ontstaan van ziekte. In deze assay maakten
we gebruik van serum, apoptotische thymocyten en macrofagen uit dezelfde muis
(autoloog). Onder deze condities vertoonden macrofagen van zieke MRL/lpr,
(NZWxNZB)F1 en NZB muizen een verlaagde fagocytose. De afgenomen
fagocytose was het gevolg van een factor in het serum, aangezien het toevoegen van
serum van zieke muizen aan macrofagen en apoptotische cellen van niet-zieke
muizen leidde tot een afgenomen fagocytose in de in vitro assay. In tegenstelling tot
andere studies, vonden we geen constitutief defect in de macrofagen van SLE
muizen. We vonden echter wel een verschil wanneer we de fagocytose van
apoptotische cellen van verschillende normale muizenstammen vergeleken. Dit zou
het gevonden verschil met andere studies misschien kunnen verklaren, omdat de
meeste studies als controle stam BALB/c muizen gebruiken die een hogere
fagocytotische capaciteit vertonen ten opzichte van andere controle of SLE
muizenstammen.
Wij concludeerden dat gedurende de ontwikkeling van SLE de opruiming
van apoptotische cellen in lupusmuizen is verminderd door een factor in het serum
wat vervolgens kan leiden tot een verergering van de ziekte. Deze serumfactor in
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zieke lupusmuizen zou een tekort aan een belangrijke component nodig voor
fagocytose of een remmer van de fagocytose kunnen zijn. Er zijn verschillende
kanditaten aanwezig in het plasma die betrokken zijn bij de opruiming van
apoptotische cellen, waaronder IgM, complement, DNaseI, serum amyloid P (SAP),
thrombospondine, C-reactive eiwit, nucleosomen en autoantistoffen.
Anti-nucleosoom en anti-C1q autoantistoffen in patiënten met lupus
nefritis
Anti-nucleosoom autoantistoffen worden het meest frequent gevonden in
SLE patiënten. De titers van autoantistoffen tegen nucleosomen lijken in SLE
patiënten overeen te komen met de activiteit van de ziekte en de aanwezigheid van
glomerulonefritis, de meest serieuze aandoening in SLE patiënten. Bovendien
kunnen anti-nucleaire autoantistoffen al 10 jaar voor het ontwikkelen van de ziekte
worden gevonden in toekomstige SLE patiënten. Autoantistoffen tegen nucleosomen
kunnen onderverdeeld worden in drie categoriën: 1) antistoffen die DNA herkennen
(anti-DNA); 2) antistoffen die histonen herkennen (anti-histon); en 3) antistoffen die
alleen intacte nucleosomen herkennen (nucleosoom-specifieke antistoffen). Binnen
de eerste studie naar de behandeling van SLE glomerulonefritis, uitgevoerd door de
Nederlandse SLE Werkgroep, hebben we de respons tegen nucleosomen, DNA en
histonen bestudeerd in 87 SLE patiënten met een proliferatieve lupusnefritis
(hoofdstuk 5). Deze patiënten werden behandeld met cyclofosfamide en prednison
(CY) of azathioprine, methylprednisolon en prednison (AZA). Deze laatste
behandeling werd vergeleken met de meer standaard CY behandeling, omdat
cyclofosfamide vaak leidt tot onvruchtbaarheid in deze jonge vrouwelijke patiënten.
We maten deze antistoffen bij deze patiënten gedurende het eerste jaar van de
behandeling. Wij vonden geen verschillen in het beloop van antistoffen tegen
nucleosomen, DNA of histonen tussen de twee behandelingsgroepen. We vonden
een reactiviteit boven de achtergrond (+3x SD) tegen nucleosomen in 81% van de
patiënten, tegen DNA in 96% van de patiënten, tegen histonen in 23% van de
patiënten en tegen complement C1q in 62% van de patiënten. De titer van deze
antistoffen ging direct na de start van de behandeling snel omlaag. We vonden een
correlatie tussen anti-nucleosoom, anti-DNA en anti-histon reactiviteit, maar niet
met anti-C1q reactiviteit. We konden ook een correlatie tussen anti-nucleosoom,
anti-DNA en de ziekteactiviteit aantonen. We vonden echter geen correlatie tussen
de autoantilichamen en parameters voor de nierfunctie. Wij concluderen dat bijna
alle patienten met proliferatieve nefritis positief zijn voor anti-nucleosoom en/of
anti-DNA antilichamen, met geen klinische verschillen tussen patiënten met hoge of
lage antilichaam titers. Behandeling met cyclophosphamide of azathioprine
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induceert een vergelijkbare daling in anti-nucleosoom, anti-DNA en anti-C1q
autoantilichamen. 
Selectie en identificatie van mimotopen voor nucleosoom-specifieke
autoantistoffen: a mission impossible
Hoewel nucleosoom-specifieke autoantistoffen aanwezig zijn voor anti-
DNA autoantistoffen in SLE en deze antistoffen ook een belanrijke rol spelen in de
ontwikkeling van lupusnefritis, is de specifieke detectie niet eenvoudig. Wanneer
nucleosomen worden gebruikt als coating kunnen anti-DNA en anti-histon
antistoffen ook binden. Een oplossing hiervoor zou het gebruik zijn van
‘mimotopen’ voor nucleosoom-specifieke autoantistoffen. Dit zijn peptides die het
epitoop van een nucleosoom-specifieke autoantistof nabootsen (mimicken).
Bovendien, kunnen mimotopen toegepast worden in de behandeling van SLE, door
tolerantie te induceren of door de formatie van anti-nucleosoom/nucleosoom
immuuncomplexen te voorkomen. In navolging van mimotopen voor anti-DNA
antistoffen, eerder gevonden in andere studies, hebben wij een monoklonale
nucleosoom-specifieke antistof (mAb #32) gebruikt om een faagbank te screenen
die peptides met een willekeurige sequentie tot expressie brengt (hoofdstuk 6). Wij
vonden een mimotoop met de aminozuursequentie NRKDWIERTL (MIMO#0
genoemd). Deze sequentie bevat zowel negatieve (D/E) als positieve ladingen
(K/R), die respectievelijk DNA (negatief geladen) en histonen (positief geladen)
zouden kunnen nabootsen. Tot onze verbazing en onze spijt bleek het
geïdentificeerde mimotoop een DNA-bindend motief te zijn in plaats van een
epitoop voor mAb #32. Ten eerste, vonden we dat de binding van mAb #32 aan het
mimotoop afhankelijk was van een van de reagentia die we gebruikten tijdens de
ELISA, namelijk het blokkingsreagens dat gebruikt wordt om aspecifieke binding te
voorkomen. Ten tweede, bleek dat het merendeel van onze monoklonale
nucleosoom-specifieke, anti-DNA en anti-histon antistoffen kon binden aan het
MIMO#0 peptide, weer afhankelijk van de gebruikte blokkingreagentia. Ten derde,
na DNase behandeling van de blokkingreagentia was de reactiviteit van alle
monoklonale antistoffen met MIMO#0 verdwenen. Ten vierde, konden we de
aanwezigheid van DNA en histonen direct aantonen in de verschillende
blokkingreagentia. Ten slotte, bleek dat het MIMO#0 peptide in staat was om direct
nucleosomaal materiaal (i.e. DNA/histonen) en gelabeld DNA te binden. We
moesten concluderen dat het MIMO#0 mimotoop in feite een DNA-bindend peptide
is! Belangrijk is dat we dezelfde resultaten vonden voor een DNA mimotoop, eerder
geïdentificeerd door Yong-Jiang Sun et al. Ook dit peptide bleek een DNA-bindend
peptide te zijn. Dus nucleosomaal materiaal aanwezig in experimentele reagentia,
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zoals blokkingreagentia en bacteriële groeimedia, die worden gebruikt tijdens de
procedures voorkomen de selectie en een correcte karakterisatie van mimotopen
voor nucleosoom-specifieke en anti-DNA autoantistoffen. Daarnaast bleek
nucleosomaal materiaal in blokkingsreagentia ook de reactiviteit van autoantistoffen
in patiëntensera met mimotopen, maar ook met DNA, histonen en nucleosomen, te
verstoren. Tot nu toe blijkt uit onze resultaten dat anti-DNA, anti-histon en anti-
nucleosoomreactiviteit het beste kunnen worden uitgevoerd met als
blokkingsreagens respectievelijk foetaal calf serum (FCS), DNaseI-behandelde
melk en FCS, hoewel het gebruik van deze blokkingsreagentia het probleem niet
geheel oplost. Belangrijk is dat de zoektocht naar blokkingsreagentia zonder
nucleosomaal materiaal wordt voortgezet. Bovendien is het de vraag of deze
techniek gebruikt kan worden voor de identificatie van mimotopen voor anti-
chromatine autoantistoffen, ondanks dat er met deze techniek mimotopen voor niet-
nucleosomale niet-eiwit mimotopen zijn gevonden.
Anti-histon autoantilichaam is specifiek voor histone variant H3.1
In tegenstelling tot de identificatie van mimotopen voor nucleosoom-
specifieke autoantistoffen, beschreven in hoofdstuk 6, bleek het screenen van
peptide faagbanken zeer geschikt om epitopen van autoantistoffen gericht tegen
histonen te bepalen. In aanvulling op de identificatie van het epitoop voor KM-2
beschreven in hoofdstuk 3, hebben we ook het epitoop gevonden voor de
monoklonale autoantistof (mAb) #34 (hoofdstuk 7). Dit resulteerde in de
identificatie van het S/G-A-P-A-S/T-G motief, dat overeenkomt met de
aminozuurresiduen 28-33 van de N-terminale staart van histone H3. Voor histone H3
zijn vier verschillende varianten beschreven: H3.1, H3.2 en H3.3, die een
vergelijkbare sequentie hebben en de totaal verschillende centromere histon H3
variant, CENPA. Recentelijk is de H3.3 variant geassocieerd met transcriptioneel
actief chromatine, terwijl de H3.1 variant gekoppeld is aan DNA replicatie. Het
enige verschil in de terminale staart tussen H3.1 en H3.3 is op positie 31 een alanine
voor H3.1 en een serine voor H3.3. We hebben laten zien dat mAb#34 specifiek is
voor histonvariant H3.1 in zowel de directe ELISA als in de inhibitie ELISA. Verder
hebben we ook een aantal modificaties of combinaties van modificaties, zoals
acetylering van lysine 18/23, fosforylering van serine 28 en di-methylering van
lysine 27, getest die in of in de buurt van het S-A-P-A-S/T motief gevonden zijn. We
vonden dat acetylering en/of fosforylering leidde tot een afname van de binding van
mAb #34, terwijl di-methylering nauwelijks effect had. Het effect van deze
modificaties op de binding was echter veel minder duidelijk dan de substitie van een
aminozuur in H3.3. Aangezien antistoffen die specifiek zijn voor histone H3
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varianten zeldzaam zijn, heeft de opmerkelijke specificiteit van dit antilichaam
geleid tot het gebruik in een studie naar het voorkomen van histon H3 varianten in
vroege zygoten (Van der Heijden et al. Mech Dev, in druk). 
Binding van anti-nucleosoom/nucleosoom complexen aan het C-
terminale peptide (83-119) van het SmD1 autoantigeen
Anti-nucleosoom/nucleosoomcomplexen kunnen zowel binden aan negatief
geladen (via de positief geladen histonen) en positief geladen moleculen (via het
negatief geladen DNA). Hoewel directe binding van vooral anti-DNA antilichamen
is beschreven voor vele eiwitten, waaronder alpha-actinine, alpha-enolase en de
glutamaatreceptor, schuilt er een groot gevaar in het gebruik van gecontamineerde
anti-DNA antistoffen en/of gecontamineerde reagentia (zie ook hoofdstuk 6). Dat
kan leiden tot misleidende resultaten. In hoofdstuk 8 laten we zien dat er niet alleen
anti-SmD1 autoantistoffen, maar ook anti-DNA autoantistoffen gecomplexeerd aan
DNA kunnen binden aan het belangrijkste autoepitoop op het SmD1 antigeen
(SmD1(83-119)). Een DNaseI behandeling van zowel de gebruikte
blokkingsreagentia als van patiëntensera leidde tot het verdwijnen van bijna de
gehele reactiviteit met het SmD1(83-119) peptide bij een deel van de patiëntensera.
Bovendien konden we de binding van DNA en nucleosomen aan het SmD1(83-119)
peptide aantonen. Aangezien het SmD1 peptide voor 50% bestaat uit positief
geladen residuen, kunnen anti-DNA/DNA complexen zeer goed binden via het
negatief geladen DNA. Immunisatie van het SmD1 peptide leidt tot de produktie van
anti-DNA antistoffen, dat tot nu toe door ‘antigeen-spreiding’ werd verklaard.
Bovendien laten recente resultaten zien dat het SmD1(83-119) peptide tolerantie kan
induceren in SLE muizen via de activatie van regulatoire T-cellen. Onze data duiden
op een mogelijke rol van anti-DNA/DNA complexen gebonden aan SmD1 in de
initiatie en modulatie van de autoimmune response tegen nucleosomen.
Binding van anti-nucleosoom/nucleosoomcomplexen aan de GBM
Anti-DNA en nucleosoom-specifieke antistoffen spelen een beslissende rol
in de ontwikkeling van lupusnefritis, aangezien deze antistoffen gecomplexeerd met
nucleosomen kunnen binden aan het glomerulaire basaalmembraan (GBM) en een
locale ontsteking kunnen veroorzaken. In het verleden is dit fenomeen in ons
laboratorium voor het eerst gevonden en daarna uitgebreid bestudeerd (samengevat
in hoofdstuk 9). Intrarenale perfusie van autoantilichamen gericht tegen chromatine
en gecomplexeerd met nucleosomen bleek te leiden tot glomerulaire binding en een
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eiwitlek, in tegenstelling tot de perfusie van niet-gecomplexeerde anti-chromatine
autoantilichamen. In deze studies bleek dat autoantilichamen gericht tegen
chromatine geëlueerd konden worden uit glomeruli van zieke SLE muizen, en dat
nucleosomen (i.e. histonen en DNA) werden gevonden in glomerulaire deposities in
SLE muizen. Een afname van heparansulfaat werd gevonden in de GBM van muizen
met een eiwitlek, Deze proteinurie vertoonde een negatieve correlatie met
immunoglobulline (Ig) deposities in de GBM. Dit duidt waarschijnlijk op een
maskering van het negatief geladen heparansulfaat (HS) in de GBM door de
interactie van cationische residuen in de histonen en anionische residuen in HS,
leidend tot een verstoring van de filterfunctie van de glomerulus en het ontstaan van
een eiwitlek. Nucleosoom/Ig complexen werden in vivo geïnduceerd door ‘nude’
BALB/c muizen intraperitoneaal in te spuiten met hybridoma die monoklonale anti-
DNA, anti-histon en nucleosoom-specifieke autoantistoffen produceerden.
Immuunglobuline deposities werden vaker gevonden in de muizen geïnjecteerd met
hybridoma die antilichamen tegen DNA of nucleosomen produceerde, vergeleken
met muizen geïnjecteerd met hybridoma die antilichamen tegen histonen
produceerde. Hieruit bleek dat vooral anti-DNA en nucleosoom-specifieke
autoantistoffen schadelijk voor de nier waren. Wij postuleerden dat de binding van
deze antilichamen de negatieve lading van het nucleosoom maskeren, wat leidt tot
een meer positief geladen nucleosoom, dat vervolgens de depositie in de GBM
mogelijk maakt.
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Toekomstig onderzoek
De studies beschreven in dit proefschrift roepen een aantal interessantevragen op over de rol van chromatine en anti-chromatine
autoantilichamen in de pathogenese van SLE. De bevinding dat apoptose-
geïnduceerde histonmodificaties het doelwit zijn van autoantistoffen in SLE
bewijst dat nucleosomen die vrijgekomen zijn uit apoptotische cellen een
belangrijke prikkel zijn voor de immuunrespons tegen chromatine, zoals
oorspronkelijk was voorgesteld in ons model voor de initiatie van SLE en SLE
nefritis. Toekomstig onderzoek zou moeten leiden tot de indentificatie van meer
apoptose-geïnduceerde modificaties op histonen die herkend worden door SLE
autoantistoffen. Het effect van apoptose-gemodificeerde nucleosomen op de
maturatie van dendritische cellen, de processing en presentatie door dendritische
cellen aan T-cellen en de regulatie van de respons van T en B cellen tegen
nucleosomen, zou onderzocht moeten worden. De mogelijke rol van gemodificeerde
nucleosomen in de binding aan de GBM vraagt ook om aanvullend onderzoek.
Aangezien antistoffen tegen gemodificeerde histonpeptides gevonden zijn in jonge
SLE muizen zou een mogelijke diagnostische toepassing in SLE patienten
onderzocht moeten worden. In reumatoïde artritis zijn er al autoantilichamen tegen
gemodificeerde antigenen gevonden, die specifiek en voorspellende zijn voor deze
ziekte. Belangrijk is dat histonpeptides die apoptose-geïnduceerde modificaties
bevatten, mogelijk gebruikt kunnen worden om tolerantie op te wekken. Dit zou
kunnen leiden tot de ontwikkeling van nieuwe middelen voor de behandeling van
SLE. Veel belovende resultaten zijn er al verkregen met een gefosforyleerde U1-70K
peptide (een ander autoantigeen in SLE), dat de ontwikkeling van SLE in MRL/lpr
muizen kon remmen. 
Selectie en karakterisering van mimotopen voor nucleosoom-specifiekeautoantistoffen bleek een onmogelijke opgave. De identificatie van deze
mimotopen blijft echter belangrijk voor diagnostische en therapeutische doeleinden.
Toekomstig onderzoek zou gericht moeten zijn op de ontwikkeling van reagentia die
niet gecontimeerd zijn met nucleosomaal materiaal. 
Ten slotte heeft de binding van anti-nucleosoom/nucleosoomcomplexen aan andere eiwitten mogelijk een
pathofysiologische rol in de inductie van de autoimmuunrespons in SLE, vooral met
betrekking tot ‘epitoop-spreiding’ en in het ontstaan van weefselschade. Hoewel de
meeste wetenschappers nog steeds geloven in de directe binding van anti-DNA
autoantistoffen, is de binding van anti-nucleosoom/nucleosoom complexen een
attractief alternatief. Zoals we in het verleden en in deze thesis hebben laten zien zou
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het gebruik van antistoffen gericht tegen chromatine die gecontamineerd zijn met
nucleosomaal material en/of het gebruik van reagentia die nucleosomaal materiaal
bevatten, moeten worden voorkomen. Hoewel niet de intentie van dit onderzoek in
eerste instantie, zou de identificatie van mimotopen voor nucleosoom-specifieke en
anti-DNA autoantilichamen als DNA-bindende peptides kunnen leiden tot een beter
inzicht in het pathogene effecten van chromatine/anti-chromatinecomplexen. 
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Dankwoord
Het proefschrift is af! Terugkijkend kan ik zeggen dat velen hebben bijgedragenaan dit proefschrift. Ik wil hierbij al die mensen bedanken. Maar een aantal
mensen toch in het bijzonder: 
Allereerst Johan, als mijn co-promotor ben jij de persoon geweest die het meest
betrokken was bij mijn promotie. Met je motivatie en enthausiasme voor het
onderzoek was je een voorbeeld en een stimulator tijdens mijn promotie. Je hebt
veel tijd in mijn project gestopt, vaak zelfs tot in the late uren. Hiervoor kan ik je
niet genoeg bedanken. Ondanks dat de zoektocht naar mimotopen in een
teleurstelling eindigde, zijn wij er toch in geslaagd om het te publiceren na bijna 2
jaar. Al snel kwam jij met het idee om naar histon modificaties te gaan kijken. De
ervaring en protocollen die je uit Amsterdam meebracht waren (en zijn nog steeds)
van grote waarde. Het is ons dan ook gelukt om voor het eerst aan te tonen dat deze
modificaties herkend worden tijdens SLE. Ik denk dat er nog veel toekomst zit in dit
onderzoek, zeker nu je erin geslaagd bent een aantal vervolgprojecten binnen te
halen. Bovendien blijf ik geïnteresseerd in de apoptose-geïnduceerde modificaties.
Ik weet zeker dat we in de toekomst nog zullen blijven samenwerken. Ook bij het
schrijven van het FEBS project om drie extra maanden in Straatsburg te financieren,
heb je (natuurlijk) een belangrijke bijdrage geleverd. Vaak waren wij 's avonds nog
aan het discusseren over de experimenten van die dag, en vele ideeën zijn ook
voortgekomen uit die avondsessies. Ik zal ze missen… Gelukkig houden we nog
steeds contact, gezien de vele telefoongesprekken die we gehad hebben sinds ik in
Straatsburg zit. Maar er is niet alleen werk, ook als persoon ben je altijd nauw
betrokken geweest. Soms wel erg dichtbij (Berlijn). Mijn 'camping uitrusting' heeft
zijn functie gehad, als we weer (laat) terugkwamen van bijvoorbeeld een pool-
avond. Bedankt voor de leuke tijd. 
Jo, als mijn promotor heb een belangrijke rol gespeelt tijdens mijn promotie. Ik kan
mij het gesprek nog herinneren dat wij een jaar of 7 terug hadden na afloop van het
nieuwjaarsdiner. Ik liep als HLOer stage en jij vond dat ik mijn carriere ten volle
moest benutten… En inderdaad anderhalf jaar later belde ik je op om te informeren
naar een baan als AIO. Bedankt dat je me de kans hebt gegeven om te gaan
promoveren. Een keuze waar ik nu zeker geen spijt van heb. Tijdens de afgelopen 5
jaar hebben we vele interessante discussies gehad, zo heb ik onder andere kunnen
leren dat je niet een artikel schrijft voor je promotie of in het belang van de
wetenschap, maar 'to please the editor'. Bovendien kwam de queste naar de
onthulling van de kruisreaktiviteit van anti-nucleosoom antilichamen, waar maar
weinig mensen in wilden geloven, altijd terug. Er ligt nog een publicatie op stapel
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('Cross-reactivity revisited…'), en uiteindelijk moeten we iedereen kunnen
overtuigen. 
Cor, ik ken je nu alweer zo'n 8 jaar. Als HLO-broekie kwam ik tijdens mijn stage
als eerste bij jouw terecht. Ik kan mij de eerste dag nog herinneren. Tijdens de
kennismaking met de mensen van CHL was de reactie meestal: "Moet jij met Cor
gaan werken? Nou veel sterkte dan…". Maar dat viel ontzettend mee. Zowel tijdens
mijn stage als later tijdens mijn promotie onderzoek was je een belangrijke steun.
Zeker ook buiten het werk... Wij hebben nu alweer vele pool-avonden erop zitten en
in al die jaren is er niet veel veranderd, de ballen vliegen nog steeds de zaal rond.
Tijdens één van die pool-avonden kwam jij ook met het idee of de AIO-baan bij
Nierziekten niet iets voor mij was… Jij was ook de grote organisator achter de
jaarlijkse lab-BBQ en de sinterklaas/kerstmis-cadeau-doorgeef-spelavond op jouw
'landgoed' in Groesbeek. Meestal mocht ik dan overnachten in 1 van de slaapkamers
van jouw ' villa' , en ondertussen heb ik al een eigen tandborstel verworven die nog
volgens mij steeds in de la van het nachtkastje ligt. Bedankt voor alle gezelligheid!
Hilde, ondanks dat je helaas maar een jaar als analiste op mijn project hebt kunnen
werken, ben je er toch in geslaagd vele antilichamen op te zuiveren en een start te
maken met het opzetten van phage display, hier heb ik later nog veel plezier van
gehad.
Marinka, Wim, jullie expertise heeft mijn onderzoek stukken gemakkelijker
gemaakt. Als ik met een vraag kwam werd er een boek van vroeger uit de kast
getrokken of een IF-foto van CD op het beeldscherm getoverd. Maar ook was er
altijd een gezellig gesprek tijdens de koffie.
Mijn mede-AIOers/junior onderzoekers/postdoc: Dames, gelukkig had jullie als
rekenwonders mijn hulp nooit nodig... in ieder geval kon ik jullie ervaring als coupe-
snijdsters goed gebruiken vlak voordat ik wegging. Mabel, bijna ieder morgen
begon ons gesprek met: ...koffie? En ik heb begrepen dat sinds ik weg bent, je bijna
geen koffie meer drinkt. Dus het zal zeker wel gezellig zijn geweest. Buiten koffie,
heb je me al die jaren ook vaak van soep voorzien als we tegen de avond flauw
werden na een dag hard werken. Bovendien hebben we er samen voor gezorgd dat
de organisatie van de electroforese en blot spullen goed verliep en hebben we voor
een (schone) blotplaats gezorgd. Ik wens je nog vele leuke blot(avont)uurtjes.
Angelique, het gezellige meisje uit het zuiden. Bovendien was je altijd bereid je
enthausiasme, je frustraties (en je zangtalent) met anderen te delen. Jij bent de
volgende die moet gaan promoveren, dus veel succes met het afronden van je
promotie. Justin, helaas begon je pas toen ik bijna weg zou gaan, maar het was fijn
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om toch nog een tijdje een mede-lupus AIO op het lab te hebben. Onze (soms
verhitte) discussies over voetbal mis ik wel. Peter, als kenner van de immunologie
en als gepromoveerde diende je als vaak als vraagbaak en was je zelfs bereid om in
het weekend terug te komen om voor mij een MLR te doen. Nils, 3 jaar lang mijn
U-genoot, met soms een aparte kijk op zaken, maar toch hebben we vele (leuke)
discussies gehad. Cassandra, mijn opvolgster, ik wens je veel succes met het
project. Ik denk dat ik nog wel wat vragen kan verwachten... 
Dan de studenten, ze kosten veel tijd, maar je krijgt er ook iets voor terug (hoop je).
En dat was ook zo, ik heb veel experimenten aan jullie kunnen overlaten en het
leverde ook nog veel gezelligheid op. Jorieke, Dennis, Niels (nee epje, ja kun
krijgen), Marloes (de vrolijke blotmachine), ik wil jullie bedanken voor jullie inzet
en vooral het enthausiasme waarmee jullie meegwerkt hebben aan mijn promotie
onderzoek. Natuurlijk wil ik ook de overige studenten op andere projecten bedanken
voor het creeëren van een leuke sfeer op het lab.
Tijdens mijn nog korte carrière heb ik buiten de personen die ik al genoemd heb, met
een aantal anderen samengewerkt. De technici van het CDL: Ilona, Debby en
Geert, ik ben blij dat ik veel muizenwerk in jullie zeer kundige handen kon leggen.
Birgitte, Mieke, ik wist tijdens mijn stage nog niet dat alles wat ik van jullie zou
leren zeer goed van pas zou komen tijdens mijn promotie. Ruud, jouw promotie
onderzoek heeft nog een hoofdstuk in dit boekje bijgedragen. Jacco, Miriam, jullie
steun en geloof in mij hebben een belangrijke rol gespeeld in mijn keuze om te gaan
promoveren. Marc, Bart, als medegebruikers van het lab op het CDL, bedankt voor
de gezelligheid.
Mocht ik nog iemand zijn vergeten, mijn dank is er niet minder om.
Dit proefschrift was nooit tot stand gekomen zonder de vele samenwerkingenmet andere onderzoeksgroepen. Eigenlijk is zelfs elk hoofdstuk weer onderdeel
van een andere samenwerking. Gdfrd, Alwin en Peter ('de gynaecologen'), onze
samenwerking heeft ervoor gezorgd dat al het werk dat we gestopt hadden in de
karakterisatie van antilichaam #34, toch nog kon worden gebruikt voor een mooie
publicatie. De patiënten studie was voor mij, vooral op statistisch gebied, een nieuw
terrein. Gelukkig, had ik iemand achter de hand met veel meer statistische ervaring.
Cecile, bedankt voor al je hulp. Samen zijn we erin geslaagd om de patiënten
database in Nijmegen op te zetten, waar we vele 'uitvul'-uurtjes aan hebben besteed.
Ook wil ik iedereen in Leiden (Fabian, Anja, Moh) bedanken voor de anti-C1q,
IgG en MBL metingen. Gelukkig waren jullie in staat om de metingen op zeer korte
termijn te voltooien. Josephine en Adriaan bedanken wil ik voor de hulp bij het
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opzetten van de random peptide phage display technique.
Then I will go to the collaborations abroad. These people, some I've never met,have put much effort in or provided essential materials for my research. Marc
Monestier, many thanks for all the antibodies that you provided us with. I certainly
enjoyed our meeting 3 years ago in your lab in Philadelphia. Yong-Jiang Sun,
although we've never met, the collaboration we started on the identification of
mimotopes for anti-DNA and nucleosome-specific antibodies ended up into proving
the technique could not be applied this way, and it took some time, but we finally
managed to publish the article last year. Gabriela Riemekasten, the congress in
Berlin lead to a collaboration on the binding of DNA to the N-terminal SmD1
peptide, I hope we can soon publish the article. I also want to thank Chaim
Putterman and George Smith for providing us with the random peptide phage
libraries. 
Jean-Paul, your peptides were most valuable to my research. I appreciate that you
were always able to synthesize the peptides on a very short notice.
Sylviane, it started with a meeting 4 years ago in Strasbourg, then the congress in
Berlin, many e-mails, and now I'm already several months working in your lab. I
want to thank you for all the materials you send to Nijmegen, the expertise opinion
you gave on our results and manuscripts, but above all for giving me the opportunity
to perform a Postdoc project in your lab. I hope this will lead to some exciting
results...
Hereby, I'm also very grateful to my new colleagues at the ICT, who already made
me feel at home despite my lack of knowledge of the French language. Especially
'les pompon girls', who have already introduced me to the Alsacian food and drinks,
and who are trying to improve my French by their (often female) discussions during
lunch each day.
Tenslotte, Pap, Mam, Chris ik wil jullie bedanken voor alle steun en vertrouwen
gedurende de afgelopen jaren. Het is heerlijk en zeer belangrijk om een fijne
thuishaven te hebben tijdens drukke en/of stressvolle periodes. Bovendien, Chris, als
computer-expert ben je van grote waarde geweest bij het tot stand komen van dit
proefschrift.
Jürgen
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